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Abstract 
The aim of this thesis was to assess the diffusive properties of functionalised and 
unfunctionalised nanomaterials in a variety of different media.  The main goal was to gain 
an insight into the fundamental mechanisms underpinning nanoparticle diffusion and how 
the surface properties of nanoparticles alter their net movement through different 
environments.  Initially a library of polymer-functionalised silica nanoparticles were 
synthesised and characterised.  The polymers chosen were; poly(ethylene glycol) (PEG), 
poly(2-oxazolines) (POZ) and poly(n-isopropyl acrylamide) (PNIPAM).  
Firstly, the diffusion of different sized gold nanoparticles was assessed in concentrations 
of Pluronic F-127, in order to determine how the solution properties affected diffusion.  It 
was found that as the solution undergoes a transition in response to environmental stimuli, 
there is an increase in diffusion coefficient; however the area they move in becomes more 
confined (assessed using a bespoke python script written for use with NTA). 
PNIPAM- and PNPOZ-silica nanoparticles were assessed for their aggregation and 
diffusion using DLS, NTA, and SANS.  It was found that the position of a nitrogen atom in 
the amide group, present in both polymers, plays a key role in governing how the particles 
aggregate in solution, which in turn affects how they diffuse through solvents of varying 
polarities. 
POZ-silica nanoparticles were assessed for mucus penetration against a positive control 
of PEGylated nanoparticles.  It was found that POZ-silica was effective at enhancing 
nanoparticle mucus penetration, and the hydrophilicity of these polymers plays a key role 
in determining the degree of permeation (with methylated POZ significantly more diffusive 
than propylated POZ). 
These finding provide valuable insight into some of the molecular mechanisms governing 
nanoparticle diffusion and how surface chemistry governs these effects.  
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Chapter 1                            
Introduction: 
 Functionalised nanomaterials and principles of 
diffusion 
1.1 Introduction 
Over the past few decades there has been an increase in research into functionalised 
nanomaterials.  Due to their small size and large surface area, they carry unique physical 
and chemical properties not present in larger bulk materials.1  These quantum-like 
properties are dependent on size, morphology, and elemental composition of the material.  
By altering these parameters, it is possible to tune and engineer nanoparticles to have 
specific properties designed for bespoke applications.  Nanoparticles can have unique 
magnetic,2 optical,3 and surface properties4 making them ideal for use in a wide range of 
industries and scientific disciplines including drug delivery,5 diagnostics,6 cosmetics,7 
environmental sciences,8 energy applications,9 and manufacturing industries,10 amongst 
others. 
Nanoparticles are defined by the European Union as “A natural, incidental or 
manufactured material containing particles, in an unbound state, as an aggregate, or as 
an agglomerate where, for 50 % or more of the particles in the number size distribution, 
one or more external dimensions is in the size range 1 nm - 100 nm.”11  The nanoscale, 
defined in Fig 1.1, exists between 1 and 100 nm and ranges from the size of a glucose 
molecule (~1 nm) up to a virus (~100 nm). 
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Fig 1.1 The nanoscale in perspective, with a size-bar showing the area of interest in this 
project 
 
Under recent legislation (Regulation (EC) no 1223/2009, 2013), all nanomaterials used for 
cosmetic and pharmaceutical applications need to be fully characterised for size.  Despite 
this, there are many properties of nanoparticles which are not considered during their 
design, manufacture and regulation, such as their interactions with the local environment 
and how they behave in different systems.   
With the increased interest in nanomaterials in the scientific community, especially those 
which have been further modified with small molecules or polymers, there is an increased 
importance to understand how their surface properties affect their behaviour in different 
environments, particularly with regards to their diffusion.  This is especially true for 
nanoparticles used in drug delivery applications, when considering how they will cross 
biological barriers such as mucus. 
Diffusion is one of the most important transport phenomena in nature, and is relevant to all 
fields of science from the atomic level out into the wider universe.  Diffusion was first 
described in the 1830’s by Thomas Graham,12 who noted that gasses of different densities 
diffused through each other and remained as a mixture rather than separating out. Later in 
1855, Adolf Fick studied diffusion by measuring the movement of gas through a 
nm Area of interest 
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permeable membrane, and founded the Fick equations governing diffusion, known as 
Fick’s laws.13  This is where the classic definition of diffusion arises; the net movement of 
particles/molecules from a region of high concentration to a region of low concentration. 
An expansion on Fick’s principles of diffusion was described by Albert Einstein during 
work on his PhD thesis looking at the kinetic mobility or “random walk” of particles in 
solution.14  The same connection was made independently by Marian Smoluchowski in 
1906.15  It was found that Brownian motion (a process where particles/molecules travel by 
continuous bombardment from the media they are suspended in)16 was the mechanism by 
which diffusion was occurring, explaining Ficks observations.  By taking the diffusion 
principles described by Einstein and Smoluchowski and combining them with Stokes law 
of fluid dynamics (which measures the friction on a particle in a continuous environment), 
it is possible to calculate the diffusion coefficient for a spherical particle in a given 
medium.  This is known as the Stokes-Einstein equation (Equation 1.1).17 
𝐷𝑐 =
𝑘𝐵𝑇
3𝜋𝜂𝑑
    Equation 1.1, 
where 𝐷𝑐 is the diffusion coefficient, 𝑘𝐵 is the Boltzmann constant, 𝑇 is the absolute 
temperature (in Kelvin), 𝜂 is the viscosity of the system, and 𝑑 is the particle radius.  The 
Stokes-Einstein equation is highly important in the field of nanoscience, as it provides a 
direct method for determining particle size based on their diffusion coefficient.  As already 
discussed, the size of nanoparticles can govern their quantum-like properties and is also 
required for regulatory reasons, highlighting the importance of this equation.   
Although the primary use of the Stokes-Einstein equation in current technologies is for 
particle sizing, it can still be used to measure the diffusion coefficient of particles in a 
viscous environment.  
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1.2 Stokes-Einstein equation 
The Stokes-Einstein equation combines Stokes law, describing the frictional force exerted 
on a spherical object in a continuous viscous environment, and the Einstein-
Smoluchowski relation on the kinetic mobility of particles undergoing Brownian motion.  By 
combining these two relationships it is possible to calculate the diffusion coefficient of a 
particle, based on its movement in a non-turbulent liquid of known viscosity.  How this 
equation is constructed will briefly be discussed in this section. 
1.2.1 Stokes law 
George Stokes, a pioneer of fluid dynamics, identified that it was possible to determine 
information on the frictional or drag force, exerted on a spherical object in a fluid of sheer 
viscosity, moving under a continuous velocity, defined by Equation 1.2.18   
𝐹 = 3𝜋𝜂𝑑𝑣    Equation 1.2, 
where 𝐹 is the frictional force, 𝜂 is the sheer viscosity, 𝑑 is the particle diameter, and 𝑣 is 
the velocity.18 This equation, one of the Navier-Stokes equations describing fluid 
mechanics, assumes a small Reynolds number (a dimensionless number which helps 
predict similar flow patterns in different fluid flow situations) and as such can only be used 
under these conditions.19   
Reynolds number is the ratio of the inertial forces to the viscous forces in a solution, and 
quantifies how a solution will flow by determining the solutions specific flow conditions, 
such as laminar or turbulent flow.  At low Reynolds numbers, the viscous forces are 
dominant, resulting in laminar flow (which is required for Stokes law), and a continuous, 
smooth fluid motion is achieved.  At high Reynolds numbers, the inertial forces are 
dominant, resulting in turbulent flow.19        
Looking at Equation 2, the frictional force (𝐹) can be determined assuming the viscosity 
and particle diameter are known.  The frictional force expressed by this equation refers to 
the force at the interface between particle and the fluid (known as the solvation shell).  
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From the frictional force, the friction coefficient can be determined using Equation 1.3, 
where 𝑓 is the friction coefficient.20   
𝐹 = 𝑣𝑓    Equation 1.3  
It is the relationship between the friction and friction coefficient which allows Stokes law 
which Einstein theorised could be used to define rotational diffusion.21 
1.2.2 Einstein-Smoluchowski relation 
During their work on Brownian motion, both Albert Einstein and Marian Smoluchowski 
derived independently a relationship between the diffusion coefficient of a particle and its 
movement caused by Brownian motion (described by Equation 1.4).14,15 
𝐷𝑐 = 𝜇𝑘𝐵𝑇    Equation 1.4, 
where 𝐷𝑐 is the diffusion coefficient, 𝜇 is the ratio of the particle’s drift velocity to an 
applied force, 𝑘𝐵 is the Boltzmann constant, and 𝑇 is the absolute temperature (in Kelvin).  
Einstein theorised that the diffusion coefficient could be linked to the friction coefficient by 
equation 1.5. 
𝐷𝑐 =
𝑘𝐵𝑇
𝑣𝑓
    Equation 1.5 
Giving (Equation 1.6) 
𝐷𝑐 =
𝑘𝐵𝑇
𝐹
    Equation 1.6 
By using Stokes law (Equation 1.2) to calculate 𝐹; the Stokes-Einstein equation is 
generated (Equation 1.1), allowing for a calculation of a diffusion coefficient for different 
sized particles. 
1.2.5 The Stokes-Einstein equation and its relevance to nanoscience 
Besides determining the diffusion coefficient, the Stokes-Einstein equation has another 
very important use in the field of nanoparticle science.  By rearranging the equation, it is 
possible to determine a particle size (Equation 1.7). 
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𝑅ℎ =
𝑘𝐵𝑇
6𝜋𝜂𝐷
    Equation 1.7 
By using techniques which can determine the diffusion coefficient independently of the 
Stokes-Einstein equation (such as particle tracking technologies, NMR, and scattering 
techniques), it is possible to rearrange the Stokes-Einstein equation to generate a particle 
size.  With the advancement of technology this process is becoming more accurate, 
provided the particles are suspended in a solution with a well-known and constant 
viscosity, such as water.  Techniques such as dynamic light scattering (DLS),22 particle 
tracking (e.g. Nanoparticle Tracking Analysis, NTA),23 and Nuclear Magnetic Resonance 
(NMR)24 can be used to determine particle size, making it easily accessible for many labs. 
This rearranged equation is arguably the most common use of the Stokes-Einstein 
equation, and demonstrates the importance of its use in modern nanoscience.   
1.2.4 Limitations of the Stokes-Einstein equation 
Although the Stokes-Einstein equation is widely used, it has some limitations.  Several 
authors have noted that there are deviations between the experimentally determined 
diffusion coefficient and those predicted using this equation.25–27 These can be related to 
the several factors, including; size of the particle/solute, dynamics of the solvent, and 
shape of the particle.28 
Stokes law makes several assumptions of the system being tested (mainly: laminar flow, 
spherical particles with smooth surfaces, homogenous material, and non-interacting 
particles).  Therefore deviations from this norm can cause variations in the resulting 
diffusion coefficient.  The equation also assumes constant, non-changing sheer viscosity, 
therefore non-Newtonian fluids can lead to unexpected results.29  Despite this, attempts 
have been made to correct for these changes.  A study by Achuthan et al,30 proposes a 
modified Stokes-Einstein equation which takes into account the effective viscosity of the 
solvent, and also deviations from non-spherical particles.  This revised equation has been 
shown to effectively model the diffusion coefficients of proteins and aggregates in 
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solutions of varying viscosities.  However, this equation adds more components, making 
calculations more challenging and potentially more ambiguous. 
In addition to viscosity, the particle size can also alter the calculated diffusion coefficient.  
If the particle size is too large (or has a non-spherical morphology) then there is reduced 
Brownian motion exhorted on the particle (causing very little movement), and also the risk 
of inappropriate flow conditions.  This means the diffusion coefficient of larger particles 
cannot necessarily be easily predicted by the equation. 
In addition, if the solute (particle) size is significantly smaller (more than 5 times smaller) 
than the radius of gyration (Rg) of the solvent molecules, or any macromolecules 
dissolved in the suspension, then the equation is not valid.31  The general principle is that 
where the polymers interact in a solution, the viscosity between the fibres will be smaller.   
Therefore, if the polymer Rg is higher than the Rh of the particle, then they can potentially 
move in between the mesh fibres of the polymer, where they will be exposed to a different 
microenvironment than particles larger than the Rg, and will appear to diffuse quicker than 
predicted.  However, if the particles are larger than the polymer’s Rg they will be 
subjected to movement around the polymer chains as they will not fit in the gaps.  
Therefore they will be subjected to the viscosity of the polymer solution, meaning they will 
conform to the Stokes-Einstein equation.32    
Despite its limitations, the Stokes-Einstein equation remains relatively accurate in 
determining the diffusion coefficient for particles in certain environments, and has been 
used widely in the literature.33–35  However, given the above, the results need to be 
analysed with the limitations in mind and not treated as absolute, a factor commonly 
overlooked.  Other limitations of this equation has been observed by several authors,36–39 
and are assumed to be due to viscosity, temperature and particle size.   
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1.2.5 Techniques 
There are several key techniques which can be used to measure nanoparticle diffusion.  
These will briefly be discussed, highlighting their strengths and limitations. 
1.2.5.1 Franz diffusion cells 
Franz diffusion cells are commonly used in the pharmaceutical industry to measure the 
net movement of small molecules,40 proteins/peptides,41 or particles42 through a 
physiological barrier such as the skin,43 ocular tissue,44 or mucosa.45  Use of a Franz 
diffusion cell makes it possible to measure the permeability and flux of a molecule through 
a barrier, which can then be used to estimate bioavailability and calculate the dosage of a 
drug molecule, in addition to predicting whether it can be delivered by that specific route. 
Franz diffusion cells are most commonly used in the development of topical and 
transdermal formulations and assessing in vitro permeation through the skin.46  An image 
showing the basic set-up of a Franz diffusion cell can be found in Fig 1.2. 
 
Fig  1.2 The set-up of a Franz-diffusion cell, taken from Karpanen et al.
47 
 
Simply, a solution containing the drug, protein, or particle to be studied is placed in the 
donor compartment, and left to diffuse through the barrier (in this case skin).  By taking 
samples at given time-points and measuring the concentration of molecules/particles in 
the receptor compartment, it is possible to determine the rate of permeation, lag-time of 
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the molecule, and when it has reached a steady-state.  From this it is possible to calculate 
the flux and diffusion coefficient of the molecules. 
Although a very widely used technique in the pharmaceutical industry and academia with 
numerous publications, the biggest problem with Franz diffusion cells is time.  In order to 
run an effective experiment, samples should ideally be taken over a minimum of 24 hours, 
which can result in long experiments, especially when measuring numerous different 
samples.  In addition, following collection samples need to be measured to determine the 
concentration permeating through the tissue.  As such, techniques such as HPLC, UV/vis 
or fluorescence spectroscopy are used.  This requires the use of a calibration curve, and 
adds further time extensions to data analysis.   
1.2.5.2 Particle tracking techniques 
Particle tracking technologies, such as Nanoparticle Tracking Analysis (NTA), Multiple-
Particle Tracking (MPT), and Single Particle Tracking (SPT), allow a diffusion coefficient 
to be measured by analysing the movement of individual particles in a specific 
environment.   
By tracking individual particles, undergoing random Brownian motion from frame to frame, 
the average spatial displacement of the particles per unit time can be calculated, and this 
displacement can be related to the hydrodynamic diameter of the particles through the 
Stokes-Einstein equation (Equation 1.1). Although translational Brownian motion is a 
three-dimensional process, it is possible to use a one, two, or three dimensional diffusion 
coefficient to determine a particles hydrodynamic diameter as described by Equation 
1.8:                                                                                                        
4
(x,y)2
= Dxyt =
4kBTt
3πηd
    Equation 1.8 
It should be noted that there is no assumption of 2-dimensional movement of particles. All 
particles are assumed to be moving freely in all 3 dimensions while the measurement is 
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sampling the projection of each x, y and z component of that movement onto the xy 
observation plane.  
NTA and MPT provide information on particles both in and out of the nanoscale, up to 
sizes of 2000 nm.  However, generally the technology works best at smaller sizes, and 
optimum conditions are between 20 and 1000 nm, depending on refractive index of the 
particle and solvent, and system set-up.48  Because of this, particle tracking techniques 
are well refined for the study of nanoparticle diffusion, and can show the effects caused by 
the quantum properties of nanoparticles on diffusion.  One major limitation however is 
hard-drive space.  As high-resolution videos need to be recorded, a single 60 s video is 
around 0.5 GB, therefore a whole sizing experiment (including repeats etc) can generate 
up to 10 GB of data.  This number increases for more complex experiments, which require 
a larger number of replicates. 
Although the use of NTA as a technique to measure diffusion has received less attention 
compared to MPT (with very few papers reported in the literature), it is possible to 
measure diffusion directly based on the Brownian motion of the particles,49 in a similar 
manner to MPT.  The primary difference between MPT and NTA is the fact that NTA is a 
closed system, whereas MPT involves the use of independent techniques and equipment 
to determine diffusion coefficients. 
Single particle tracking is a similar technique to those already mentioned, however 
focuses more on tracking particles through biological systems, such as cells.50  Again, it 
identifies particle movement through a three dimensional environment, and tracks the 
particles undergoing Brownian motion over a given time period.  From this, a mean 
squared displacement is calculated, followed by a diffusion coefficient.  This technology is 
commonly used in imaging studies to investigate diseases such as cancer.51  By tracking 
particles in a biological system, it is possible to determine protein interactions, and has 
been used to evaluate cell surface receptor interactions,52 DNA monitoring,53 and vesicle 
movements.54  Despite its wide use, SPT does carry some limitations compared to NTA 
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and MPT.  It provides less information on the diffusion of particle through liquids and 
focuses more on the tracking of individual particles in a complex system such as cells, 
meaning it is hard to measure whether functionalization of particles alters the diffusion and 
assign quantitative data.  These values can be determined using the other two 
techniques. 
Despite the strengths and weaknesses of each technique, particle tracking is becoming 
increasingly used in the literature, primarily for particle sizing; however it holds great 
potential in the evaluation of diffusion through a multitude of different systems. 
1.2.5.3 Diffusion-ordered spectroscopy 
Diffusion-ordered spectroscopy (DOSY) is a nuclear magnetic resonance (NMR) 
technique used to measure the diffusion of molecules in a given environment.  In a DOSY 
experiment a series of pulse-field gradients of different strengths are applied to a sample, 
producing a series of spin-echo spectra.  By using a gradient, it is possible to specifically 
label individual molecules in their environment.  By application of a second gradient (i.e. 
from a second pulse), it is possible to measure the diffusion time and ultimately a diffusion 
coefficient for that molecule based on how it moves.  Application of different gradient 
strengths allows for a more accurate determination of the diffusion coefficient.55  In 
addition to determining a diffusion coefficient, there are reports on using DOSY to 
determine other properties about a molecule, such as molecular weight (with use of 
external calibration curves and normalised diffusion coefficients),56 particle size (by 
rearranging the Stokes-Einstein equation),24 and structure assessment/particle 
interactions (by assessing how diffusion coefficients change in the presence of different 
species in the mixture).57  
Regarding nanoparticle diffusion, DOSY has been extensively studied to examine the 
diffusion coefficient of particles in numerous sample environments, and of multiple 
different make-ups,58 including polymer functionalised nanoparticles.59  This helps provide 
insight into how the particles are behaving on a molecular basis (generating information 
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on their shape, structure, and interactions).  It is therefore useful in several fields, such as 
catalysis where nanomaterials are becoming of increased interest due to an enhanced 
surface area.60,61 
Although DOSY is a highly accurate technique for measuring diffusion and will allow for 
easy determination of any contaminants in the sample (i.e. starting materials), its major 
limitation is cost.  NMR experiments can be expensive to perform, limiting their 
accessibility.  They can also be very lengthy, depending on the number of samples and 
temperatures being measured at, and require specialist expertise for both running the 
experiment and analysing the data.    
With the advancement in technology over the past several decades, the ability to measure 
nanoparticle diffusion at higher resolutions and more accurately makes it possible to 
further probe the interactions between particle and environment, and also makes it 
possible to develop systems with a manipulated diffusion coefficient, making them more 
efficient for their application. 
1.3 Why use nanoparticles? 
As already described, nanoparticles are very small, and therefore have a large surface 
area and can exhibit quantum-like properties (dependent on the size and elemental 
composition of the material).  As such, they carry significant advantages over larger bulk-
materials.  There are many examples in the literature of different nanomaterial 
formulations including metallic nanoparticles,62 organic nanoparticles,63 and silica 
nanoparticles.64  By further functionalising these particles with small molecules, 
biomolecules or polymers, it is possible to further expand upon their physicochemical 
properties whilst still maintaining all the advantages of using a nanomaterial.  Thus, 
combining specific moieties to a particle surface allows for numerous applications such as 
targeted drug delivery,65 or controlled/triggered drug release.66,67  
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1.3.1 Effect of nanoparticle core 
Due to their small size, nanoparticles offer several advantages over larger particles of 
similar compositions, and are currently being used in various formulations available on the 
market in a variety of industries.  Table 1.1 provides some examples on the use of 
nanoparticles in consumer products, their composition and reason for use. 
 
Table 1.1 Nanoparticles found in different consumer products, and why they are used. 
Nanoparticle Application Reason for use Reference 
Copper 
nanoparticles 
Deodorant Odour elimination 
 
68 
 
Titanium dioxide and 
zinc oxide 
Sun-cream 
Block the sun’s rays 
through reflection, and 
leave no noticeable 
residue on the skin 
69 
Iron nanoparticles 
Environmental 
remediation 
Transformation and 
detoxification of 
environmental 
contaminants 
70 
Silver nanoparticles Clothing Antimicrobial activities 
71 
Quantum dots 
Electronic 
displays and 
light emitting 
technologies 
High luminescence 
efficiency, tuneable 
colour spectrum, and 
very energy efficient 
72 
Liposomes/polymeric 
nanoparticles 
Drug delivery 
Small, highly 
penetrating, and low 
toxicity 
73 
 
These are just some of the applications nanoparticles are currently being used in; 
however there are numerous other applications presented in the literature.  Despite their 
versatility across numerous industries, one of their biggest applications is in the 
pharmaceutical industry, mainly as drug delivery systems.   
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1.3.2 Nanoparticles in the pharmaceutical industry 
There are many examples in the literature of different applications of core-nanoparticles 
made from different composites.  Some of the most widely studied nanoparticles will be 
discussed here. 
1.3.2.1 Gold nanoparticles 
Gold nanoparticles (AuNPs) have been in use since ancient Roman times, where they 
were used in the manufacture of stained-glass windows.  Due to their rapid and facile 
synthesis,74 ease of functionalisation allowing for a large array of surface moieties,75 and 
wide range of morphologies (such as spheres, rods, stars, and rings)76,77 they are very 
attractive for biological and pharmaceutical applications, especially in bioimaging and drug 
delivery.  
There are numerous reports on the optical properties of gold nanoparticles with various 
morphologies.  These optical properties stem from a surface-plasmon resonance effect, a 
phenomenon which is size dependent.78  Smaller particles (<20 nm) appear red in colour, 
however as the particles get larger, their colour changes to purple, blue, and (in larger 
sizes) exist in the near-IR region.  This is because when light interacts with the electrons 
on the surface of the particles, it causes them to oscillate.  For larger particles, there is a 
denser cloud of electrons around the particle, causing them to oscillate at a different 
frequency, thus emit light at a lower wavelength, and so appear different in colour.79  
These changes are clearly detectible using UV-Vis spectroscopy, giving a clear sharp 
absorbance peak.80,81  By changing the morphology and surface chemistries of the 
particles, it is possible to tune their optical properties making them ideal for bespoke 
applications in the bio-imaging field, phototherapy and other novel applications.82   
The optical properties of gold nanoparticles combined with their ease in synthesis, large 
array of surface functionalities, and good biocompatibility make them of particular interest 
to the pharmaceutical industry, especially in the field of diagnostics.83 
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1.3.2.2 Silica nanoparticles 
Silica nanoparticles (SNPs) are another popular system.  Their interest to the 
pharmaceutical industry stems from the fact that they can be synthesised to contain pores 
on their surface.  These so-called mesoporous SNPs can allow for easy loading of a small 
molecule, and controlled release by using environmentally-sensitive polymers.84  As with 
gold nanoparticles, they can be easily synthesised using cost-effective methods, and can 
be readily functionalised with a variety of surface moieties, allowing for further 
modifications.   
Traditionally SNP’s are made from SiO2 in the presence of a rod-like structure or 
surfactant, allowing for the formation of pores.85  The strong silica-oxygen bonds make the 
particles very stable in harsh environments, such as the stomach or endosomes.  Despite 
this, their biocompatibility is disputed by several factors, including; size, method of 
synthesis, and surface functionality, and there is much debate in the literature concerning 
their toxicity.86  In general, these particles appear to be safe at low concentrations, thus 
making them an ideal model particle to study.  SNP’s will be covered in more detail in 
Chapter 2.     
1.3.2.3 Quantum dots 
Quantum dots (QDs) are semiconductor devices, which exhibit bright fluorescence (and 
narrow fluorescence emission bands), very long Stokes shifts, good resistance to 
photobleaching, and tuneable emissions at a single excitation wavelength.87  Traditionally, 
QDs are composed of a semiconductor core (usually CdSe) surrounded by a shell 
composed of another semiconductor (such as ZnS).  By controlling the size, shape, and/or 
chemical composition of the core and shell, it is possible to tune the emission wavelength 
over a wider range than the individual semiconductors themselves.88 
Typically, QDs exist in sizes <10 nm as larger particles start to emit light outside the 
visible range.  Although their size is not necessarily a problem in some applications, it 
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limits their application as potential fluorophores and in electronic devices.  It is possible to 
functionalise them with various surface ligands87 or polymers89 allowing them to be used 
as fluorophores for cell labelling, and in vivo imaging.90  Indeed, they have been referred 
to as the next-generation of fluorophore. 
QDs have applications in several industries.  They have an emerging interest in the 
electronics industry for applications in technologies such as quantum computing,91 and 
light emitting devices (such as televisions, mobile phones, and monitors).92  However, one 
of their most widely reported applications is in the field of biology, as next-generation 
fluorophores.  
Due to their sub 10 nm size and wide versatility of their surface chemistry, QDs can be 
functionalised to interact with specific targets, allowing DNA, RNA, and protein 
conjugation for use in bioimaging;93 there are examples in the literature of QDs used for 
both in vitro and in vivo labelling.94  Despite their popularity, a question does remain over 
their cytotoxicity and there is much debate in the literature over this subject.95,96  This 
unknown cytotoxicity is the major draw-back of QDs, and despite attempts to minimise 
their toxic nature97  in vivo applications of QDs are very limited.  As such their main 
application lies in in vitro cell labelling, and as encapsulated fluorophores. 
1.3.2.4 Magnetic nanoparticles  
Magnetic nanoparticles (MNPs) are nanoparticles which can be manipulated by 
application of a magnetic field.  There are several reported synthetic techniques used in 
the literature, including; the co-precipitation of metal salts composed of the magnetic 
elements (iron, cobalt, or nickel), the thermal decomposition of organometallic 
compounds, or using reverse-micelles in a microemulsion.98  Different routes of synthesis 
produce particles with different compositions, which allow them to have a wide-range of 
properties suitable for multiple applications, including cancer treatment (using a technique 
called magnetic hyperthermia, where a magnetic field is applied to magnetic nanoparticles 
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in vivo, which produces heat and kills local cancer cells),28  targeted drug delivery99, MRI 
contrast agents100, bioimaging101, and energy storage102 
Due to their magnetic nature, MNP’s have been broadly investigated for targeted drug 
delivery.  By encapsulating the particles in a shell allowing for sustained circulation, it is 
possible to target these so called “smart nanoparticles” to a specific area of the body by 
applying a magnetic field to said area.103  In addition to targeted delivery, there are studies 
exploring the application of MNP’s in thermotherapy.  When exposed to an alternating 
magnetic field, MNP’s generate heat due to oscillations in the magnetic elements which 
make-up the core.  By taking advantage of the enhanced permeability and retention effect 
(EPR), which is the localisation and bioaccumulation of nanoparticles in tumour tissue, it is 
possible to localise nanoparticles in tumour tissue, and produce a localised increase in 
temperature, which causes the cells to die.104  
Although a highly promising therapy, there are concerns over the safely and removal of 
MNP’s from the body after treatment is complete.  As with other nanomaterials, MNP 
toxicity is centred on several key parameters, namely; composition, size, surface 
chemistry, and physical properties (charge, solubility etc.).  The disadvantage MNP’s have 
over other nanoparticle formulations is that, by definition, they have to be made up of 
magnetic elements, which can lead to leaching of free metal ions causing a large increase 
in reactive oxygen species leading to systemic toxicity.105  In addition to this risk, there is a 
large volume of evidence suggesting MNP’s will accumulate in the body and not be 
removed, thus extending the risk of toxicity.106  As such, MNP’s need to be extensively 
modified making them more biocompatible which could have detrimental effects to their 
magnetic properties, rendering them less effective. 
In addition to targeted drug delivery and thermal therapy, MNP’s have also been used as 
MRI contrast agents.  Superparamagnetic iron oxide nanoparticles have been investigated 
in this regard, as they can increase the signal intensity detected by MRI by shortening the 
longitudinal and transverse relaxation of nearby protons.107  Given their tuneable magnetic 
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properties, and versatile surface chemistries, MNP’s carry significant advantages over 
other MRI contrast agents,108 and indeed some formulations are available on the market, 
such as Feridex IV, Sinerem, and Ferumoxsil.109  
1.3.2.5 Polymersomes, liposomes, and micelles 
From a biological and pharmaceutical perspective, one of the most interesting 
nanoparticle types are polymersomes, liposomes, and micelles.  Indeed current 
nanoparticle formulations available on the market (Doxil)110 fit into this category.  Although 
all three are either monolayered or bilayered vesicles, there are some key differences 
between them.  
Polymersomes are artificial vesicles composed of synthetic block-polymers.  Traditionally 
they are hollow, allowing for the easy encapsulation of a drug.111  These block polymers 
are composed of a hydrophobic core, surrounded by hydrophilic blocks (or vice versa), 
and assemble in solution to form bilayered particles,  Due to their synthetic nature, 
polymersomes are highly versatile in nature and can be designed to show specific 
properties, allowing for a more controllable release.  Although they can be tailored much 
more readily to specific applications, the down-side is that the potential for polymersomes 
to be cytotoxic is greater due to their synthetic origin. 
Liposomes are particles made-up of lipids or surfactants which comprise a polar head 
group and a non-polar body.  In solution, a liposome will exist as a bilayer, similar to a 
polymersome.  The difference is that they are from natural origin rather than synthetic and 
are comprised of lipid bilayers which self-assemble to form vesicles.  In contrast to 
polymersomes, they are less toxic in nature, exhibit good biocompatibility and offer a long 
circulation time.  However, they have a high start-up cost, are poorly soluble in water, and 
can exhibit leakage of materials which have been loaded inside the particle.112 
Micelles are different in that they are monolayered in nature, and can be comprised of 
either polymers (such as surfactants) or lipids.  Because of this, they are generally much 
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smaller in size and can therefore penetrate into tissues and cells via more passive 
mechanisms than their larger counterparts and exhibit good vascular permeability.113  Due 
to their smaller size, they have a much larger surface area, and therefore allow for a 
greater degree of drug-loading.  However, they are relatively unstable in suspension, and 
will readily leak encapsulated molecules with ease, leading to unwanted premature 
release.114   
For drug delivery applications, micelles and micelle-type nanoparticles are one of the most 
heavily studied due to good biocompatibility, easy and cost effective production, and ease 
of loading.  Polymers and lipids are also used in combination to make these formulations, 
which will further enhance their stability and biocompatibility.  This combination can be 
used to minimise the disadvantages of using polymersomes and liposomes.115  There are 
many types of polymer used in such cases such as poly(ethylene glycol),116 and 
poly(lactic-co-glycolic acid).117  These nanoparticles are most promising as drug carriers, 
and are being widely studied for such applications. 
1.3.2.6 Virus-like particles 
Virus-like particles (VLPs) are empty (non-pathogenic) virus particles, which have been 
engineered to remove any genetic information, inhibiting their ability to replicate and 
reproduce.  VLPs are produced by transducing prokaryotic or eukaryotic cells with viral 
DNA or plasmids, in order to create the protein coat, or envelope.   
The main application for VLPs is in the production of vaccines, as they provide safer 
alternatives to attenuated viruses (due to their inability to replicate).118  Two good 
examples are the hepatitis B vaccine, and human papilloma virus vaccine,119 and there 
are many others in development or undergoing clinical trials.120 
Although the bulk of the literature looks at the vaccine potential of VLPs, there are 
examples of VLPs being studied as drug delivery vehicles.121  As they can be mass 
produced at cost-effective prices, alongside good biocompatibility, they are very attractive 
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to pharmaceutical companies as delivery vectors.122  As they are protein-structures, it is 
also possible to modify the surface amino acids, allowing for more facile control over the 
particle, and its drug release parameters, making them potentially a very robust particle.  
1.3.3 Surface modifications 
Nanoparticle surface coatings are primarily used to maintain the stability of the particle 
itself and limit aggregation.  In addition, by using specific pharmaceutically-relevant 
molecules, it is possible to: target the particle to specific proteins,123 target specific 
cells/bacteria,124 or increase the bioactivity of drug complexes and alter bio-distribution.125  
With the addition of these surface modifications there is the potential for altered diffusion.  
This is due to factors such as size, shape, hydrophobicity, and charge changing the 
interactions between the particle and the surrounding environment.  This makes surface 
modifications a very promising strategy for manipulating the diffusion coefficient of 
nanoparticles. 
1.3.3.1 Polymer coatings 
In addition to their core chemistry, it is common practice to functionalise nanoparticles with 
polymers in order to improve their colloidal stability.  In addition, it is possible to further 
expand their application, by manipulating the particles physico-chemical properties.  By 
combining these with the novel properties of the core nanoparticle itself, it is possible to 
create diverse systems suitable for multiple applications.  Table 1.2 provides some 
examples of polymer functionalised nanomaterials, with their reported applications. 
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Table 1.2 Core-shell composition and applications to the pharmaceutical industry of 
polymer functionalised nanomaterials 
Polymer Core Application Reference 
Poly(vinyl pyrrolidone) Silver 
Anti-viral, 
specifically HIV 
126 
Poly(ethylene glycol) Polystyrene 
Increases rate of 
diffusion through 
mucus 
127 
Poloxamer Polystyrene 
Drug delivery, low 
phagocytic 
uptake 
128 
Poly(vinyl 
benzyllactonamide) 
Polystyrene 
High affinity for 
hepatocytes, 
targeted 
hepatocyte 
delivery 
129 
poly(methyl 
methacrylate) 
Polymersome 
Increased uptake 
of particles in 
endothelial cells 
of the blood brain 
barrier 
130 
Dextran Polymersome 
Hemaglutinating 
and targeted oral 
delivery 
131 
Chitosan Liposome Insulin delivery 132 
poly(N-
isopropylacrylamide) 
Superparamagneti
c Iron Oxide 
Enhanced MRI 
imaging 
133 
 
poly(2-methyl-2-
oxazoline) 
Polymersome 
Delivery of non-
viral DNA. 
134 
poly(hydroxyethyl-L-
asparagine) 
Liposome 
Longer blood 
circulation time 
than PEG 
135 
N-(2-
hydroxypropyl)methac
rylamide 
Polymersome 
Intracellular drug 
delivery 
136 
poly(vinyl alcohol) Polymersome 
Oral delivery of 
anticancer drugs 
137 
 
22 
 
From Table 1.2, it is clear that the potential application of polymer-functionalised 
nanoparticles is vast and diverse.  As such, there is continuing research into this area, 
using several different grafting techniques; grafting from, grafting too, and during 
synthesis.138 
The “grafting from” approach is where polymers are synthesised off the surface of 
nanoparticles using living radical polymerisation reactions.  This method allows the 
nanoparticles to be functionalised in a controlled manner, using techniques such as atom 
transfer radical polymerisation (ATRP) or reversible addition-fragmentation chain transfer 
(RAFT).139  For this to be successful however, the nanoparticles need to carry a specific 
surface moiety.  This varies depending on the type of reaction; e.g. a RAFT agent for 
RAFT polymerisation (such as trithiocarbonates, or dithiocarbamates), or a halide ion in 
ATRP reactions.  By controlling the mass of monomer units, and the choice of 
catalyst/initiator, it is possible to generate polymers with a well-defined molecular mass 
and low polydispersity (a measure of how heterogeneous a polymer/particle size is).  This 
is highly advantageous for polymer-nanoparticle composites as it ensures even coverage 
on all nanoparticles in the suspension, each with a well-defined, monomodal polymer 
distribution functionalised onto its surface.  This technique also allows nanoparticles of a 
different elemental make-up to be functionalised without the risk of adverse reactions.  
Indeed, there are numerous examples of different core nanoparticles functionalised using 
the “grafting from” approach, such as CdSe nanocrystals functionalised with polystyrene, 
poly(methacrylate) and poly(butyl acetate),140 silica nanoparticles functionalised with 
polystyrene,141  and cellulose nanocrystals functionalised with poly(ε-caprolactone).142 
Although this technique is very useful for functionalising nanoparticles with a well-defined 
structure and even coverage of polymer, it does carry some drawbacks; it can only be 
used to generate polymers of low molecular weight, it requires specific reaction conditions 
which could affect the core nanoparticle itself, and it requires very specific surface 
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moieties in order for the monomer to initially bind to the particle surface, which must be 
taken into consideration during the synthesis of the particle itself.143 
The “grafting too” approach on the other hand, allows polymers to be added onto the 
surface, rather than grown off the surface.  This technique involves polymers with specific 
end-group functionalities to be attached covalently to specific surface moieties of the 
nanoparticles.  As such, there is much more versatility compared to the “grafting from” 
approach, meaning core particle synthesis can be more varied.  It also allows attachment 
of commercially available polymers, eliminating the polymerisation step.144  Again, this 
technique does not discriminate against the composition of the core, however does 
require the polymer to be synthesised separately before grafting, and thus can take longer 
(unless a commercially available polymer is used).  In addition, when using commercially 
available polymers, this process can be more costly than the “grafting from” approach.   
There are numerous examples in the literature of polymer coated nanoparticles using the 
“grafting too” approach, including; silica nanoparticles functionalised with 
poly(oxazolines),145,146 gold nanoparticles functionalised with poly(2- vinylpyridine),147 and 
superparamagnetic iron oxide nanoparticles functionalised with PEG.148  Due to the more 
versatile nature and ability to use commercially available polymers, the “grafting to” 
approach appears more popular in the literature, as more varied chemistries available.   
Another popular form of synthesising polymer functionalised nanomaterials is to add the 
polymer into the reaction mixture during nanoparticle synthesis, or used to drive the 
synthesis itself.  This method provides a more rapid synthesis, and can be more cost-
effective as all the reagents and starting materials are used in the first instance and there 
are no subsequent synthetic steps.  However, it can lead to more polydisperse 
nanoparticles, as there is little chance of an even coverage on each nanoparticle.  In 
addition, depending on the size of the polymer, they can be harder to purify to obtain a 
pure sample.  There are fewer examples of this technique in the literature, as its 
limitations out-weigh the benefits of a one-pot reaction.149 
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As discussed here, there are numerous applications and synthetic strategies in the design 
of polymer functionalised nanoparticles.  Not only do the polymers act as stabilising 
agents to the colloidal dispersion, making them less prone to aggregation, but they also 
enhance their applications; making the particles more versatile in nature, adding to their 
unique properties. 
1.3.3.2 Protein/antibody functionalised nanoparticles 
In addition to polymer functionalised nanoparticles, there are examples in the literature of 
nanoparticles functionalised with proteins or antibodies.  Indeed, a commercially available 
protein-bound nanoparticle formulation is already on the market for treatment of breast, 
lung and pancreatic cancer (Abraxane).150,151 
Due to their charged surfaces in conjunction with large surface area, unfunctionalised 
nanoparticles exhibit strong interactions with proteins in vivo and is a major concern 
regarding their safety as drug delivery vectors.152  This can be overcome with further 
modification, using small molecules/polymers.  However, it is also possible to covalently 
bind proteins or antibodies to the surface of nanoparticles.  By doing so, it is possible to 
enhance the colloidal stability of the particles (where the proteins act in a similar structural 
manor to polymers, as already discussed), and also enhance their biocompatibility due to 
the biological origin of proteins.  In addition (certainly in the case of antibodies), it is 
possible to target the nanoparticle to specific cell types and tissues by taking advantage of 
protein-receptor interactions on the cell surface.  This is a popular strategy for use in 
combination with magnetic nanoparticles which can induce hyperthermia conditions when 
exposed to a magnetic field.  By functionalising the nanoparticles with proteins which have 
an affinity to cancer cells, and applying a magnetic field, the nanoparticles will cause the 
cancer cells to die, leaving healthy cells alive.153–155 
In addition to protein functionalised nanoparticles, examples of antibody functionalised 
nanoparticles can be found in the literature.156,157  Given that antibodies bind to specific 
epitopes, they can be used to target specific cells, and are often used in fluorescent 
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imaging techniques.  Based on this, some researchers158 have grafted antibodies to 
nanoparticles to achieve more potent targeted drug delivery systems.  Antibody based 
treatments are becoming more common as pharmaceutical agents and are available as 
marketed therapeutic drugs, for example Herceptin.  It has been shown that by 
functionalising silica nanoparticles with Herceptin, the drug has greater specificity and can 
be readily internalised into cells via endocytosis.  This is due to the enhanced surface 
area of the nanoparticles and high degree of antibody binding on the surface.  This is not 
the only example of using antibody functionalised nanoparticles for enhanced therapeutic 
effects.  Other examples include; antibody functionalised superparamagnetic 
nanoparticles for enhanced MRI visualisation of specific targets,159 antibody functionalised 
calcium phosphate nanoparticles as intracellular targeting for gene delivery,160 and 
antibody functionalised gold nanoparticles for drug detection via fingerprint analysis in 
forensic investigations.161 This method also has potential in the visualisation of cancerous 
tissues both in vitro and in vivo.162   
Although protein and antibody functionalised nanoparticles show potential in the field of 
drug delivery, they do contain some inherent weaknesses.  Due to the complex nature of 
proteins, and their highly conserved structure, binding molecules to them could initiate 
conformational changes, thus rendering them inactive.  The chemistry involved (such as 
high/low temperatures, solvents and harsh chemicals), could also affect the protein 
structure, rendering it ineffective.  In addition, it is possible that this conformational change 
could invoke an immune-response from the body, making the treatment ineffective and 
potentially causing adverse reactions for the patient.   
Despite these weaknesses, protein and antibody functionalised nanoparticles show good 
potential, especially in cancer research and gene delivery.163 
1.3.3.3 Small molecule functionalised nanoparticles 
Another method of nanoparticle functionalisation is the attachment of small molecules.  By 
functionalising nanoparticles with small molecules, such as sugar residues, amino acids or 
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drug molecules, it is possible to alter their surface chemistry and allow them to interact 
with specific cellular targets, such as membrane protein receptors. 
One of the most common small-molecule functionalities grafted to nanoparticles is 
fluorophores.  By fluorescently labelling a nanoparticle it is possible to monitor their transit 
in biological tissues either in vitro or in vivo.164  This allows information to be generated on 
specific tissue interactions of the nanoparticles, or if they are localising in specific 
organelles or tissues.   It also allows for the detection of particles in more complex 
systems, making it possible to assess their interactions with the surrounding environment, 
such as in diffusion studies across mucus barriers, or across the cornea.52,165  The 
limitation to this however, is that the fluorophores can quench at a faster rate than normal 
due to their large surface area and small point of detection. 
As an alternative to fluorophores, it is possible to label nanoparticles with a radioactive 
tag.  This makes it possible to track nanoparticles in a living system, whereas in vivo 
fluorescent imaging requires the organism to be dead as the fluorescent emission will not 
penetrate out of the organism.  Radioactive isotopes can either be included in the 
synthesis of the particle itself, or used as labels, functionalising the surface allowing for 
detection.166  This technique is regularly used to assess the EPR effect of nanoparticles, 
and measure their localisation in the body and tumour cells.167,168  Although this technique 
is very useful for tracking and mapping the locations of nanoparticles in real-time in an in 
vivo system, it is very expensive, can be dangerous due to the radioactive nature of the 
samples, and requires specific handling and safety assessments.  Therefore it is rarely 
used for in vitro imaging. 
In addition to labelling moieties, such as radio labelled and fluorescent probes, there are 
also reports of nanoparticles functionalised with biomolecules, such as amino acids,169 
nucleic acids,170 and sugar residues.171  The addition of biomolecules to the surface of a 
nanoparticle will not only enhance its biocompatibility, but also allow it to interact with 
specific cellular targets, allowing for a targeted delivery mechanism on the nanoparticle.   
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The attachment of small molecules to a nanoparticle surface allows for many different 
features, especially in bioimaging and tracking technologies.  Small molecule 
functionalisations are often used in combination with polymer or protein additions, making 
it possible to track the movements of these particles, or enhance their potential to interact 
with specific cell types. 
1.3.3.4 Stimuli-responsive nanoparticles 
Nanoparticles with stimuli-responsive polymers, such as poly(N-isopropyl acrylamide) 
(PNIPAM), or poly(acrylic acid) (PAA), allow for novel surface properties of a nanoparticle 
which gives them unique properties not expressed by other functionalised nanoparticles.  
These so-called “smart” nanoparticles, are being extensively studied, in part for controlled 
release studies, controlled biodegradation, wound-healing, environmental remediation, 
and energy storage.172   
PNIPAM is a commonly used temperature responsive polymer (TRP).  As PNIPAM 
undergoes coil-globule phase transition, it is an ideal surface modifier for porous silica 
nanoparticles, as (below the lower critical solution temperature (LCST) of 32 oC) it allows 
the pores to open up and release their contents.173  By using targeted cooling techniques, 
it is possible to initiate the release of a drug molecule this way.  Several authors have 
found that it is possible to reach a level of controlled uptake and release of a drug using 
this technique.  For example, You et al174 reported that fluorescein uptake was retarded 
when PNIPAM was in its globule conformation, however when in its coil conformation 
(below the LCST), the molecules are free to diffuse out through the pores of the silica and 
through the polymer.  It was found that around 80% of the fluorescein was released over 
48 hours at 25 oC, as opposed to <20% release at 38 oC.  This is useful in terms of 
loading (as drug molecules can be readily trapped inside the particles by a change in 
temperature), however, in terms of systemic release, as the LCST exists below 
physiological temperature, the release mechanisms need to be further enhanced.  
However for use as a local subcutaneous release, this could be of great interest, as the 
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local temperature of the skin can be decreased easily without the addition of long-term 
adverse effects. 
By combining the coil to globule phase transition of PNIPAM to the surface of porous 
nanoparticles, it is possible to trap molecules inside.  This is because the polymer (in its 
hydrophobic globule state) will block the pores in the particle, thus not allowing molecules 
to escape. However, below the LCST in its coil conformation, molecules are free to diffuse 
out the pores, and into the external environment.  This is depicted in Fig 1.3.173 
 
Fig 1.3 Porous silica nanoparticles functionalised with PNIPAM can undergo phase 
transition allowing the globular hydrophobic form of PNIPAM (above the LCST) to block the 
pores, thus not allowing release of any encapsulated molecules.  Below the LCST (in its 
hydrophilic coil conformation), PNIPAM allows molecules to be readily released from the pores
173
 
 
However, this in itself can cause problems in some areas, for example drug delivery.   
With an LCST 32 oC, the polymer will undergo phase transition prematurely in a 
physiological system, where the temperature is 37 oC.  Therefore using PNIPAM in this 
respect will be of little use, as no drugs can be released systemically.  However by 
combining this polymer with other polymers (for example pH responsive polymers such as 
poly(acrylic acid)), it is possible to overcome this obstacle and obtain a dual-responsive, 
switchable nanoparticle that can effectively release a drug compound175. 
Although silica functionalised-PNIPAM nanoparticles show some limitations with regards 
to drug delivery, there are methods to overcome this.  Baeza et al176 reported on the use 
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of poly(ethyleneimine)-b-poly(N-isopropylacrylamide) grafted to porous silica 
nanoparticles which contain magnetic iron core.  By loading drug molecules into the 
hydrophilic PNIPAM shell, and a protein into the silica pores, it was found that upon 
heating by an alternating magnetic field, these two components would release separately, 
where the drug molecule being released instantly as the PNIPAM undergoes phase 
transition followed by a slow release of the protein.  This illustrates that multiple drugs can 
be released from a single nanoparticle composite, and that release can be remotely 
controlled by use of an alternating magnetic field.  However, the severe limitation of this 
study remains that the LCST of PNIPAM is around 32 oC, where physiological 
temperature is 37 oC.  Therefore the polymer will undergo phase transition before it can 
reach its target, so the components will release prematurely, a fact overlooked by the 
authors in this study.  Despite this, the particle designed in this study offers potential in the 
field of drug delivery, as it shows the remote controlled release of two compounds from 
one particle.    
Another useful TRP grafted to silica nanoparticles was described by Sun et al,177 who 
created a biocompatible zwitterionic sulphobetaine copolymer, functionalised onto the 
surface of a silica nanoparticle.  Poly(2-dimethylamino)ethyl methacrylate (PDMAEMA) 
was initially grown off the surface of the silica nanoparticles by RAFT polymerisation, 
followed by further functionalisation of the tertiary amine groups in the polymer by 3-
dimethyl(methacryloyloxyethyl)ammonium propanesulphonate (DMAPS).  Upon 
functionalisation with the DMAPS, no phase transition was seen and the particle size 
remained constant at temperatures between 25 and 65 oC.  However, when the particles 
were in an ionic solution of either 0.1 or 0.2 M NaCl, the particles underwent phase 
transition between these two temperatures.  The zwitterionic DMAPS enhances the 
particles biocompatibility, and indeed they exhibited little toxicity in the MTT assay, 
whereas the PDMAEMA defines the particles temperature-responsive nature.   
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To test drug release behaviour, the particles were loaded with rhodamine B.  The release 
kinetics greatly improved at temperatures above 45 oC, at pH 7, 0.2 M NaCl.  However 
release was severely impaired at 30 oC under the same conditions.  With the LCST of the 
system being 45 oC, this explains the release profile demonstrated, making the particles 
potentially suitable for thermal therapy. Therefore, due to the presence of ions, these 
particles will undergo a phase-transition in physiological systems, whilst remaining stable 
in pure water; making them ideal vehicles for drug delivery. 
A further study with PDMAEMA grafted onto SiO2 nanoparticles examined the phase 
transition using two variables; temperature and pH.178  As PDMAEMA is both temperature 
and pH responsive, it offers potential for drug delivery, despite its high LCST (>45 oC).  
Although no release studies were performed in this specific study, the lack of toxicity of 
reducible PDMAEMA179 means that this polymer is attracting a lot of attention in terms of 
drug delivery. 
1.4 Biological barriers and how to overcome them  
As nanoparticles are so small, they can cross membranes and barriers designed to stop 
foreign objects entering systemic circulation, and causing harm to the body.  
Encapsulated poorly water soluble drugs may benefit from this, as they could be 
administered orally whilst reducing their typically poor bioavailability.  Therefore 
understanding how nanoparticles diffuse through biological barriers is of key importance, 
in order to maximise effectiveness of the encapsulated drug. 
As nanoparticles can act as either drug carriers or as drugs themselves (with the drug 
conjugated to the particle surface), understanding how they diffuse through biological 
barriers, such as mucus membranes, and whether the rate of diffusion can be 
manipulated to speed up diffusion, is gaining interest in the literature.180   
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1.4.1 Mucosal barriers 
In the body there are numerous barriers a drug or nanoparticle will need to cross in order 
to reach its therapeutic target.  Mucosal membranes are one such example and coat parts 
of the body exposed to the harsh external environment, such as the lung airways, nasal 
cavity, and gastro-intestinal tract.  Mucosal barriers consist of five distinct layers; a layer of 
mucus, the mucosa, the submucosa, and the muscularis externia and serosa. 
1.4.1.1 Mucus 
Mucus is a complex mixture of glycoproteins, salts, lipids and cellular debris which form a 
hydrogel protecting mucosal cells from the harsh external environment.  Apart from water 
(which makes up 95-99.5% of mucus)181 the primary components are mucin proteins, 
heavily glycosylated proteins which are secreted by goblet cells located in the epithelium.  
According to HUGO (the Human Gene Nomenclature Committee), there are currently  21 
known mucin genes in the human genome,182 of which there are two distinct types; the 
secretory mucins, and adherent mucins; both of which are between 0.5 and 20 MDa in 
size.   
Secretory mucins have two distinct regions; a central block containing tandem repeats of 
serine, threonine, and proline residues which are heavily modified by glycosylation, and 
two cysteine rich domains at the N and C termini, respectively.  These cysteine-rich 
domains allow the protein to cross-link with other mucins by the formation of disulphide-
bridges, creating a mesh-like structure.183  Typically, each oligosaccharide unit contains 8-
10 sugar residues, of which the main constituents are galactose, fructose, N-
acetylglucosamine, N-acetylgalactosamine and sialic acid.184  These are bound to the 
amino acid backbone by O-linked glycosylation.  Adherent mucins differ in that they 
contain a hydrophobic terminus, allowing it to anchor into the cell membrane.185 They are 
smaller than secretory mucins and are secreted by foveolar cells rather than goblet cells, 
and is around 100-200 µm thick.186 
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Both the adherent and secretory mucins form a gel which lines surface epithelial cells 
exposed to the external environment, such as the GI tract, airways, vagina, and ocular 
tissue.  This gel traps foreign bodies and molecules, preventing them from reaching the 
underlying cells thus causing damage.  This is a significant barrier to overcome in terms of 
drug delivery, as it prevents lipophilic compounds from entering systemic circulation.  In 
addition, large particles (>300 nm) cannot penetrate through the mucin fibres and will 
become trapped.183  However, there are examples of mucoadhesive systems which have 
been specifically engineered to allow sustained release over a period of time for the 
treatment of certain forms of cancer, fungal infections, anti-inflammatory drugs and 
ulcers.187  However, the limitation to these kinds of formulation is mucus clearance.   
Mucus clearance is where the mucus layer is stripped away, and replaced with a fresh 
one, allowing removal of any trapped compounds.  The rate of clearance depends on the 
location.  For example, the intestinal mucosa is estimated to be replaced every 47–
270 min,188 whereas in ocular tissue it is between 15–20 h.189 This adds another barrier, 
as the rate of mucus clearance needs to be considered as to allow the formulation 
sufficient time to achieve its therapeutic effect. 
In addition to protective roles, mucus also serves to lubricate certain tissues, allowing 
easy passage of food and other compounds to their destination.  This is especially 
important in tissues such as the oesophagus and airways.   
1.4.1.2 Mucosa 
Underneath the mucus layer, lies the mucosa. The mucosa consists of a layer of epithelial 
cells, the lamina propria ( a loose layer of connective tissue which keeps the epithelium 
rigid and in place), and the muscularis mucosae (a thin layer of smooth muscle).190   
The mucosa epithelia also contains specific cells allowing the normal function of the organ 
in which it is located.  For example, the gastric mucosa contains parietal cells which 
control the pH balance of the stomach and secretes HCl and chief cells which secrete 
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digestive enzymes such as pepsin and gastrin.191  The intestinal epithelia on the other 
hand, contains a large number of enterocytes, which enhance the absorption of 
nutrients.192  In addition to changes in cell type, the general histology of the epithelia also 
changes depending on location.  The stomach contains gastric pits, whereas the small 
intestine contains villi and microvilli which enhance absorption. 
Underlying the epithelia is the lamina propria.  The lamina propria is a layer of loose 
connective tissue, comprised mainly of fibroblasts, fibrocytes, and endothelial cells.  It also 
contains capillaries and lymphatic tissue, providing the epithelial cells with a blood 
supply.193  The lamina propria contains a large number of cells from the immune system, 
including B-cells, T-cells, and dendritic cells.194  As the mucosa protects the body from the 
external environment, the immune cells are needed to remove any pathogens that cross 
the mucus and epithelial cells, before they reach systemic circulation.  Indeed, the 
mucosa contains many lymph nodes such as the Payer’s patch in the small intestine.195 
The final layer of the mucosa is the muscularis mucosae, a thin layer of smooth muscle 
which allows the tissue to contract and move depending on its biological function. 
1.4.1.3 Submucosa, muscularis externia and serosa 
The submucosa is a dense layer of connective tissue which contains larger blood and 
lymph vessels and also nervous tissue.196  The submucosa of the stomach and intestine 
contains the submucosal plexus, one of the major sets of neurons in the enteric nervous 
system and controls digestion.  The primary role of the submucosa is to connect the 
mucosa to the muscularis externa, and provide a blood and lymphatic supply to the 
mucosa.   
Depending on the location in the body, the muscularis externa is made of either smooth or 
skeletal muscle.  The tissue has two layers of muscle and controls movement of the 
tissue, such as peristalsis.  The final layer is the serosa, which is a final layer of 
connective tissue, containing more blood vessels, lymphatics, and nervous tissue. 197 
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1.4.2 Other physiological barriers to drug delivery 
As already discussed, the primary role of the mucosa is to protect parts of the body 
exposed to the external environment.  However there are other physiological barriers 
which are designed to protect specific organs, such as the brain, the immune system, and 
also metabolic pathways which will breakdown molecules making them safe to remove 
from the body before a physiological effect can be achieved. 
1.4.2.1 The blood-brain barrier 
The blood-brain barrier (BBB), a complex network of highly selectively permeable 
capillaries, protects the brain from damage by molecules and pathogens.  The endothelial 
cells which make up the walls of the capillaries are held together by very strong tight-
junctions, which restricts the movement of molecules, particles and bacteria so as not to 
cause adverse effects to the brain.198  In addition to the tight junctions, the capillary 
network also contains several specific cell types, including pericytes (contractile cells 
which wrap around the capillaries and aid in the regulation of the permeability of the 
BBB),199 astrocytes (brain-specific cells which control homeostasis, aid in repair, and 
control extracellular ion balance and help maintain biochemical processes in and around 
the endothelial cells),200 and microglial cells (brain specific macrophages, maintaining the 
immune system and removing pathogens passing through the BBB).201 
There are several key properties for a molecule to cross the BBB, namely size, charge, 
hydrogen-bonding potential and lipophilicity.  Apart from biomolecules essential for normal 
cell growth and control (amino acids, proteins, carbohydrates etc.), only small lipophilic 
compounds less than 500 Da can cross the BBB.202  This is a major limiting factor in the 
development of a pharmaceutical agent for delivery to the brain, and one that must be 
considered for the treatment of brain-specific diseases.  Drug delivery to the brain is of 
increasing concern due to age-related diseases and neurodegenerative diseases such as 
Alzheimer’s disease.  
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1.4.2.2 Immune system 
Another biological barrier which needs to be considered in the development of 
pharmaceutical formulations is the immune system.  The immune system protects 
organisms from damage by microbes, viruses, and toxic agents. 
The immune system consists of highly specialised cells which can provide rapid defence 
(the innate immune system), or long-term protection (adaptive immune system) from 
pathogens and other harmful compounds, especially those of biological origin.  Cells of 
the innate immune system (such as macrophages, dendritic cells, and natural killer cells) 
provide immediate response to a pathogen or potentially toxic compound, removing them 
before they can cause harm to the body.203 
Immunogenicity mainly affects drugs of a biological origin, such as proteins, or antibodies.  
This is because the protein is recognised as foreign by the immune system, and therefore 
attacked to be removed from the body.  Over the past few decades, there has been an 
increase in the number of biotherapeutics on the market (such as Herceptin)204 which are 
of biological origin, and can therefore generate an immune response.  Due to the power of 
the immune system, this can lead to complete removal of the drug before it can achieve 
its therapeutic effect and can be a big hurdle to overcome, due to the adaptive nature of 
the immune system.205 
1.4.3 Ways of overcoming physiological barriers 
Given the wide variety of defence mechanisms in humans and other organisms against 
foreign bodies, there is a great deal of interest in developing formulations that can bypass 
these barriers.  
1.4.3.1 Pro-drugs, precursors and analogues 
Prodrugs are compounds which can be administered to a patient in an inactive form and 
become active upon enzyme or chemical activation.  Reasons for using prodrugs are 
multiple; enhanced absorption through the GI tract or other membranes, reduce the 
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adverse effects caused by the active compound, provide greater chemical stability thus 
improving the efficacy of the drug, penetration across the BBB or protection against rapid 
metabolism allowing the drug to have a longer systemic circulation.206 
A prodrug is made by attaching a small molecule (designed to improve bioavailability, 
stability, etc.) to an active drug via a biodegradable link, such as an ester bond.  This will 
allow enzymes to attack this bond, releasing the small molecule and creating the active 
drug.  It is also possible to attach a targeting molecule to a prodrug, allowing the prodrug 
to interact with specific cellular targets in specific organs, where they can become the 
active drug.  This strategy is especially useful in chemotherapeutics, as drugs can be 
targeted to cancer cells where they can be metabolised and become active, destroying 
the cancer cells avoiding adverse effects to healthy cells.207,208 
There are numerous examples of FDA/OECD approved prodrugs on the market, for 
example Capecitabine, used in the treatment of some cancers.  The active drug, 5-
fluorouracil, is modified to the prodrug Capecitabine, to modulate the adverse effects 
caused by the potent anti-metabolite drug, and enhance oral absorption.  Upon ingestion it 
is converted to 5′-deoxy-5-fluorouridine in the liver by enzymatic action from two enzymes; 
carboxylesterase and cytidine deaminase.  This is then further metabolised into the active 
compound by thymidine phosphorylase and/or uridine phosphorylase, both of which are 
enzymes overly expressed in cancerous tissue.209  The addition of small molecules to 5-
fluorouracil thus provides enhanced oral bioavailability (improving patient compliance), 
and also controls the action of the drug. 
Precursor biomolecules are small molecules which are converted to different molecules 
through metabolic pathways.  For example, amino acids are used in the body as precursor 
molecules to various bioactive compounds such as glutathione (a detoxifying molecule), 
nitric oxide (a cell signalling molecule), porphyrins (used in the synthesis of haemoglobin), 
and GABA (neurotransmitter).210  As they have good biocompatibility, precursor 
biomolecules can be used as drugs, especially in the case of neurological orders, for 
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example L-dopa (the precursor for dopamine).  The dopamine molecule itself cannot cross 
the BBB, whereas its precursor (L-dopa) can, allowing it to be converted into dopamine in 
the brain.211  This strategy is used in the treatment of Parkinson’s disease. 
An analogue is a compound which is structurally similar to an active biomolecule, which 
either exhibits a pharmaceutical effect itself, or becomes metabolised into an active form.  
Analogues have the same mechanism of action as the biocompound, however, they can 
have either diminished or enhanced effects depending on their potency, for example 
codeine.  Codeine is an analogue of morphine, and follows the same metabolic pathway, 
however at a reduced potency.  In addition, a small amount of codeine is metabolised into 
morphine in the liver by the cytochrome P450 CYP2D6.212  Codeine mimics morphine, 
allowing it to be used as a potent pain medication, and also helps to reduce the side-
effects associated with morphine.  Further, codeine can be delivered by the oral route, 
due to enhanced absorption through the GI tract, whereas morphine needs to be delivered 
intravenously as it cannot cross the mucosa into systemic circulation. 
The use of prodrugs, analogues and precursors are strategies to avoid the bodies defence 
mechanisms, however they can still be prone to premature degradation and reduced 
efficacy, and a strong understanding of their mechanism of action needs to be understood 
in order to make an effective formulation. 
1.4.3.2 PEGylation 
Poly(ethylene glycol) (PEG) is a polyether compound synthesised by the ring-opening 
polymerisation of ethylene oxide.  It is non-toxic, non-immunogenic, non-antigenic, and 
highly soluble in water making it suitable for use in pharmaceutical applications.  By 
functionalising molecules, proteins/peptides, or drug delivery vehicles with PEG 
(PEGylation), it is possible to enhance solubility, increase circulation time in the blood 
stream, enhance stability, decrease enzymatic degradation, and avoid detection by the 
immune system.213  There are numerous examples of PEGylated formulations which have 
gained regulatory approval in the EU and USA, such as; Pegaptanib (used for age-related 
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muscular degeneration),214 Certolizumab Pegol (used in the treatment of Chrone’s 
disease),215 and Pegylated interferon alfa-2a (used in chronic Hepatitis B patients).216 
Despite its wide range of applications in the pharmaceutical industry; PEG has some 
significant drawbacks.  These include lack of biodegradation, in vivo fate of PEG, and 
bioaccumulation in vacuoles for small molecular-weight polymers.217  Despite this, PEG is 
actively used in formulations, and extensively studied in the literature. 
There are several reported ways in which PEG can avoid the bodies defence 
mechanisms.  The development of mucus-penetrating nanoparticles, (particles 
functionalised with PEG) provides a vehicle for drugs to be delivered by the oral route.  
This is especially useful for the delivery of hydrophobic drugs which need to be given via 
subcutaneous or intravenous injection.218  By modifying the surface of nanoparticles with 
polymers, such as PEG, it is possible to reduce the surface properties of that particle, 
minimising the mucoadhesive interactions between the particle and the mucus 
environment due to its uncharged, hydrophilic nature.  By doing so, it is possible to 
enhance the penetration of larger particles (larger than the mesh-size of mucin, ~300 nm).  
Particles up to 500 nm have been reported to show enhanced mucus penetration through 
PEGylation.183,218,219  This has paved the way in the development of other mucus 
penetrating particles, nanoparticles functionalised with other polymers including poly(vinyl 
alcohol),220 and poly(2-oxazolines).145 
Another application of PEG is using its so-called “stealth” properties.  By functionalising 
peptides or proteins with PEG, it is possible to reduce their non-specific binding to cells of 
the immune system, thus avoiding an immune response raised against them.221  In 
addition, PEG will help stabilise the system, and allow a longer circulation time.  The 
stealth properties of PEG are very popular in the literature, and there are numerous 
examples of PEGylated proteins,222 nanoparticles,223 and viruses.224 
The pharmaceutical usefulness of PEG cannot be overlooked, and it is one of the most 
studied polymers for applications in drug delivery and dosage formulation.  Due to its 
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unique abilities, it is being increasingly used in formulations, and they are readily used to 
evade the bodies defence mechanisms. 
1. 4.3.3 Nanoparticles 
Nanoparticles, due to their sub-micron size, can penetrate through barriers more readily 
than larger particles.  As discussed previously, PEGylated nanoparticles are mucus 
penetrating, allowing them to diffuse rapidly across a mucin network.  Although the 
addition of PEG does play an important role in this phenomenon, the particles size also 
plays a significant role.  Smaller nanoparticles were more diffusive than larger ones,219 
and indeed, particles larger than 500 nm were found not to penetrate at all, clearly 
showing the size does matter. 
In addition to their mucus penetrating effects, nanoparticles have also been utilised for 
delivery across the BBB.  There are many studies in this area, as drug delivery to the 
brain is a major challenge to the pharmaceutical industry.  As such, nanocarriers are 
being designed and engineered with specific surface properties allowing them to 
permeate across the BBB.  Again, this process appears to be size dependent, and it has 
been found that particles >70 nm will not cross the BBB.225 
As with drug permeability across the BBB, the composition and surface properties of the 
nanoparticle will dictate its ability to permeate into the brain.  Neutral, uncharged species 
more readily cross the BBB and allow delivery into the brain.  For example, PEG nanogels 
have been developed to deliver of oligonucleotides into the brain.226  Given that 
oligonucleotides are promising candidates for gene227 and cancer228 therapy and they do 
not naturally cross the BBB, this is a promising therapy.229  This is but one example of 
nanoparticles which have been engineered to allow for delivery of molecules through the 
BBB, overcoming the body’s defences. 
In addition to the BBB, another strong physical barrier to drug delivery is the skin and 
indeed, the skin is one of the major routes of drug delivery either by subcutaneous 
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injection or the use of dermal patches/hydrogels.230  The subject of nanoparticle 
permeation across the skin is highly debated in the literature, and indeed remains 
inconclusive.  Generally it is understood that nanoparticles will permeate across the skin, 
dependent on several key parameters, namely; size, charge, hydrophilicity, isoelectric 
point, how the particles are being administered, exposure times, location of the skin (i.e. 
thickness) etc.231  Due to all these confounding factors, it is hard to accurately assess the 
degree of nanoparticle penetration. 
Despite this, nanoparticles are being developed for transdermal drug delivery, specifically 
those targeted to specific layers of the skin.  For example, solid-lipid nanoparticles 
delivering encapsulated vitamin A to the upper layers of the skin,42 delivery of highly 
lipophilic drugs encapsulated in biodegradable poly(caprolactone) nanoparticles,232 and 
nanoemulsions containing paclitaxel for use in the treatment of psoriasis (an auto-immune 
disease which leaves patchy, itchy rashes on the skin).233  An area of specific interest is 
the use of silver nanoparticles for use as anti-fungal and anti-microbial formulations in skin 
lesions.234  Indeed, silver nanoparticles have also been shown to aid in wound healing,235 
giving rise to new applications for silver nanoparticles with regards to dermal treatment.  
As already discussed, one of the major advantages of using nanoparticles is the ability to 
functionalise them with small molecules or polymers, further expanding their 
characteristics and enabling more varied applications.  Based on the advantages PEG 
has to the pharmaceutical industry, there are multiple examples in the literature of 
PEGylated nanoparticles as drug delivery vectors.  In addition to the enhanced diffusion of 
nanoparticles through a mucus gel, PEG also helps nanoparticles avoid the immune 
system,236,237 and prolong circulation time of the functionalised nanoparticle.238  In addition, 
PEG (along with poly(lactic-co-glycolic acid) (PLGA)), are regularly used in the synthesis 
of polymeric nanoparticles, due to their good biocompatibility, good circulation times, and 
reduced toxicity, and further modified with targeting molecules allowing for targeted drug 
delivery.239 
41 
 
As well as PEGylated nanoparticles, there are also examples of nanoparticles 
functionalised to form a pro-drug.240–242  By taking advantage of the high surface-area of 
nanoparticles, along with their small size (allowing them to enter cells more readily than 
larger molecules), and wide versatility in chemistry, the use of nanoparticles as either 
carriers of prodrugs, or surface-modified with prodrugs is very interesting.  Functionalising 
or incorporating a prodrug into a nanoparticle system allows for a more controlled 
delivery/release, and also provides stability to the drug complex itself.243   
1.5 Nanoparticle diffusion  
In the pharmaceutical industry, measuring the diffusion of a compound across different 
barriers is of fundamental importance as it allows the permeability of drug formulations to 
be assessed.  There are numerous reports in the literature on the use of Franz-diffusion 
cells to measure the diffusion of small molecules,244 polymers,245 nanoparticles43 and 
peptides41 across different tissue types including skin,246 ocular tissue,44 buccal mucosa,45 
and the bladder.40 
However, with the advancement of nanotechnology, there is a need to understand the 
diffusive properties of nanomaterials through different biological systems, such as mucus 
gels and blood.  Due to continuous environmental exposure to nanomaterials, their 
biological fate needs to be studied, which includes their route of exposure.  Given that 
environmental nanoparticles are likely to be either inhaled, or ingested, their diffusion is 
the first barrier they need to overcome.247  Therefore, from a safety stand point, 
understanding the diffusive properties of nanoparticles, and how size, shape, and surface 
modification affect these properties is of fundamental importance. 
In addition to the risk-factors associated with exposure to engineered nanoparticles along 
with their increasing popularity of as drug delivery systems, the need to understand how 
particles are interacting and diffusing in physiological systems is becoming increasingly 
important, and an area which is generally lacking in the literature. 
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To date, nanoparticle diffusion through several different mucosal tissues has been studied 
as a potential for drug delivery, namely; cervicovaginal mucus,218 intestinal mucus,248 
sputum,249 gastric mucus,145 and mucus from chronic rhinosinusitis patients.250  Due to the 
complex nature of the physicochemical characteristics of nanoparticles and that of 
biological systems, nanoparticle diffusion for pharmaceutical applications is exceedingly 
complex and much is still to be learned. 
Nanoparticle diffusion is also highly important in other areas of science, not just the 
pharmaceutical industry.  In the physical sciences, nanoparticle diffusion is important in 
providing insights into how the particles are behaving in different solutions and systems, 
and indeed provides the ground-work in the development of nanoparticle formulations for 
use in drug delivery.  As diffusion is caused by particles undergoing Brownian motion, 
understanding this process can be of importance in diverse fields, such as printing,251 
agrochemicals,252 and energy storage.253 
This chapter has highlighted the process of nanoparticle diffusion, different techniques 
used to measure diffusion, and why nanoparticles are important in different industries, 
particularly the pharmaceutical industry, and how this relates to diffusion.  To conclude, 
understanding diffusion processes and the diffusion coefficients of different nanomaterials, 
and different functionalities in a variety of different media is of fundamental importance in 
generating the next-generation medicines, storage devices and many other state-of-the-
art technologies.   
1.6 Aims and objectives  
Previous work in this area has shown that nanoparticle modification via PEGylation 
significantly enhanced particle diffusion through a range of mucosal tissues; however the 
mechanisms of mucus penetration, and how the properties of the particle/polymer corona 
can affect this permeation, have not been studied in depth.  It is thought that the surface 
charge/ζ-potential plays an important role in permeation but the work in this thesis shows 
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that other factors also need to be considered.254  Given that the physicochemical 
properties of  mucosa vary, depending on factors such as diet, geography, and disease 
states, the physicochemical properties of the environment around the particles also needs 
to be studied. 
The aim of this thesis was to design, synthesise and characterise a series of 
functionalised nanomaterials, and assess how their diffusion can be manipulated in a 
variety of different media, primarily focused on the development of novel nanomaterials for 
enhanced transmucosal delivery by the oral route.  By using diverse analytical tools, such 
as scattering techniques, NMR, microscopy, and particle tracking analysis, it was possible 
to further assess how the structure and functionality of these particles related to their 
diffusion, based on surface chemistry/composition of the particle, or solution properties of 
the surrounding media. 
To meet this overall aim, the following objectives were met: 
 Develop the nanoparticle tracking methodology. 
 Synthesise and characterise a library of polymer-functionalised silica 
nanoparticles.  
 Study the diffusion of inert gold nanoparticles in a solution of biocompatible 
polymers (Pluronics F-127) in order to gain insights into how nanoparticles behave 
in a complex mixture of polymer networks, and micelles. 
 Study the effects of temperature on the diffusion of temperature-responsive silica 
nanoparticles in a range of organic solvents with different polarities. 
 Finally, study the diffusion of mucus penetrating nanoparticles in mucin 
dispersions and asses their permeation through a gastric mucosa, using PEG as a 
standard.    
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Chapter 2    
Synthesis and characterisation of   
functionalised and unfunctionalised 
amorphous silica nanoparticles                                          
2.1 Introduction 
Silica nanoparticles are one of the most studied core-nanoparticle systems and are 
regularly used in both industry and academia.  Silica nanoparticles exist in two forms; 
crystalline and amorphous.  The most common form of crystalline silica is found naturally 
in the Earth in the form of quartz.  Crystalline silica particles (<10 µm) are often formed as 
by-products of industrial and chemical processes, and also found in soil samples.1  There 
have been many studies exploring the toxicity of crystalline silica, and it has been shown 
to be both toxic2 and carcinogenic.3–5  Epidemiological studies have demonstrated a large 
number of cases where crystalline silica has induced lung cancer via industrial exposure 
in many industries (including mining, work in the diatomaceous earth industry, agriculture 
and construction).1,6–8  For this reason it has little application in the food and 
pharmaceutical industries. 
Amorphous silica nanoparticles on the other hand, have a non-crystalline structure, and 
are used in a variety of applications in many different industries including cosmetics, 
paints, dental formulations, drug delivery, and bioimaging.9,10  This wide range in 
application stems mainly from their ease in synthesis, controllable particle size, tuneable 
surface moieties (allowing for further modification with other molecules), and reduced 
toxicity.11–13   
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The first report on the synthesis of silica micro/nanoparticles was by Stöber in 1968,14 who 
described the synthesis of silica particles by hydrolysing alkyl silicates followed by the 
condensation of silicic acid in alcoholic solutions with an ammonium catalyst.  It was found 
that by varying the alkyl chain length and the type of alcohol used, particles of varying 
sizes could be readily synthesised.  However, by producing larger particles, the particle 
size distribution widens and the particles become more polydisperse in nature.  Since then 
many reports on the synthesis of silica nanoparticles has been published, creating both 
small and large particles which are highly monodispersed in nature,  and ideal for 
biomedical applications.15–18   
By changing the progenitor chemical and reaction conditions used to synthesise the silica, 
it is possible to create particles with a variety of surface groups including; amine,19 
carboxyl,20 and thiol groups.21  Different surface functionalities aid in providing a more 
stable colloidal suspension and also allow for easy and more versatile modification with 
other molecules such as polymers.  In addition, by synthesising the core silica 
nanoparticles in the presence of a surfactant or a rod-like structure, it is possible to create 
porous particles, with a larger surface area, thus expanding their potential applications.15  
It is the diverse nature of silica nanoparticles which makes them an ideal model 
nanoparticle system to further investigate the effects of different polymer coatings on their 
diffusion through different systems, hence why they were chosen in this study.  
Core-shell silica nanoparticles, made-up of an amorphous silica core and polymer shell, 
are gaining concomitant popularity in the literature, as they allow for additional surface 
properties not shown by the core particle alone.  With the addition of a polymer corona to 
a nanoparticle, it is possible to manipulate their properties, allowing for controlled/modified 
release of a substance, increased biocompatibility, greater biodistribution, and/or targeted 
delivery.22,23  These functionalisations can make the particle more versatile by enhancing 
specific surface properties, and/or providing molecules for interactions with protein 
receptors and antibodies.  For drug delivery purposes, the addition of a polymer corona 
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around a particle is very interesting as it allows for increased biocompatibility and reduced 
toxicity, selected interactions with specific cellular targets, and controlled release of a 
formulation encapsulated inside the particle itself.24 
This chapter focuses on the synthesis of the core silica nanoparticles, and their further 
functionalisation with three polymers; poly(ethylene glycol), poly(2-oxazolines), and 
poly(N-isopropyl acrylamide).  In addition, information on their full characterisation is 
provided which was used for later experiments concerning their diffusion in different 
media, and penetration through biological barriers. 
2.2 Materials and methods 
2.2.1 Materials 
(3-Mercaptopropyl)trimethoxysilane (MPTS), 95% purity, alkyne terminated poly(2-ethyl-2-
oxazoline) (POZ), average molecular weight 5 kDa, maleimide terminated poly(ethylene 
glycol) (PEG)  average molecular weight 5 kDa, and maleimide terminated poly(N-
isopropyl acrylamide) (PNIPAM) average molecular weight 5 kDa were purchased from 
Sigma-Aldrich (Gillingham, UK).  Dimethyl sulphoxide (DMSO) was purchased from Fisher 
Scientific (UK).  All other chemicals and reagents (including solvents) used were of 
analytical grade or higher and were purchased from Sigma-Aldrich unless otherwise 
stated.  All water used in this study was ultrapure water generated from a PureLab UHQ 
water purification system (18 MΩ), unless otherwise stated. 
Part of this project involved collaboration with Prof Richard Hoogenboom from the 
University of Ghent.  In this study, Prof Hoogenboom provided three different variations of 
poly(2-oxazolines), namely; poly(2-methyl-2-oxazoline) (PMOZ), poly(2-ethyl-2-oxazoline) 
(PEOZ), and poly(2-n-propyl-2-oxazoline) (PNPOZ).  All three polymers were alkyne 
terminated and had a molecular weight of 5 kDa. 
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2.2.2 Synthesis of thiolated amorphous silica nanoparticles 
Thiolated silica nanoparticles were synthesised by self-condensation of MPTS according 
to previously published methods, with no further modification.21,25   0.75 mL MPTS was 
added to 20 mL DMSO, and reacted with 0.5 mL NaOH (0.5 mol/L).  The reaction mixture 
was left stirring at room temperature for 24 hours, whilst being continuously bubbled 
through with air.  The formation of nanoparticles could be observed by the formation of a 
translucent, white suspension. 
Following synthesis, the nanoparticles were purified by dialysis using a cellulose 
membrane with a molecular-weight cut-off of 12-14 kDa (Medicell International Ltd, UK).  
Particles were sealed inside the tubing and dialysed against 4 L deionised water, over a 
48 hour period.  A minimum of 8 water changes were carried out.  Following dialysis, 3x1 
mL aliquots were removed and frozen for lyophilisation.  The remainder were stored in the 
fridge at 4 oC until further use. 
2.2.3 Determination of reactive thiol content 
In order to effectively functionalise the nanoparticles with both polymer and fluorophore, 
the total concentration of reactive thiol groups present on the nanoparticles needed to be 
determined.  This was carried out using Ellman’s assay,26 by the method of Bravo-Osuna 
with minor modifications. 27   
Prior to the assay, a sample of the nanoparticle suspension required freeze-drying.  3x1 
mL samples were frozen before being placed in a Heto PowerDry LL3000 freeze drier and 
left for 48 hours.  Each 1 mL sample was then weighed and the dry weight of the particles 
recorded, providing an average concentration of particles (mg/mL).  The samples were 
then pooled together for further solid-state analysis. 
For Ellman’s assay, 3 mg lyophilised nanoparticles were resuspended in 10 mL 
phosphate buffer (pH 8, 0.5 mol/L) and left to incubate for 1 hour.  Following this 
incubation, 10x0.5 mL aliquots were removed and placed in Eppendorf tubes.  The 
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aliquots were then reacted with 0.5 mL 5,5'-dithiobis-(2-nitrobenzoic acid) (0.3 mg/mL) 
and left for a further 3 hours in the dark.  Samples were then centrifuged for 10 min at 
13,000 g to remove any dirt and dust, before the UV/vis absorbance was measured at 420 
nm. 
In order to quantify the total amount of free thiol groups, a calibration curve of cysteine-
HCl was recorded.  Cysteine-HCl was dissolved in phosphate buffer and then diluted into 
the following concentration range; 1.26, 0.63, 0.32, 0.16, 0.08, and 0.04 mmol/L.  Each 
sample was then reacted with 0.5 mL 5,5'-dithiobis-(2-nitrobenzoic acid) (0.3 mg/mL) and 
left for 3 hours.  The absorbance was measured at 420 nm.  In all cases, a blank of 0.5 
mL phosphate buffer and 0.5 mL 5,5'-dithiobis-(2-nitrobenzoic acid) was used which was 
subtracted from the absorbance of all other values during calculations.. 
2.2.4 Polymer functionalisation 
In this work, the thiolated silica nanoparticles were functionalised with 3 different 
polymers; PEG, POZ, and PNIPAM.  3 different isomers of POZ were used. 
2.2.4.1 PEGylation of silica nanoparticles 
PEGylated nanoparticles were synthesised according to Mun et al.28  To a 10 mL 
suspension of nanoparticles (5.5 mg/mL in water), was added 100 mg maleimide 
terminated PEG (5 kDa).  The mixture was reacted under constant stirring for 24 hours at 
ambient temperature, before being purified by dialysis, using the same procedure as 
described in section 2.2.2. 
2.2.4.2 POZylation of silica nanoparticles 
In total, 4 different polymers were used; poly(2-ethyl-2-oxazoline), purchased from Sigma-
Aldrich (PEOZ Sigma), as well as PMOZ, PEOZ, and PNPOZ, provided by Prof Richard 
Hoogenboom.   All the polymers used were alkyne-terminated.    
POZ-functionalised nanoparticles were used in two separate studies in this thesis; one 
comparing the diffusive capabilities of PEG and PEOZ (Sigma) through gastric mucus, 
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and the other comparing the diffusive properties of POZ macromolecules with different 
pendant groups.   
For synthesis of the POZylated particles used in the PEG vs POZ study, a 5 mL 
suspension of nanoparticles (5.5 mg/mL in water), was diluted into 5 mL DMSO, and 
reacted with 100 mg PEOZ, purchased from Sigma-Aldrich.  The reaction was catalysed 
by the addition of 200 µL triethylamine (TEA) and left for 24 hours.  Following completion, 
the sample was purified by dialysis as described in section 2.2.2.   
In a pilot study exploring different reaction times, it was found that leaving the particles 
reacting for 4 days rather than 1 resulted in a higher degree of polymer loading on the 
particle surface (assessed by thermal gravimetric analysis (TGA)).  Therefore, in the 
second study, investigating the effect of alkyl chain length on nanoparticle diffusion, 
reactions were left for 96 hours rather than 24 hours, using the same protocol described 
above.  This second study used the POZ macromolecules obtained from Prof. 
Hoogenboom. 
2.2.4.3 PNIPAM functionalised silica 
Here, a 5 mL suspension of silica nanoparticles (5.5 mg/mL) was diluted into 5 mL 
ultrapure water, before the addition of 100 mg PNIPAM.  The reaction was left stirring for 
24 hours at room temperature and purified by dialysis (as discussed in section 2.2.2). 
2.2.5 Size characterisation 
Two principle sizing techniques were used in this work; Dynamic Light Scattering (DLS) 
and Nanoparticle Tracking Analysis (NTA). 
2.2.5.1 DLS 
DLS is a light scattering technique which determines a hydrodynamic particle size based 
on a photon auto-correlation function and the refractive index of the sample.  This is used 
to determine a diffusion coefficient which is then used to calculate the hydrodynamic 
diameter of the particle using the Stokes-Einstein equation. 
66 
 
DLS measurements were recorded using a Zetasizer NanoZS (Malvern Instruments Ltd., 
UK).  Prior to functionalisation, a pilot study was carried out to determine the optimum 
dilution of nanoparticles used in this study.  The stock solution of silica nanoparticles was 
serially diluted by a factor of 10 each until readings became nonsensical.    It was found 
that a 1 in 10 dilution (from a 5.5 mg/mL stock solution of particles) provided accurate 
reproducible data, whereas 1 in 1,000 was the lowest level of detection. 
Based on the results of this test, a 1:10 dilution was used for all remaining DLS 
experiments.  Each nanoparticle suspension was diluted by 1:10 using ultrapure water 
into low-volume cuvettes (Fisher Scientific, UK) and placed in the DLS instrument.  All 
readings were recorded for an average of 12 runs, with 10 seconds per run.  This was 
repeated three times for each measurement.  3 independent samples were measured for 
each particle type.  In all cases, a refractive index of 1.432 was used (based on the works 
of van der Pol et al).29  The results are presented as the mean ± standard deviation of the 
determined z-average values for the independent repeats.  All experiments were 
performed at 25 oC. 
In addition to particle size experiments, the Zetasizer NanoZS was also used to determine 
the ξ-potential of the nanoparticle suspensions.  Again, a 1 in 10 dilution was used from 
stock, and the samples placed in DTS-1070 folded capillary tubes, which were sealed to 
prevent solvent evaporation.  Each measurement was carried out in triplicate over an 
average of 20 runs, which was repeated for 3 independent samples.  The results were 
processed using the Smoluchowski model (Fκa = 1.50), and presented as the mean ± 
standard deviation of three independent repeats.  Again, all experiments were performed 
at 25 oC. 
2.2.5.2 NTA 
In addition to DLS, a complimentary technique, NTA, was used to confirm the particle 
size.  NTA is a relatively new technique which tracks the movement of individual particles 
by shining a laser through a nanoparticle suspension, causing them to scatter light.  This 
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is then detected by a sCMOS camera attached to a microscope.  Video recordings are 
made of the particles moving under Brownian motion, particles are tracked on a frame by 
frame basis, with the number of pixels that a particle crosses in a given period of time 
recorded.  This distance is used to determine the mean-squared displacement (MSD) for 
the particle, which is then used to derive the diffusion coefficient, followed by a particle 
size (again using the Stokes-Einstein equation). 
As NTA requires particles to be tracked individually, the dilution generally needs to be 
much greater than that of a DLS experiment.  As this can vary from sample to sample 
(depending on initial concentration), the correct dilution was determined on a sample by 
sample basis.  The unfunctionalised thiolated silica and PEGylated silica were diluted 
1:50,000 (from a 5.5 mg/mL stock solution of particles), and the POZylated and PNIPAM-
silica nanoparticles were diluted 1:10,000; so around 20-40 particles were detected on the 
screen at any given time.  All samples were diluted in ultrapure water. 
NTA experiments were carried out using a NanoSightLM10 system (Malvern Instruments 
Ltd., UK), with an LM14 laser module, metal top-plate, green 532 nm laser, syringe pump, 
and sCMOS camera.  1 mL of diluted nanoparticle suspension was injected into the NTA 
system using a plastic syringe, before inserting the syringe into the syringe pump.  For 
each sample, 6 x 60 second videos were recorded whilst under a constant flow of 30 AU.  
Each video was then analysed using the NTA software (v3.0 or 3.1) to determine a modal 
particle size.  In addition to size, the diffusion coefficient for the nanoparticles was 
determined.  Data are presented as mean ± standard deviation of three independent 
repeats (using the modal particle size and diffusion coefficient generated in the report 
summary).  All experiments were performed at 25 oC. 
2.2.6 Surface functionality 
To confirm the presence of polymer in a sample of lyophilised nanoparticles, Fourier 
transformed infrared spectroscopy (FT-IR), and Fourier transformed Raman spectroscopy 
(FT-Raman) were used.  In addition, TGA was used to estimate the degree of polymer 
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loading, and used as further confirmation of polymer presence, by assessing the degree 
of thermal decomposition compared to that of unfunctionalised silica and free polymer. 
2.2.6.1 FT-IR 
FT-IR experiments were performed on a Spectrum 100 FT-IR spectrometer (Perkin Elmer, 
UK).  A small amount of lyophilised (solid) nanoparticles were placed on the sample 
holder and spectra were recorded over an average of 32 runs, at a resolution of 4 cm-1.  
Prior to analysis, a background of air was recorded and subtracted from the recorded 
spectra.  Spectra were recorded between 4000 and 550 cm-1. 
2.2.6.2 FT-Raman 
FT-Raman experiments were performed on a Nicolet NXR 9650 Raman spectrometer 
(Thermo Scientific, UK).  Prior to analysis, the instrument was calibrated against a sulphur 
standard until a clear signal was present.  For sample analysis, lyophilised nanoparticles 
were placed in glass HPLC vials, about a quarter full and tapped to remove any air 
pockets.  They were then loaded into the instrument, and spectra recorded over an 
average of 1000 scans, between 4000 and 10 cm-1, at a resolution of 4 cm-1. 
2.2.6.3 TGA 
TGA experiments were performed on a Q500 instrument (TA Instruments, UK) using 
nitrogen as an inlet gas.  Before analysis, the instrument was calibrated against an empty 
platinum TGA pan, loaded with an empty Tzero aluminium DSC pan.  Lyophilised 
nanoparticles were then placed into the empty DSC pan, ensuring even coverage of the 
bottom of the pan.  This was then loaded back into the TGA pan, and loaded into the 
instrument.  Thermal decomposition was measured by a temperature ramp between 35 
and 500 oC at 10 oC/min. In addition to lyophilised nanoparticles, samples of the polymer 
alone were measured to identify the point of thermal decomposition. 
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Polymer loading was determined by subtracting the weight loss observed for the 
unfunctionalised silica nanoparticles from the weight loss seen for the functionalised silica 
nanoparticles.  This was then expressed as a percentage of total mass. 
2.2.6.4 Solid-state NMR 
In addition to the characterisation experiments already discussed, solid-state NMR 
experiments were carried out to determine how the POZ macromolecules were bound to 
the silica core.  Given that a new chemistry was developed for POZ-functionalisation, this 
technique acts as an extra level of proof, confirming the binding of the macromolecule to 
the particle.  This study used freeze-dried thiolated silica and POZ-silica nanoparticles, 
and was compared to a kaolinite standard.  29Si solid state NMR spectra were recorded 
using a Bruker 500 MHz Avance III spectrometer at a Larmor frequency of 99.35 MHz 
(11.75 T), that of 29Si.   
Single pulse magic angle spinning (SPMAS) spectra were recorded, where the standard 
bore 4 mm MAS probe was spun at 10 kHz.  The 29Si 90° pulse length was 6.25 µs 
(at the power level of 67.86 W) and the relaxation delay time was 150 s.  In 
addition, cross-polarisation magic angle spinning (CPMAS) measurements were 
performed, where the 1H 90° pulse length was 3.7 µs (at the power level of 38 W).  
The CP contact time was 3 ms and the relaxation delay time was 5 s.  Between 500 
and 4096 signal transients were accumulated, averaged into a single spectrum and 
analysed using the TopSpin software.  All spectra were referenced to external kaolinite 
signals as a secondary reference (well resolved peaks at -90.0 ppm and -91.4 ppm with 
respect to TMS). 
2.3 Results and discussion 
2.3.1 Functionalisation and reaction mechanisms 
Amorphous thiolated silica nanoparticles were chosen as a model nanoparticle, due to 
ease and cost effective synthesis, as well as containing a high concentration of reactive 
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thiol groups for further functionalisation with different polymers. Two different synthetic 
pathways were utilised in the functionalisation reactions; maleimide-thiol conjugation (for 
PEG and PNIPAM), and alkyne-thiol conjugation (for POZ). 
The maleimide-thiol conjugation is a very well characterised reaction which produces high 
yields in short periods of time.30,31  The mechanism of the thiol-maleimide reaction is 
shown in Fig 2.1.   
Fig 2.1 Reaction mechanism for the maleimide-thiol addition.  The carbon double bond in the 
aromatic ring is attacked by the thiol group, causing a covalent interaction between the sulphur 
atom and the maleimide ring. 
 
The reaction is a Michael addition, where the highly reactive carbon double bond in the 
aromatic ring is attacked by the thiol nucleophile, causing a covalent interaction between 
the sulphur atom and the maleimide ring.  This reaction is widely used in click-chemistry 
applications due to the high speed and good favourability resulting in high yields. 30,32 
In addition to the maleimide-thiol reaction, a less common synthetic pathway was used in 
the conjugation of alkyne-terminated POZ’s to the thiolated silica nanoparticles.  Here, the 
thiol group is activated by the TEA molecule via hydrogen bonding which causes the thiol 
to become a stronger nucleophile, which then reacts with the alkyne forming a covalent 
bond.  Simultaneously the alkyne dissociates the thiol-TEA bond, releasing the catalyst 
(summarised in Fig 2.2).  It is possible (dependent on the proximity of the thiol groups to 
each other) that the resulting alkene formed in the reaction can further react with a thiol 
Thiolated 
particle 
Maleimide-terminated 
polymer 
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group, eliminating all double bonds in the system.  However, this secondary reaction is 
highly dependent on the proximity of the thiol groups.  Given that the length of a carbon-
sulphur bond is 1.82 Å, this pathway is highly unlikely.33  This reaction has previously been 
used in the literature by Ganivada et al,34 who created 3D gel networks using an thiol-
alkyne reaction catalysed by TEA.  
 
Fig 2.2 Reaction mechanisms for the alkyne-thiol reaction catalysed by TEA.  The thiol group 
is activated by the TEA molecule via hydrogen bonding which causes the thiol to become a 
stronger nucleophile.  This reacts with the alkyne forming a covalent bond.  Simultaneously the 
alkyne dissociates the thiol-TEA bond, releasing the catalyst.  A secondary reaction between the 
formed alkene and an adjacent thiol group could occur, eliminating all double bonds in the system.   
 
2.3.2 Polymer loading 
To assess the degree of functionalisation of polymer onto nanoparticle surface, two 
techniques were used; TGA (to measure the amount of polymer present in a pure sample 
of nanoparticles), and Ellman’s assay (to assess the number of free thiol groups before 
and after functionalisation). 
TEA 
Alkyne-terminated 
polymer 
Thiolated 
particle 
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2.3.2.1 TGA 
TGA was used to estimate the degree of functionalisation based on the thermal 
decomposition of the unfunctionalised and functionalised nanoparticles.  By comparing the 
weight loss exhibited by the unfunctionalised silica and the functionalised silica, it is 
possible to calculate the amount of polymer present in the sample.  Fig 2.3 shows the 
thermal decomposition of the functionalised and unfunctionalised silica nanoparticles. 
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Fig 2.3 TGA graphs showing the thermal decomposition of functionalised, unfunctionalised 
nanoparticles, and the free polymer.  A) shows thiolated, PNIPAM, and PNPOZ silica 
nanoparticles.  B) Shows thiolated, PEGylated and POZylated silica nanoparticles. C) shows 
thiolated, and POZylated silica nanoparticles. 
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As can be seen, upon functionalisation there are significant differences in the thermal 
decomposition of the nanoparticles.  This suggests the addition of another species, such 
as a polymer in the system; further confirming the functionalisation of the nanoparticles. 
By calculating the % difference between weights before and after decomposition and 
subtracting the weight loss from thiolated silica alone, it is possible to determine the 
amount of polymer present on the particle surface.  This was carried out using Equation 
2.1. 
%𝑝 =
𝑊0(𝑝)−𝑊𝑓(𝑝)
100
−
𝑊0(𝑠)−𝑊𝑓(𝑠)
100
   Equation 2.1 
Where %p is the amount of polymer present in the sample, Wo(p) is the weight of the 
polymer functionalised particles at the start before thermal decomposition, Wf(p) is the 
weight of the polymer functionalised particles after the thermal decomposition, Wo(s) is 
the weight of the thiolated silica particles at the start before thermal decomposition, and 
Wf(s) is the weight of the thiolated silica particles after thermal decomposition.  Similar 
calculations have been used in the literature to determine the degree of polymer loading 
onto functionalised nanomaterials.41–43 
From this equation, the %-loading of the polymers onto the nanoparticle surface was 
determined (Table 2.1). 
Table 2.1 Percentage loading of polymers onto the nanoparticle surface based on TGA data 
Nanoparticle composite % loading 
PEG-silica 35% 
POZ-silica 12% 
PNIPAM-silica 36% 
PMOZ-silica 29% 
PEOZ-silica 37% 
PNPOZ-silica 33% 
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From the data in Table 2.1, it is clear that the maximum loading onto the nanoparticle 
surface appears to be between 30-40%, with one exception.  The reason for this cap 
around 30% could be due to steric hindrance around the particle.  As the particles are 
very small, only a limited amount of polymer can penetrate through to the particle and 
react with the thiol groups. 
The initial reaction for POZ-grafting onto a nanoparticle surface was 12%, however 
following some further grafting experiments; it was found that by extending the reaction 
time, and the degree of polymer loading was increased (from 12 to ca. 35%).  This is why 
the reaction time changed from 24 hours initially to 96 hours. 
TGA analysis was used in this study for two reasons; 1) to act as a further proof for the 
presence of polymer on the nanoparticle surface, and 2) to quantify the degree of polymer 
loading onto the nanoparticle surface based on the thermal decomposition of the samples, 
in relation to the unfunctionalised silica samples. 
2.3.2.2 Ellman’s assay 
Ellman’s assay can be used to determine the concentration of free thiol groups in a 
system.  There are many examples in the literature of where this assay has been used in 
determining the reactive thiol content in polymers,44 nanoparticles,45 and proteins.46  Here 
it was used to quantify the reactive thiol content both before and after nanoparticle 
functionalisation to determine; 1) the reactive thiol content available for functionalisation 
and fluorescent labelling, and 2) a reduction in reactive thiol content after functionalisation 
to confirm polymer binding.  Fig 2.4 shows the calibration curve used to determine the 
total concentration of free thiol groups, and Fig 2.5 shows the reactive thiol content for 
each particle type used in this study, determined using Ellman’s assay. 
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Fig 2.4 Calibration curve used to determine the concentration of reactive thiol groups.  Mean 
± standard deviation, n=3. 
 
Fig 2.5 Concentration of reactive thiol groups present on the surface of the functionalised 
and unfunctionalised silica nanoparticles.  Mean ± standard deviation, n=3 *P<0.05. 
 
As can be seen (Fig 2.5), there is a significant reduction (P<0.05)  in reactive thiol content 
from the unfunctionalised silica (210 ± 47 µmol/g) to the functionalised silica (93 ± 13 
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µmol/g for PEGylated silica, 128 ± 10 µmol/g for PNIPAMated silica, and ~20 µmol/g for 
POZylated silica). 
Based on these values it is clear there is a reduction in reactive thiol content confirming 
the binding of polymer to the particles.  Despite this, it is interesting to note that there is a 
clear difference in the amount of reactive thiol groups between the different samples.  
PEGylated silica has a final reactive thiol content of 93 ± 13 µmol/g, whereas POZylated 
silica has a final concentration of ~20 µmol/g.  The reason for this could be two-fold.  
Firstly, it is possible that the alkyne group is reacting with two thiol groups (as seen in the 
second reaction step in Fig 2.2).  Upon formation of the initial C-S bond, there is still the 
presence of a C=C linkage on the end group of the polymer.  It is possible that this moiety 
could further react with another thiol group, theoretically causing two sulphur atoms to 
bind to a single POZ molecule.  However in order for this to be the case, the sulphur 
atoms would have to be in very close proximity, as C-S typically has a bond length of ~1.7 
Å in length,47,48 depending on the spatial arrangement of the atoms.  Although there is a 
high density of free thiol groups on the particle surface, it is unlikely they are close enough 
together to form these bonds.  The more likely reason is due to the size of the end group.  
The alkyne moiety is much smaller than the maleimide moiety, so there will be a greater 
degree of steric hindrance around the particle surface for the PEG and PNIPAM polymers 
compared to POZ. 
2.3.3 Particle size 
Particle size was determined using both DLS and NTA and compared to gain a 
comprehensive estimation on the overall particle size. 
2.3.3.1 DLS 
DLS is a light scattering technique where a laser is shone through a suspension of 
particles which causes the laser light to scatter (Rayleigh scattering).   Fluctuations in the 
scattering, due to particles moving under Brownian motion, are measured at specific time 
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intervals, which are then fitted to an autocorrelation function.  A diffusion coefficient is then 
determined using Mie theory (based on this autocorrelation function and the refractive 
index of the sample), followed by a particle size using the Stokes-Einstein equation. 
The data in Fig 2.6 shows the particle size distribution of the functionalised nanoparticles 
used in this study, compared to the unfunctionalised silica nanoparticles (shown in blue in 
all cases).  For comparison, each particle size distribution has been separated into the 
specific chapter where that particle type will be used.  In addition to the size distributions, 
the z-average values, PDI’s and ξ-potentials of each sample were also determined using 
DLS (Table 2.2).   The relevant particle size information is provided at the start of the 
results section in which that population of particles was used.  
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Fig 2.6 DLS size distributions for unfunctionalised thiolated silica nanoparticles and 
functionalised nanoparticles. A) shows the particles used in Chapter 4, B) shows the particles 
used in Chapter 5, and C) shows the particles used in Chapter 6.  (Mean, n=3) 
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Table 2.2 DLS data for both functionalised and unfunctionalised silica nanoparticles.  (Mean 
± standard deviation, n=3) 
Nanoparticle 
z-average 
(nm) 
PDI 
ξ-potential 
(mV) 
Thiolated silica 52±1 0.072±0.003 -46±2 
PNIPAM-silica 70±1 0.111±0.004 -29±1 
PNPOZ-silica 61±1 0.194±0.018 -21±2 
*PEG-silica 70±1 0.175±0.070 -24±1 
PMOZ-silica 61±4 0.188±0.046 -23±1 
*PEOZ-silica (Sigma) 56±1 0.117±0.015 -22±3 
PEOZ-silica 59±4 0.106±0.012 -20±2 
*It should be noted that these particles used a separate batch of stock thiolated nanoparticles for 
synthesis.  However no significant difference was noted between the two in all parameters. 
 
As can be seen, upon functionalisation there is a significant (P<0.05, Student’s T-test) 
increase in particle size, as is mimicked in the size distributions shown in Fig 2.6.  These 
stats were determined using a standard Student’s T-test.  The size increase is due to the 
addition of a polymer onto the particle surface which increases the hydrodynamic radius of 
the particles.  Despite all the polymers being 5 kDa, it would be expected that the final 
particle sizes be relatively similar.  Although this is the case for the PNIPAM and PEG 
functionalised silica, it varies for the POZ-functionalised silica.  This is further explored in 
chapter 6, and is due to the way the polymer binds to the particle.  In the case of PEG and 
PNIPAM, a brush border is formed, but for POZ, the polymer wraps around the particle. 
In addition to the change in size, there are also changes in ξ-potential and PDI.  ξ-
potential is a measure of particle stability, and is the difference in electric potential of a 
particle at the interface of the slip plane (the outermost hydration layer of a particle) and 
that of the bulk solvent (depicted in Fig 2.7).35 
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Fig 2.7 Dynamics of a particle and its solvation shell.  The Difference between the 
hydrodynamic particle size and the particle diameter, and the location of the slip plane (yellow) 
surrounding the hydration shell. 
 
The data in Table 2.2 shows a significant change (P<0.05,) in ξ-potential upon 
functionalisation (from -42 ± 2 mV to around -20 mV).  Upon functionalisation the charge 
around the particle will change, thus causing a change in zeta potential.  As the particles 
synthesised in this study are highly negatively charged (due to the large presence of 
surface sulphur and Si-O-Si moieties), the overall charge will be reduced after 
functionalisation as these groups will be masked by the polymer.   
Alongside ξ-potential, a change in PDI is also observed.  PDI (polydispersity index) is a 
measure of how monodispersed a colloidal suspension is.  A sample with a low PDI (<0.2) 
is considered monodisperse in nature, where the particles are of a uniform size and are 
not aggregated.  A larger PDI (between 0.2 and 1) shows that the particles are more 
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polydisperse, meaning a sample of multiple different sizes, aggregation or contamination, 
and is based on a fit to the correlation data.36   
The PDI is calculated based on the mean and standard deviation particle size generated 
during data processing, and not from the particle distribution.  As can be seen in Table 
2.2, the unfunctionalised silica particles are highly monodispersed with a PDI of 0.07 ± 
0.003.  Upon functionalisation, the PDI increases to a maximum of 0.194±0.018, shown 
for the PNPOZ-silica particles.  This increase was unexpected, as by functionalising 
nanoparticles they are becoming more stable and less likely to aggregate, hence the PDI 
should decrease.  By functionalising a particle, the polymer should act as a protective 
barrier around the particle, reducing the surface interactions between particles, thus 
generating a more stable suspension.  This is due to a reduction of intermolecular forces 
existing between individual particles, which would usually cause them to aggregate. 
However, upon functionalisation (as has already been discussed), there is a drop in zeta 
potential suggesting a decrease in stability in the sample, which could encourage 
aggregation.  The particles exist as a highly negative species in suspension (shown by the 
low ξ-potential), which lessens upon functionalisation.  Therefore, this decrease could 
reduce repulsion, encouraging particle interactions, thus increasing the PDI. 
From the DLS data, it is clear that the particles change size following functionalisation, 
suggesting successful modification.  In addition to DLS data, further sizing experiments 
were carried out using NTA to establish a more robust indication of particle size. 
2.3.3.2 NTA 
NTA is a complimentary particle sizing technique to DLS.  Here, a laser is fired through a 
suspension of particles and the light scattered off them is detected by a camera.  This 
allows videos to be recorded, showing the movement of the particles over a given period 
of time.  During analysis, individual particles are tracked, and from the speed at which the 
particles are moving, a diffusion coefficient and particle size can be calculated.  As the 
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technique requires individual particles to be tracked, a very low concentration of 
nanoparticles is required (in these experiments samples were diluted by at least 1:10,000, 
and then adjusted for optimum concentrations). 
Similar to DLS, size distributions can be determined (Fig 2.8), in addition to the mean and 
modal particle size (Table 2.3), complementing the z-averages form DLS.  Along with the 
particle size, the diffusion coefficient of the particles in an aqueous environment can be 
determined (Table 2.3).  Also shown in Table 2.3, are the calculated diffusion coefficients 
for the particles in water, based on the particle size determined by NTA.  For all sizing 
experiments, a standard operating procedure (SOP) was written and applied ensuring all 
data were collected under the same circumstances to minimise error. 
Table 2.3 NTA data for both functionalised and unfunctionalised silica nanoparticles.  Mean 
± standard deviation, n=3. 
Nanoparticle 
Modal 
particle size 
(nm) 
Experimental 
diffusion coefficient 
(x104 nm2/s) 
Calculated     
diffusion coefficient 
(x104 nm2/s) 
Thiolated silica 54±1 788±20 908 
PNIPAM-silica 63±3 698±29 778 
PNPOZ-silica 58±1 811±33 811 
PEG-silica 62±2 687±41 791 
PMOZ-silica 61±4 798±2 817 
PEOZ-silica (sigma) 57±2 744±82 860 
PEOZ-silica 59±1 787±28 831 
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Fig 2.8 NTA size distributions for unfunctionalised thiolated silica nanoparticles and 
functionalised nanoparticles. A) shows the particles used in Chapter 4, B) shows the particles 
used in Chapter 5, and C) shows the particles used in Chapter 6.  Mean n=3. 
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The PEG-silica and PNIPAM-silica nanoparticles however do show some discrepancy in 
particle size between the two techniques.  The PEGylated silica by DLS has a size of 
70±1 nm, whereas by NTA it has a size of 62±2 nm.  Likewise, the PNIPAM functionalised 
silica show sizes of 70±1 and 63±3 for DLS and NTA, respectively.  This discrepancy, 
although only 7 nm, is probably due to the way the data is collected, and was not 
statistically significant (P<0.05, Student’s T-test).  Both NTA and DLS are light scattering 
technique, however NTA uses scattered light to track particle movement over a given time 
period, whereas DLS uses an auto-correlation function to determine particle size.  
Therefore it is likely that background light is causing the NTA particle sizes to appear 
lower than DLS.  Despite this, the DLS and NTA size data corroborate each other, and 
provide accurate definitions on the size of the nanoparticles used in this study. 
In addition to the values shown in Table 2.3, the size distributions obtained for 
functionalised and unfunctionalised nanoparticles (blue), show a difference upon 
functionalisation, corroborating the size distributions obtained for DLS.  This further 
confirms successful conjugation of the polymer to the particle surface.  As NTA tracks 
individual particles, it is possible to obtain a more realistic size distribution compared to 
DLS.  
NTA can also be used to determine the diffusion coefficient of nanoparticles suspended in 
a given media.  Also shown in Table 2.3, are the diffusion coefficients of functionalised 
and unfunctionalised silica nanoparticles in water.  Comparing the experimental and 
theoretical diffusion coefficients, it is clear that there are discrepancies.  It would be 
expected that as the particle size increases, the diffusion coefficient also decreases, as 
larger particles move less rapidly under Brownian motion.  This can be seen in Fig 2.9, 
which shows the calculated diffusion coefficient of different sized nanoparticles as 
determined using the Stokes-Einstein equation.  For the calculation, the temperature was 
assumed to be 25 oC, and viscosity was 0.89 cP (that of water at 25 oC).  An example of 
how the calculation was carried out can be found in Fig 2.9. 
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𝐷𝑐 =
𝑘𝐵𝑇
3𝜋𝜂𝑑
 
𝑘𝐵 = 1.38 × 10
−23 𝑚2 kg ∙ 𝑠−2𝐾−1 
𝐷𝑐 =
1.38 × 10−23 × 298.15 
3𝜋 × (8.9 × 10−4)  × (5 × 10−8)
 
𝐷𝑐 = 9.8 × 10−12 𝑚/𝑠  
𝐷𝑐 = 981 × 104 𝑛𝑚2/𝑠  
Fig 2.9 Calculation to determine the diffusion coefficient based off the Stokes-Einstein 
equation, and the diffusion coefficient for particles in water.  The calculation is a step-by-step 
guide on how the diffusion coefficient was calculated based on 50 nm particles suspended in water 
(viscosity = 0.89 cP) at 25 
o
C (298.15K). 
 
The experimental diffusion coefficients for PMOZ-silica, PEOZ-silica, and PNPOZ-silica 
are all in good agreement with the calculated diffusion coefficients.  However, the diffusion 
coefficients for thiolated silica, PNIPAM-silica, PEG-silica and PEOZ-silica (Sigma) appear 
different.  Interestingly, in all cases the diffusion coefficient appears to be 100 x104 nm2/s 
lower in each case.  The likely reason for this is the applicability of the Stokes-Einstein 
equation.  As discussed in Chapter 1 (section 1.2.4), the equation has some limitations i.e. 
it assumes that all particles are spherical; the same size and are moving under constant 
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laminar flow.37  By deviating from these required conditions, the calculated diffusion 
coefficient will differ from the experimentally determined one, a phenomenon which has 
been reported in the literature before.38,39  In addition to this, looking at the shape of the 
bell-curves (Fig 2.8) and the fact that peaks become visible (at ~30 nm for thiolated silica, 
and >100 nm for the functionalised particles), it is obvious that there are populations of 
different sized particles in the suspension, likely due to either background noise or 
vibrations in the environment.  Considering NTA is a particle-tracking technique, any 
vibrations in the local environment could cause the particles to move unnaturally (i.e. not 
under Brownian motion).  These vibrations could alter the movement of the particles, 
causing bias in the data set.  Although the particles would be the same size, the vibrations 
would make them appear to be different sizes.  This will also change the experimental 
diffusion coefficients, making them appear different to what they are naturally.  The 
presence of larger particles (possibly due to aggregation) in the suspension alters the 
shape of the bell curve, and gives rise to small secondary peaks (Fig 2.8).  It is the 
presence of these smaller peaks which could also explain the difference in diffusion 
coefficient between experimental and predicted values. 
The NTA size data presented here is in good agreement with the DLS data.  From the 
size increase between functionalised and unfunctionalised nanoparticles determined by 
two independent techniques, it is clear that the polymer has successfully been conjugated 
to the nanoparticle surface. 
2.3.4 Particle functionality 
In order to further probe this particle size increase, and determine the presence of the 
polymer alongside the amorphous silica nanoparticles, FT-IR and FT-Raman 
spectroscopy were carried out. 
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2.3.4.1 FT-IR spectroscopy 
FT-IR analysis was carried out on lyophilised samples of nanoparticles in order to confirm 
the presence of the polymer in the sample along with the nanoparticles themselves.  The 
spectra (Figs 2.10, 2.11, and 2.12) were also compared to free polymer (shown in brown 
in all cases) and the free unfunctionalised nanoparticles (blue). 
 
Fig 2.10 FT-IR spectra for thiolated, PEGylated and POZylated silica nanoparticles.  PEG and 
POZ were purchased from Sigma-Aldrich. 
 
Fig 2.10 shows the spectra for thiolated, PEGylated and POZylated silica.  The spectrum 
of the thiolated silica (blue) shows two major peaks at 1032 and 1102 cm-1; these appear 
in all spectra for the thiolated silica and represent the Si-O-Si stretches from the 
disiloxane.  Due to the complex nature of the siloxane moiety in the nanoparticles, 
because of different functionalities attached to the silicon atoms, they exhibit two distinct 
features between 1300 and 1000 cm-1.40  This agrees well with the nanoparticle structure 
proposed by Irmukhametova et al.21 
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Both of these peaks appear in the other spectra for functionalised particles (red and 
green) confirming the presence of the silica nanoparticles in these samples.  By 
comparing the peaks that appear in these samples to that of the free polymer (shown in 
brown and grey) it is possible to further identify the polymer presence in the funcitonalised 
sample. 
In the PEGylated silica (red) spectrum, there is the emergence of several peaks, most 
noticeably; 2876 cm-1 (CH2), 1702 cm-1 (C=O), 1642 cm-1 (aliphatic C-C), 1342 cm-1 (C-O-
C), and 1242 cm-1 (aliphatic C-N).  These peaks also appear in the spectrum for 
unfunctionalised polymer.  The presence of the C=O stretches (from the ketone in the 
maleimide) and C-O-C (ether vibrations), along with the peak representing the Si-O-Si 
bonds in the silica particle, clearly demonstrate the successful functionalisation of the 
nanoparticles with PEG. 
Similarly,  for the POZylated silica spectrum (Fig 2.10), the presence of peaks at 2940 cm-
1(CH2), 1630 cm-1 (C=O),1476 cm-1 (C-H), 1422 cm-1 (CH3),and 1236 cm-1 (C-N) 
demonstrate the presence of POZ in this sample.  Once again the presence of the Si-O-Si 
stretches at 1032 and 1102 cm-1 show the presence of the silica nanoparticle.  The signal 
generated by the alkyne end group on the polymer is very weak and not detectable.  The 
peaks present for the POZylated silica (green) also appear in the spectra for 
unfunctionalised POZ, further illustrating the presence of the polymer in the sample. 
The next set of spectra to be analysed are those concerning the POZ macromolecules 
with different pendent groups (Fig 2.11).  In this case, the spectra were compared to the 
unfunctionalised silica nanoparticles (blue), and also that of the PEOZ (Sigma) sample.  
PEOZ (Sigma) was chosen as a comparison due to a larger abundance of polymer 
compared to those obtained from Prof Richard Hoogenboom.  As the macromolecules 
only vary by a single methyl group, the spectra should all be relatively similar. 
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Fig 2.11 FT-IR spectra for unfunctionalised thiolated silica and POZylated silica 
nanoparticles.  POZ samples were synthesised by Richard Hoogencoom. 
 
Again, by comparing the spectra obtained for the unfunctionalised silica with those of the 
functionalised silica, there are clear differences.  As with the previous spectra for thiolated 
silica, there are principle peaks at 1120 and 1089 cm-1, representing the Si-O-Si 
disiloxane moiety.  In addition to this, some other smaller peaks appear in the nanoparticle 
structure at 2923 cm-1(C-H), 1237 cm-1(C-O), and 687 cm-1(Si-S). 
As with the spectra for the POZylated nanoparticles (Fig 2.10), upon functionalisation 
several distinct peaks appear; 2978 cm-1(CH2), 1629 cm-1 (C=O),1463 cm-1 (C-H), 1416 
cm-1 (CH3),and 1236 cm-1 (C-N).  Again these peaks are seen in the unfunctionalised 
polymer itself (black, Fig 2.10).  The spectra for the different variations of POZ (PMOZ, 
PEOZ, and PNPOZ) all have the same peaks, most noticeably the large C=O peak at 
~1600 cm-1. This again illustrates successful functionalisation of POZ to the silica particle. 
The final spectra compare PNIPAM functionalised silica, PNPNOZ functionalised silica 
and unfunctionalised thiolated silica (Fig 2.12). 
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Fig 2.12 FT-IR spectra for thiolated, PNPOZylated, and PNIPAM silica nanoparticles.  PNPOZ 
was synthesised by Richard Hoogenboom, and PNIPAM was purchased from Sigma-Aldrich. 
 
The spectrum for PNIPAM functionalised silica nanoparticles (Fig 2.12, green) has 
predominant peaks at 3298 cm-1 (aliphatic C-H), 1632 cm-1 (C=O), 1535 cm-1 (N-H), and 
1459 cm-1 (aliphatic C-C).  These features are not seen in the spectrum of 
unfunctionalised silica and therefore demonstrate the presence of PNIPAM bound to the 
silica particle.  In addition, to confirm the presence of the silica, the peaks at 1032, 1102 
and 695 cm-1 represent the two peaks for Si-O-Si, and one for Si-S, respectively.  The 
peaks representing the bound PNIPAM are also seen in the unfunctionalised PNIPAM 
(Fig 2.12, black), confirming that the additional peaks are indicative of PNIPAM.  The 
PNPOZ-silica particles used in this study were the same as was discussed for Fig 2.11. 
2.3.4.2 FT-Raman spectroscopy 
FT-Raman is often used as a complementary technique to FT-IR spectroscopy, and 
allows for the detection of homopolar bonding vibrations such as C=C, and is also more 
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sensitive to sulphur and silicon based vibrational modes than FT-IR.   Fig 2.13 shows the 
spectra for unfunctionalised silica, PEGylated silica, and POZylated silica along with the 
spectra for the free polymer.   
 
Fig 2.13 Raman spectra for thiolated (blue), PEGylated (red), and POZylated (green) silica 
nanoparticles.   
 
Again there are marked differences between the functionalised and unfunctionalised 
particles.  The emergence of several peaks in the spectra for functionalised particles that 
are also present in the spectra for unfunctionalised polymer, confirm polymer presence.  
The spectrum for thiolated silica (blue), shows principle  peaks at 2880 cm-1 (C-H), 2510 
cm-1 (S-H), 1400 cm-1 (CH2), 1310 cm-1  (C-C), 1250 cm-1 (C-C), 631 cm-1 (C-S), and ~500 
cm-1 (Si-O-Si and S-S).   
As with the spectra for unfunctionalised silica,  the spectrum of the PEGylated silica (red), 
shows the peaks at 2900 cm-1 (C-H), 2560 cm-1 (S-H), 1480 cm-1 (CH2), 1280 cm-1 (C-C), 
646 cm-1 (C-S), and ~500 cm-1 (Si-O-Si and S-S) are clearly present, confirming the 
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presence of the thiolated silica.  The minor discrepancies in peak positions for the two 
spectra could be two-fold; firstly (as the peaks are fairly small in some cases, they were 
not accurately measured, and secondly that the binding of the polymer has caused a shift 
in peak position.  The latter is especially true as some of the peaks for unfunctionalised 
nanoparticles and polymer appear in both, namely those representing; C-H, CH2, and C-C 
groups.  In actuality, this discrepancy is likely to be a combination of both these factors. 
However there are two additional peaks at 1140 cm-1 and 847 cm-1, representing the 
asymmetrical C-O-C and C-O-C stretch respectively.  The presence of these two peaks 
confirms the presence of the ether in PEG, and therefore demonstrates that PEG is 
present in the sample.  Interestingly the peak representing the thiol groups in this spectra 
appear larger than in the unfunctionalised silica nanoparticles.  This is unexpected as 
there should be a reduction in the number of free thiol groups due to polymer binding 
(demonstrated by Ellman’s assay, and increase in particle size).  This change is down to 
intensity from the sample, which was greater in PEGylated silica than in the 
unfunctionalised silica. 
Similarly for the spectrum of POZylated particles (green), as with the PEGylated and 
thiolated silica spectra, there are peaks at 2900 cm-1 (C-H), 2530 cm-1 (S-H), 1420 cm-1 
(CH2), 1250 cm-1 (C-C), 646 cm-1 (C-S), and ~500 cm-1 (Si-O-Si and S-S).  As before 
these are from the silica particle.  The addition of the peak at 1620 cm-1 (C=O) confirms 
the presence the amide group in POZ.   
The Raman spectra in Fig 2.14 are from the different variations of POZ functionalised to 
the silica particles. 
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Fig 2.14 Raman spectra for thiolated and POZylated silica nanoparticles.   
 
For the thiolated silica (blue), as before there are several distinct peaks; 2898 cm-1 (C-H), 
2555 cm-1 (S-H), 1406 cm-1 (CH2), 1294 cm-1  (C-C), 1242 cm-1 (C-C), 627 cm-1 (C-S), and 
~500 cm-1 (Si-O-Si and S-S).  After functionalisation with PMOZ, PEOZ, and PNPOZ it is 
possible to see two distinct changes; firstly a decrease in the size of the peak at 2555 cm-1 
(S-H), suggesting a decrease in the number of reactive thiol groups (confirmed with 
Ellman’s assay, section 2.3.2), and secondly the emergence of two new peaks; 1631 cm-1 
(C=O), and 1024 cm-1 (C-C vibrations).  These peaks also appear in the spectra for 
unfunctionalised polymer itself (Fig 2.13, black).  The combination of decrease in reactive 
thiol group and also presence of peaks representing that of POZ further confirms the 
binding of the POZ macromolecules to the surface of the thiolated silica. 
The final spectra (Fig 2.15) are that of PNIPAM-silica, PNPOZ-silica and unfunctionalised 
silica. 
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Fig 2.15 Raman spectra for thiolated, POZylated, and PNIPAM-silica nanoparticles.   
Again, the spectrum for thiolated silica (blue), has several distinct peaks; 2898 cm-1 (C-H), 
2555 cm-1 (S-H), 1406 cm-1 (CH2), 1294 cm-1  (C-C), 1242 cm-1 (C-C), 627 cm-1 (C-S), and 
~500 cm-1 (Si-O-Si and S-S), and PNPOZ has peaks at 1631 cm-1 (C=O), and 1024 cm-1 
(C-C vibrations).  Following PNIPAM functionalisation, new peaks arise at; 1628, and 837 
cm-1 again representing the C=O stretch and C-C vibrations in PNIPAM.  These peaks 
can also be found in the spectra for unfunctionalised PNIPAM (shown in brown). 
In order to compare the size of the SH peaks accurately, the ratio of SH intensity to Si-O-
Si intensity was calculated (Table 2.4).  Given that the Si-O-Si peak will not change 
following functionalisation (as these moieties do not exist in the polymers being studied), it 
can be used as an internal standard in the sample.   
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Table 2.4 Ratio of intensity for functionalised and unfunctionalised silica nanoparticles 
Nanoparticle 
Si-O-Si 
intensity 
SH intensity Ratio 
Thiolated silica 1.18 0.6 1:0.5 
PNIPAM-silica 0.51 0.06 1:0.1 
PNPOZ-silica 0.44 0.04 1:0.1 
PEG-silica 3.35 1.14 1:0.3 
PMOZ-silica 0.76 0.06 1:0.1 
PEOZ-silica (sigma) 0.28 0.06 1:0.2 
PEOZ-silica 0.7 0.04 1:0.1 
 
Looking at these values, it is clear that the proportional intensity of SH groups reduced 
upon functionalisation, suggesting a decrease in the number of reactive thiol groups in the 
sample. 
From the Raman data, it is clear that the particles have successfully been functionalised 
with the polymers, and corroborates the FT-IR data. 
2.3.5 Solid-state silicon NMR 
In addition previous characterisation experiments, NMR studies were undertaken to 
further confirm successful surface modification and that the modification process had no 
adverse effects on the silica core dimensions.   
Fig 2.16 shows the CPMAS NMR spectrum of the silica precursor, highlighting two peaks 
at -57.9 ppm and -67.8 ppm.  These resonances are attributed to the 29Si nuclei at three 
and two silicon-oxygen-silicon bridge coordination (so called T3 and T2 species), 
respectively.49  The SPMAS and CPMAS spectra do not show any significant differences 
and yield similar intensity ratios IT3/IT2 of ca. 8.6.  
Figure 2.17 compares CPMAS spectra of the thiolated silica nanoparticles and POZ 
functionalised silica nanoparticles. The resonance at -67.8 ppm remains 
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unchanged whereas the peak at -57.9 ppm shifts upfield to -58.9 ppm after 
functionalisation. The intensity ratio IT3/IT2 decreases from ca. 8.6 for the SPMAS 
experiment, to ca. 7.6 for the CPMAS experiment. The increase in the T2 intensity 
suggests the proximity of additional protons which will cause enhancement of the 
signal in the CPMAS experiment.50  Both the upfield shift and increase in the 
intensity of the T2 signal are consistent with the presence of the POZ molecules 
(the additional source of protons) on the nanoparticle surface.  
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Fig 2.16 MAS NMR spectra of thiolated silica; SPMAS spectrum is shown in red, CPMAS 
spectrum is shown in blue. 
 
 
Fig 2.17 CPMAS NMR spectra of thiolated silica (blue) and PEOZylated silica (red). 
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The changes to the T2 resonance suggest that Si-O-Si bridges are predominantly present 
on the surface of the nanoparticle and thus more sensitive to its modification.  Assuming 
that the nanoparticles are spherical (as shown by Transition Electron Microscopy- TEM) 
and that T2 species are present only on the surface, the radius of the nanoparticle can be 
estimated.  The intensity ratio IT3/IT2 (core vs surface silica) can provide a crude estimate 
of the size, because the ratio of volume to surface area of the spherical particle changes 
as the function of its radius.  Therefore, both the unfunctionalised thiolated silica 
nanoparticles and the POZ-silica nanoparticles show a radius estimated to be ~26 nm 
(both from SPMAS and CPMAS experiments).  Both particle sizes appear the same 
because there are no changes to the number of silicon moieties on the surface with the 
addition of POZ, and the single pulse experiment does not rely on signal enhancement 
(proton-carbon cross-polarisation transfer).  With the CPMAS experiment, the estimated 
size is smaller ca. 23 nm, as expected for the enhanced T2 signal intensity.  
Although these sizes are in good agreement with the DLS data, it is important to note that 
the DLS shows that the Rh of the particles is 52 nm.  As the size determined by NMR is 
carried out using solid-state (and therefore not in the presence of water), it would be 
expected that the size would be smaller (i.e. around 30 nm as depicted by TEM).  
However, this is not the case.  It is likely that the freeze-drying process causes this 
discrepancy.  As water diffusing into the core of the nanoparticle freezes, forming ice 
crystals, it would expand, thus warp the internal structure of the particle.  This would 
create pockets of empty space inside the particle, making them appear larger.  A similar 
result was reported by Sameti et al., and Abdelwahed, et al.,51,52 who found that the size 
of silica nanoparticles suspended was larger than the original particle size, without the 
presence of any cryprotectants.  
2.4 Conclusions 
This study focuses on the synthesis, functionalisation and characterisation of the principle 
nanoparticles used in this study.  Core amorphous silica nanoparticles were synthesised 
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by the self-condensation of MPTS, resulting in a hydrodynamic diameter of 52 nm core 
thiolated silica nanoparticles.  These particles were then functionalised with three 
polymers; PEG, POZ, and PNIPAM.  Characterisation studies demonstrated successful 
functionalisation of the particles, and thermal analysis revealed the level of loading 
exhibited onto the particles. 
Previously these nanoparticles have been functionalised with PEG, yielding similar results 
to those presented here (no significant difference (P<0.05, Student’s t-test) was observed.  
However this is the first time PNIPAM and POZ have been grafted to these specific 
MPTS-synthesised nanoparticles.  In addition, a novel grafting technique was developed, 
in which alkyne terminated polymers can be grafted onto the surface of thiolated silica 
using a one-pot method, without any detriment to the particle itself. 
Each particle type was used in later experiments to assess their diffusion in various 
different media.  
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Chapter 3                            
Diffusion of gold nanoparticles in 
solutions of Pluronic F-127 at 
different concentrations 
3.1 Introduction 
Colloidal gold nanoparticles (AuNPs) are one of the most widely studied nanostructures in 
the literature, mainly due to their unique optical properties, ease and versatility of 
synthesis, and good biocompatibility.  They have applications in a wide array of scientific 
disciplines, including; drug delivery,1 cancer detection,2 bioimaging,3 and catalysis.4  This 
breadth stems from their ease in synthesis, diversity in surface functionality, and also 
varying morphologies allowing them to be tailor made for bespoke applications.5–7  There 
are many reported strategies in the literature on how AuNPs can be synthesised, however 
a select number are used more often than others.  These will briefly be discussed below. 
The Frens-Turkevich method is one of the most widely used techniques for synthesizing 
AuNP’s, in part due to its simplistic one-pot method.8,9  The reaction involves boiling a 
solution of aqueous gold tetrachloride, followed by the addition of sodium citrate.  The 
addition of sodium citrate (a reducing agent) forms a gold seed around which the particles 
grow.  By adding larger volumes of reducing agent, more seeds are formed, which results 
in smaller particles (due to smaller amounts of gold precursor available to build the 
particle), as opposed to smaller volumes of reducing agent which produces fewer seeds 
resulting in larger particles.5  This technique allows the synthesis of particles ranging from 
15 nm to 150 nm, however larger particles tend to be less monodisperse than smaller 
ones.   
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Another popular synthetic strategy is the Brust-Schiffrin technique.10  Here, the clusters 
are made by reduction of gold salt in an organic solvent, such as toluene, with sodium 
borohydride and a thiolated molecule.  By taking advantage of the strong Au-S bond, it is 
possible to create highly monodisperse particles at ambient temperatures.  There are 
several examples in the literature of authors using different thiol ligands; such as 
benzylthiol and 1,4-benzenedimethanethiol,11 dodecanethiol,10 hexanethiolate12  and 
phenylethanethiol.13  The particles, traditionally between 2 and 10 nm, and can be easily 
modified by taking advantage of the thiol moiety on the particle surface. 
In addition to the use of reducing agents to synthesise AuNP’s, some more interesting and 
novel techniques of gold nanoparticle synthesis include using liposomes, 
micelles/surfactants, and bacteria. This includes various Pluronic functionalised 
AuNP’s,14–16 and also nanoparticles synthesized in the presence of Pluronic.17–19  Based 
on their increased use, a study on the diffusive properties of AuNP’s in Pluronics is 
needed to further understand how they behave in dispersion with the polymers at different 
temperatures and concentrations. 
Poloxamers (also known by their trade-name of Pluronics) are block-co-polymers 
consisting of a central hydrophobic block of poly(propylene oxide) (PPO), surrounded by 
two hydrophilic blocks of poly(ethylene oxide) (PEO).  In commercial Pluronics, their name 
is followed by a number classification which represents the molecular-weight of the 
polymer.  Pluronics are used in the drug delivery field due to their unique self-assembling 
ability to form micelles, and eventually gel upon heating, a process which is reversible by 
cooling.20  Due to this ability to gel in situ and their good biocompatibility/low toxicity,21  
Pluronics can be loaded with a drug for controlled release.  This has been demonstrated 
for ocular drug delivery,22 subcutaneous administration,23 and for use as implants.24  In 
addition to a dosage form, there are several examples of nanoparticles loaded into 
Pluronics and nanoparticles functionalised with Pluronics, in order to provide a network of 
thermally cross-linked nanoparticles.25–27  
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The aim of this study was to investigate how the diffusion of different sized AuNP’s varies 
depending on both the temperature and state of a complex polymeric system.  By 
studying how the particles diffuse in a gel, and whether increasing particle size hinders 
their diffusion, it may be possible to determine a pore-size and gain other insights into 
molecular mobility of nanoparticles in a confined polymer solution, and how this could be 
translated to a complex biological system.  
3.2 Materials and methods 
3.2.1 Materials 
HAuCl4, Pluronic F-127, and sodium citrate were purchased from Sigma-Aldrich 
(Gillingham, UK) and used without any further purification.  All water used in this work was 
ultra-pure obtained from a PureLab UHQ water filtration system (18 MΩ). In addition to the 
synthesised nanoparticles, 80 nm gold nanoparticles were purchased from Sigma-Aldrich.  
The reason for this was 2-fold; to serve as a standard of known size and PDI, and also to 
establish which method was more cost-effective (synthesis or direct purchase). 
3.2.2 Gold nanoparticle synthesis 
Gold nanoparticles were synthesized according to the Frens-Turkevich method.8,9  An 
aqueous stock solution of gold tetrachloride was made up to 10 mM, along with a 1% w/v 
solution of sodium citrate.  Following this, the gold tetrachloride solution was diluted to a 
working concentration of 0.1 mM in 10 mL water, and placed in a round-bottom flask.  This 
was heated in a paraffin bath to 80 ⁰C under constant stirring.  Temperature was 
measured using an alcohol thermometer.  Once the solution had reached temperature, 
1% w/v sodium citrate was added at the following volumes; 0.009, 0.016 0.032 0.06 and 
0.15 mL.  These values were chosen based on the literature describing how different 
volumes of sodium citrate affect particle size.28  Each volume of sodium citrate added was 
added to a separate solution of gold tetrachloride, creating a total of 5 different particle 
types.  Soon after the addition of the sodium citrate, a colour change was observed, the 
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colour depending on the size of particles produced (see Table 3.1).  The particles were 
left for a further 10 mins to ensure the reaction completed, before being removed from the 
heat and left to cool to room temperature. 
Once at room temperature, the samples were purified by dialysis, using dialysis tubing 
with a molecular weight cut-off of 12-14 kDa (Medicell International Ltd, UK).  They were 
purified against 4 L deionized water for 48 hours, where the water was changed for a 
minimum of 8 times.  All samples were stored at 4 ⁰C until further use. 
Table 3.1 Volume of sodium citrate needed for synthesis of gold nanoparticles.   
 
 
 
 
 
 
 
 
 
 
3.2.3 Particle characterisation 
Following synthesis, all the particles (including the 80 nm standard particles), were 
characterised for size using Dynamic Light Scattering (DLS), Nanoparticle Tracking 
Analysis (NTA), and Transmission Electron Microscopy (TEM). 
DLS measurements were performed on a Zetasizer NanoZS system (Malvern 
Instruments, UK).  A refractive index of 0.2 was used for all measurements, which were 
carried out in disposable 1 mL plastic cuvettes (Fisher Scientific, UK), at 25 ⁰C.  To 
prepare the samples, the stock solution of particles was diluted 1:100 into ultrapure water, 
and placed into the cuvettes for analysis.  Individual readings of 10 seconds were 
recorded for a total of 12 runs, which was repeated 3 times per cuvette.  Each sample was 
Sample name Vol sodium citrate (mL) Colour  
Au1 0.15 Red 
Au2 0.06 Red 
Au3 0.032 Purple 
Au4 0.016 Blue 
Au5* (Sigma) - Pink 
Au6 0.009 Grey 
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measured independently 3 times and the size presented as mean ± standard deviation of 
these three repeats.   
NTA measurements were performed on an LM10 system with an LM14 laser module and 
metal top-plate, syringe pump, green 532 nm laser, and sCOMS camera (Malvern 
Instruments, UK).  Prior to analysis, samples were diluted 1:10,000 into ultrapure water 
producing a 1 mL suspension for analysis.  6x60 second videos were recorded for each 
measurement, and each sample was measured a total of 3 times each.  Samples were 
measured under a continuous flow rate of 30 AU at 25 ⁰C to maximise the number of 
particles tracked.  Analysis was carried out using NTA v3.1 software, and the data 
presented represents the mean ± standard deviation of the three separate experiments. 
Transmission electron microscopy experiments were performed on a JOEM-2010 
microscope (JOEL, USA) at an accelerating voltage of 200 kV.  Sample preparation was 
carried out by placing a drop of sample onto parafilm before placing holey carbon film 300 
copper mesh grids (HC300Cu, EMresolutions, UK), carbon side down, onto the drop.  
This was left for 1 minute, before being air-dried and placed in the instrument. 
3.2.4 Diffusion studies 
Diffusion experiments were performed using the NanoSight LM10 system, LM14 laser 
module with attached LM14 top plate, green 532 nm laser, and syringe pump.  Prior to 
performing the experiments, 4 different solutions of Pluronic F-127 were made in triplicate; 
1% w/v, 5% w/v, 10% w/v, and 18% w/v by mixing the appropriate mass of Pluronic F-127 
with 30 mL ultrapure water.  Each separate concentration sample was freshly prepared to 
avoid bacterial degradation and contamination.  Three solutions of each concentration 
were made, and each was measured 3 times for each particle type, resulting in a total of 9 
measurements for each concentration.  Particles were again diluted by 1:10,000 into 1 mL 
Pluronic solution.  A control of particles suspended in water (0% w/v) was also measured 
under the same conditions as was used for the Pluronic F-127 experiments. 
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Each measurement consisted of taking a 60 second video at 2 ⁰C intervals between 24 ⁰C 
and 38 ⁰C, repeated 3 times per sample.  Recordings were made whilst the syringe pump 
was in static mode to ensure the same population of particles was being measured 
throughout the whole series.  Following each temperature ramp series, the syringe pump 
was advanced (flow rate 500 AU for 5 seconds) in order to measure a different population 
of particles.  The full script can be seen in Fig 3.1. 
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REPEATSTART 
SYRINGELOAD 500 
DELAY 5 
SYRINGESTOP 
SETTEMP 24.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 26.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 28.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 30.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 32.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 34.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 36.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 38.0 
DELAY 20 
CAPTURE 60 
DELAY 3 
SETTEMP 22.0 
DELAY 90 
REPEAT 2 
 
Fig 3.1 Script employed to measure diffusion in the Pluronic system 
 
Following collection, the data was analysed using NTA v3.1.  In all cases the viscosity was 
set as that of water.  By doing so it is possible to measure the diffusion coefficient of the 
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particles when exposed to the viscosity of the “local environment bulk viscosity” of the 
system (as described by Lai et al. for a mucus network).29  Following analysis, several 
different data files were be exported; “summary,” which provided a breakdown of the 
results obtained from each video, “all tracks,” which provided data on the x and y 
coordinates for each individual particle, and “intensity,” which provided the size and 
diffusion coefficient for each individual particle tracked.   
After analysis, both the “summary” and “all tracks” file were exported.  Data in the 
summary file was used to calculate the mean diffusion coefficients ± standard deviation of 
each separate sample at each temperature.  The “all tracks” file was used for calculation 
of heat maps, the distance each particle moved, and the area that each particle had 
moved in. 
It is important to note that this series of experiments did not use NTA in the flow mode.  
This is because the diffusion of particles was assessed in a single local environment 
rather than a continuous system. 
3.2.5 Application of a python script to calculate heat maps, distance, and area of 
particle movement 
In order to provide more information than just the diffusion coefficient from the exported 
data files, a python script was written by Dr Mark Spillman (University of Reading), to 
generate a heat-map of the particles moving, as well as information on how far each 
individual particle moved, and the area each particle moved in.   
A bespoke script written in the Python programming language was used to automate the 
procedure of trajectory analysis and plotting. The total distance travelled by a particle on a 
given trajectory was obtained via simple addition of the distance travelled in each step, 
calculated using Pythagoras’ theorem. Particle trajectories were automatically fitted with 
an ellipse using an implementation30 of the method described by Fitzgibbon et al.31 The 
area of the ellipse was calculated to provide the “area of particle movement” metric seen 
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whilst the coordinates of the centres of the ellipses were used in conjunction with a 
Gaussian convolution procedure to produce the “heat-maps.” 
3.2.6 Pluronic F-127 characterisation 
In order to characterise the Pluronic F-127 solutions, each concentration was subjected to 
a temperature ramp study using DLS.  In each case, 1 mL of the Pluronic F-127 solution 
was placed in a low-volume 1 mL plastic cuvette (with care taken to avoid air bubbles), 
before being placed into the Zetasizer NanoZS instrument.  In this experiment, the sample 
was subjected to a temperature ramp, where the temperature was raised by 1 ⁰C, left to 
equilibrate for 2 mins, and the size recorded.  The range studied was between 20 and 40 
⁰C.  A refractive index of 1.47 was used in all cases, and the solvent was assumed to be 
water.  Each sample was measured for 10 seconds, for a total of 12 runs, with 3 repeats.  
This was repeated 3 times for every solution of Pluronic F-127 used.  Data are presented 
as the mean ± standard deviation of the three independent recordings. 
3.3 Results and discussion 
3.3.1 Synthesis and characterisation 
In the present study, AuNP’s were synthesised using the Frens-Turkevich method 
whereby the addition of different volumes of sodium citrate resulted in the formation of 
particles of different sizes.8,9  The particles produced different colours due to surface-
plasmon resonance effects on the particle surface.  Different sized particles cause the 
electron clouds to resonate at different frequencies, thus producing suspensions with 
different colours.32  Again, this is reflected in this study as the different sized particles 
show different colours, and are similar to those already reported in the literature.  Kimling 
et al. reported how the size of nanoparticles can range from 9 nm up to 120 nm depending 
on the concentration of HAuCL4 in the starting solution, and the volume of sodium citrate 
added, initiating the reaction.28  Following synthesis, all particles were characterised for 
size using three independent techniques (DLS, NTA, and TEM).   
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Table 3.2 shows the size of nanoparticles synthesised, and Fig 3.2 shows TEM images of 
the particles.  In addition to the synthesized particles, a standard of 80 nm (Au5) was 
purchased from Sigma-Aldrich in order to provide a sample of known size with low PDI to 
act as a comparison.  This sample is also included in the table.  In addition, we wished to 
determine which method was more cost-effective.  Synthesising the particles was found to 
be the cheaper option. 
Table 3.2 Size of gold nanoparticles, as determined by dynamic light scattering, and 
nanoparticle tracking analysis.  Au5
#
 was purchased from Sigma-Aldrich.  (n=3, mean ±standard 
deviation) 
 
 
 
 
 
 
Sample 
name 
Size, nm 
(DLS) 
PDI (DLS) 
Size, nm 
(NTA) 
Vol sodium 
citrate (mL) 
Au1 22±1 0.376 ± 0.015 21 ± 2 0.15 
Au2 27±1 0.117 ± 0.028 22 ± 2 0.06 
Au3 38±1 0.362 ± 0.087 52 ± 13 0.032 
Au4 50±1 0.353 ± 0.114 71 ± 4 0.016 
Au5# 77±2 0.114 ± 0.025 79 ± 3 - 
Au6 95±2 0.268 ± 0.038 77 ± 7 0.009 
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Fig 3.2 TEM images showing gold nanoparticles Au1-6.  The scale bar represents 100 nm in 
each image. 
 
From the values for each particle size assessed using each technique, it is clear there are 
some discrepancies.  The likely reason for this is due to variation between data collection 
as already discussed (Chapter 2.3.2.2).  In addition, aggregates cannot be distinguished 
when using DLS and NTA (dependent on aggregate size), however they can using TEM.  
The limitation to using TEM is the amount of particles assessed, as well as the size of 
particle (TEM does not measure Rh like DLS and NTA).  DLS and NTA measures a much 
higher concentration of particle sizes and therefore a more representative data set can be 
Au1 Au2 
Au3 Au4 
Au5 Au6 
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obtained.  The formation of aggregates could also explain the large PDI values shown by 
some of the particle sizes.  Despite this, the TEM data do complement the DLS data. 
The data presented show that increasing the volume of sodium citrate results in smaller 
particles, as demonstrated in the literature.28   
3.3.2 Pluronic characterisation 
4 different concentrations of Pluronic F-127 were used in this study; 1% w/v, 5% w/v, 10% 
w/v, and 18% w/v.  Preliminary experiments using 20% w/v Pluronic F-127 revealed that 
the gelation temperature was too low (~ 24 oC), and the NTA system had a tendency to 
over-heat, thus altering the phase transition of the polymer.  Because of this, a maximum 
concentration of 18% w/v was chosen which did not cause over-heating whilst still forming 
a gel at the desired temperature range (around 34 ⁰C).   
Each system was characterised using DLS in order to identify the temperature at which 
the polymers undergo a transition and form either micelles or gels.  From this it was 
possible to determine the critical micellation temperature (CMT), or Krafft point, and also 
determine the point at which the bulk solution changed, which could be used to explain 
some of the diffusion coefficients determined.  A graph showing the size of the 
polymers/micellar structures as a function of temperature can be seen in Fig 3.3. 
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Fig 3.3 Size changes of Pluronic F-127 at different temperatures obtained using DLS.  Data 
show the mean of 3 independent repeats ± standard deviation, for different concentrations of 
Pluronic F-127 in water; 1% w/v (blue), 5% w/v (red), 10% w/v (green), and 18% w/v (purple).  The 
dotted lines show the region in which diffusion experiments were carried out. 
 
Given that the critical micelle concentration (CMC) for Pluronic F-127 is noted to be 0.26-
0.8% w/v,33 the data presented shows that the particles are likely to have formed micelles.  
Therefore, as temperature increases there is a change from small micelles (6 ± 1 nm), to 
22 ± 1 nm micelles (and therefore the CMT) in the 1% w/v solution, similar to the values 
recorded by other authors.34  Similarly, the 5% w/v solution also shows a transition from 7 
± 1 nm at 20 ⁰C to 27 ± 1 nm at 25 ⁰C, before dropping down to an average size of 18 ± 1 
nm at >30 ⁰C.  The size discrepancy between the micelles of 1% and 5% w/v can be due 
to the concentration of polymer.  A higher concentration of polymer results in smaller 
micelles, due to their special positioning similar to the effect seen in AuNP synthesis 
where higher concentrations of sodium citrate result in smaller nanoparticles.  At higher 
concentrations stable clusters of polymer aggregate more rapidly than in lower 
concentrations, leading to more rapid formation of clusters, causing smaller micelles.   
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The size increase observed between 21 and 25 oC (for 5% w/v), and <20 and 22 for (10% 
w/v) is likely due to the formation of aggregates.  It is well known that during the formation 
of micelles, the solution becomes unstable, thus increasing the chance of aggregates 
forming.  This is demonstrated here by the initial size increase followed by a decrease and 
restabilisation represented by the data plateauing.35 
The 10% w/v solution acts in a similar manner to the 5% w/v solution, with an increase in 
size up to 38 ± 1 nm as temperature rises to 22 ⁰C, followed by a decrease until the 
micelles have reached a steady size of 13 ± 1 nm.  The 18% w/v solution shows a steady 
decrease in size with increasing temperature, to 10 ± 1 nm by 31 ⁰C, likely caused by the 
micelles becoming more compact prior to gel formation.  After this point, the solution 
undergoes phase transition and becomes a gel (at >32 ⁰C).  Similar values are reported in 
the literature.36  This explains why the scattering at this point becomes more sporadic, and 
the error increases. 
The purpose of the DLS experiments was to identify regions in the polymers/micelles 
undergoing conformational change, identified by a change in size.  This could help explain 
the data obtained for diffusion experiments (section 3.3.3).  Consequently, diffusion 
experiments were carried out between 24 and 38 ⁰C (marked in Fig 3.3 by dotted lines), 
the range where polymer behaviour was well characterised by DLS. 
3.3.3 Gold nanoparticle diffusion 
NTA was used to evaluate the diffusion of various sizes of gold nanoparticles in 
suspension in differing concentrations of Pluronic F-127 over a range of temperatures, in 
order to assess how particles behave in a temperature responsive environment.  In this 
study the temperature range started at 24 oC to avoid the system overheating. 
Pluronic F-127 is well known to have unique gelation properties, where (depending on the 
formulation of the block co-polymer and concentration) it forms micelles followed by gels 
upon heating.37  With the increased use of combining Pluronics with nanoparticles 
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(including gold,16 silver,38 and magnetic iron oxide nanoparticles)39 it is important to 
understand how these particles behave, with regard to their diffusive properties, in 
solutions of varying concentrations of Pluronic F-127 at different temperatures.  The 
concentrations (1, 5, 10, and 18% w/v) were chosen as they provide solutions whereby 
the polymer is in different states (free polymer->micelles->gel).   Fig 3.4. summarises the 
data on diffusion coefficients of the different sized gold particles in the various polymer 
solutions as temperature varies. 
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Fig 3.4 Diffusion coefficients for gold nanoparticles varying in size, through different 
concentrations of Pluronic F-127, at increasing temperatures.  Mean ± SD, n=3
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In order to explain the results, the discussion will firstly consider gold nanoparticle 
diffusion with differing poloxamer concentrations, and secondly the effects of nanoparticle 
size.  In addition to measuring the particles in Pluronics, the diffusion of AuNP’s in water 
subjected to the same temperature ramp was assessed and served as a control.  
3.3.3.1 Effect of Pluronic concentration on AuNP diffusion 
From the general trend in diffusion coefficients exhibited by the particles, it is clear there 
are big differences depending on Pluronic concentration.  The general decrease in 
diffusion coefficient seen between each concentration can be ascribed to differences in 
bulk viscosity of the Pluronic solutions; the higher the concentration, the higher the bulk 
viscosity, thus more constraint is placed on the particles inhibiting their ability to diffuse.  
As can be seen in Fig 3.4; the diffusion coefficient for the particles in water increases with 
temperature.  This is to be expected, as there is a decrease in viscosity as temperature 
increases, due to a weakening of intermolecular bonds.  This causes the particles to move 
more rapidly, thus allowing them to diffuse faster.40  Wong et al.41 reported on the diffusion 
of AuNP’s in water and toluene and also found that increasing the temperature also 
increased the diffusion coefficient of the particles.  Further, this trend is predicted by 
calculating the diffusion coefficient using the Stokes-Einstein equation. 
Considering the 1% w/v solution, the diffusion coefficient also shows an initial steady 
increase as temperature rises.  However, the diffusion coefficient jumps at around 30-32 
oC and the particles become much more diffusive, even more so than their counterpart 
particle size in water.  This can be explained by considering how the Pluronic F-127 
molecules behave in solution, from the earlier DLS results.  As can be seen in Fig 3.3, 
there is a change in particle size at the same temperature, caused by the formation of 
micelles.42  
With the formation of micelles, the localised viscosity of the solution decreases (as there is 
more free water rather than polymer networks), which could explain the elevation in 
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nanoparticle diffusion.  However, the increased diffusivity is much larger than would be 
expected, and it appears to be higher than the same nanoparticles diffusing in water.  The 
most likely reason for this is that, as the micelles are being formed, they are moving 
around under Brownian motion similar to the particles.  With the increase in temperature, 
the micelles have an increased kinetic energy causing them to move faster, and thus the 
number of collisions with the gold nanoparticles will increase.  Given that the micelles are 
much smaller than the AuNP’s, they will move faster as predicted by the Stokes-Einstein 
equation.  Islam et al43 provides a potential explanation for this. Based on the theory of 
Brownian motion and the Einstein-Smoluchowski relation (Equation 3.1) there will be an 
increase in the friction coefficient placed on the particle (from Stokes law) which causes 
the “mobility” of the particle to increase, thus increasing the diffusion coefficient.  
However, this will eventually normalise (or decrease) back to a steady state (that of a 
more viscous environment), which is shown in the data presented here at temperatures 
>34 oC. 
𝐷 = 𝜇𝑘𝐵𝑇    Equation 3.1 
Where D is the diffusion coefficient, µ is the mobility (ratio of the terminal drift velocity to 
an applied force) of the particle, kB is the Boltzmann constant, and T is the temperature.   
This explanation is supported considering the three other concentrations studied and 
comparing them to the DLS data (Fig 3.3).  Both the 5% and 10 % w/v solutions show little 
change in diffusion coefficient.  As the temperature increases, it is likely a change in 
viscosity will occur which could further lead to a change in diffusion coefficient.  However, 
looking at the DLS results, there is no change to the system between the temperatures 
studied i.e. the particles have already formed into micelles and no further transition is 
occurring.   
Similar to the 1% w/v solution, the 18% w/v solution is also undergoing a transition and 
again shows a similar increase in diffusion coefficient as seen in the 1% w/v solution.  This 
is very unusual, as it would be expected that as the system gels, the particles stop moving 
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and thus no longer diffuse.  However, it is likely, as this is a dynamic system, that as the 
gel is forming, the micelle network is becoming more constraint.  As the particles are still 
moving under Brownian motion, it is possible that they are forming unnatural defects in the 
gel which could lead to an artificial increase in diffusion coefficient.  Fig 3.5 provides 
scheme of how the gold nanoparticles are behaving as the solution forms micelles 
followed by a gel which helps in explaining the above description. 
 
 
Fig 3.5 How the gold nanoparticles are behaving in the solution of Pluronics at different 
temperatures, and how this could effectively alter their diffusive properties. A) represents the 
predicted movement of particles, whereas B) shows how the particles are actually moving.  
 
It should be noted that during diffusion experiments, to ensure gold nanoparticles were 
being measured instead of micelles; the camera level was set to 5.  Given that gold 
nanoparticles are much more effective at reflecting light (due to their metallic nature), this 
ensures them to be visible in the suspension. 
 
A) 
B) 
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3.3.3.2 Effect of particle size on diffusion 
In addition to looking at the effects of polymer concentration on the diffusion coefficient, 
the effect of particle size was also studied.  From Fig 3.4, in general, as the particle size 
increases the diffusion coefficient decreases.  This is to be expected from the predicted 
diffusion coefficients calculated using the Stokes-Einstein equation (Fig 3.6).  In this 
example, the particle size used was that as obtained by the DLS.  As can be seen, as 
particle size decreases, the diffusion coefficient increases.  In addition, as temperature 
increases the diffusion coefficient increases as discussed above. 
 
Fig 3.6.  Calculated diffusion coefficient for AuNP’s in water, determined using the Stokes-
Einstein equation and the mean dimeter from DLS (taken from Table 3.2).   
 
In general, as predicted by the Stokes-Einstein equation, the diffusion coefficients for all 
sample sizes at all concentrations increases as temperature increases.  However, there 
are two main discrepancies in the data.  The first is that the predicted diffusion coefficients 
(Fig 3.6) are for that of the gold particles in water, and should therefore match the 
diffusion coefficient for the gold particles determined experimentally in water.  Although 
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the largest particle size (Au6) does match that with the predicted diffusion coefficient, 
there is some discrepancy observed for the others.  
The Stokes-Einstein equation assumes several parameters about the sample, namely; 
spherical, 100% monodisperse particles which move under slip boundary conditions by 
laminar flow.  If these conditions are not met then the equation is not reliable.44,45  The 
latter are shown in water (i.e. the particles will move under laminar flow), the presence of 
aggregates in the sample, shown by the large PDI’s, and TEM images, will change both 
the shape of the particles (i.e. they will not be spherical), and also cause a disruption to 
the nanofluidics.  As the diffusion coefficient presented by NTA is the mean for all the 
particles measured, the presence of a large number of aggregates will cause larger 
particle sizes and thus a reduced diffusion coefficient.  This will also explain the large error 
bars observed on some of the samples (and the large PDI’s seen in Table 3.2). 
The second discrepancy refers to the apparent difference in diffusion coefficient based on 
particle size i.e. Au2 has a smaller experimentally diffusion coefficient to Au3 and Au4 (Fig 
3.4).  This pattern appears across the whole temperature range studied at all 
concentrations, suggesting that the aggregates in this sample are much larger than in the 
other samples, which will cause a shift in diffusion coefficient as described above. 
Despite these discrepancies, the general trend in diffusion coefficient matches the 
calculated values. 
3.3.4 Particle mapping and local environment 
To understand how the particles move in the local environment and track their locations, a 
python script was written in order to produce a heat-map of particle movement.  Fig 3.7 
shows exemplar heat-maps produced for each particle type at the temperature range 
studied, recorded for the 1%, 5%, 10%, and 18% w/v solution, respectively, and is 
explained by Fig 3.8.   
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Fig 3.7 Heat-maps showing the movement of different sized gold nanoparticles at different 
temperatures recorded over 60 seconds.  The polymer concentration is denoted in the top left 
corner of each graphic.  The scale bar (shown in 1%, Au1, 20 
o
C) represents 200 µm.  A 
description of intensity of the heat-map can be found in Fig 3.8. 
10% 
18% 
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Fig 3.8 Intensity scale for the heat-maps depicted in Fig 3.7.  Regions in red show regions 
where there is a large amount of particle movement detected, whereas blue represents regions of 
little/no particle movement. 
 
As can be seen, the larger particles (Au4, 5, and 6) mostly show very little movement in 
the 18% w/v solution at higher temperatures (>34 oC).  This is due to the formation of the 
gel and the particles becoming trapped, unable to move.  However, there are some 
regions of high particle movement further suggesting the formation of a deformed gel, 
caused by particles undergoing Brownian motion.   
It is well known that Pluronic F-127 forms a gel at temperatures above 34 oC in 
concentrations above 18% w/v,46 and is confirmed by the DLS data (Fig 3.3), where the 
scattering caused by these temperatures becomes very incoherent (>34 oC).   However, 
the smaller particle sizes (specifically Au1 and Au2) still show general particle movement, 
suggesting that particles are moving through the gelled state.  This is likely due to the 
particles moving more rapidly due to their smaller size (due to the large degree of 
movement caused by Brownian motion of sub 25 nm particles), causing the gel to become 
warped much more readily than with the larger particles.  This could mean that the 
particles are forming an artificial cave in the gel structure, encouraging particle movement.  
As larger particles tend to move much slower under Brownian motion47 the gel could be 
forming more naturally, thus forming fewer artefacts. 
This is further demonstrated by the diffusion coefficients shown for these particles in an 
18% w/v solution (Fig 3.4).  The smaller particles (Au1-3) have steadily increasing 
 128 
diffusion coefficients, suggesting they are not trapped or demonstrate limited movement 
due to the formation of the gel, however the diffusion coefficient for larger particles (Au4-
6) starts to decline after 34 ⁰C (the point at which the solution gels), suggesting hindered 
particle movement (as illustrated by the heat maps).  However, there is still some degree 
of particle movement, although this could be due to external vibrations.   
3.3.5 Distance and area of particle movement 
In addition to generating a heat-map, the code also allowed for the calculation of the 
distance travelled by each particle, and the area of the space it was moving in.  The code 
used the x and y coordinates provided during analysis, and calculated these values based 
on the number of pixels the particle was crossing.  NTA calculates sizes based on the 
number of pixels a particle crosses, where 1 pixel equates to 188 nm.  Using this 
information, the code can calculate the distance travelled by each particle and also the 
special area it is moving in.  A chart showing the mean distance travelled by each particle 
can be found in Fig 3.9, and a chart showing the mean area of particle movement can be 
found in Fig 3.10. 
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Fig 3.9 Mean distance travelled by different sized gold nanoparticles in different 
concentrations of Pluronic F-127, as temperature ramps.  Data represent the mean of 3 
repeats. 
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Fig 3.10 Mean area in which different sized gold nanoparticles are moving in increasing 
concentrations of Pluronic F-127, as temperature ramps.  Data represent the mean of 3 
repeats. 
 
Looking at both the area and distances moved by AuNP’s in a 10% w/v solution, there is 
little change in the value obtained (shown in green), and the particles appear to move at a 
similar rate; a similar trend was seen in the diffusion coefficients.  Similarly, in the 5% w/v 
solution the mean distance appears to be similar in all the sizes studied, apart from Au6, 
where the distance decreases.  However, the area of movement appears to increase as 
the particles get larger, except for the largest particle size (Au6).  Given that these 
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particles are larger than the Au5 particles (95 nm compared to 77 nm), it could be that 
their movement is much more hindered, resulting in a decreased area of movement.  A 
similar trend can be seen in the Au6 particles in the 18% w/v poloxamer system.   
The 1% w/v samples have very interesting results, and it appears as through as 
temperature increases, the distance travelled and area of movement for each particle 
decreases - an opposite trend to that seen in the diffusion coefficients.  As with the 
diffusion coefficients, they remain relatively constant until ~34 oC, when they start to 
decrease, which (as previously discussed) will be due to phase changes within the 
solution.  The decrease in both distance travelled and area could be due to steric 
hindrance in the system.  With the formation of micelles, the particles have a smaller 
amount of space to move around in.  So despite the fact that they diffuse faster (as seen 
in Fig 3.4), they have less space to move in as shown by the distance and area graphs 
shown here (Fig 3.9 and 3.10, respectively).  Due to this confined space, there are greater 
odds of the micelles bombarding into the particles, which could cause them to diffuse 
faster (as discussed in 3.3.1). 
This information potentially allows several additional features about the particle to be 
understood, including the speed of the particles.  In addition, the “area of particle 
movement” values could potentially be used to determine a pore size of a gel.  It also 
helps explain the trends observed for the diffusion coefficients for each particle.  This 
approach adds extra levels of understanding to how nanoparticles behave in different 
environments. 
3.4 Conclusions 
The initial concept of this study was to measure the pore size of a gel which contained a 
suspension of nanoparticles.  However, by measuring the diffusion coefficients of gold 
nanoparticles in different environments allowed investigation of how the conformation and 
state of the polymer solution affected nanoparticle diffusion.   
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It would be expected that as the temperature increased, the diffusion coefficient would 
increase linearly.  This was true for 3 of the samples; the control (0%), 5%, and 10% w/v 
solutions.  However, the diffusion coefficient for particles suspended in a 1% w/v, and 
18% w/v Pluronic solution, appear to not show this pattern.  Based on this, the phase of 
the solution (solution, micelle suspension, or gel) has been shown to play a major role in 
diffusion coefficient, and the addition of micelles into a system can significantly affect 
nanoparticle diffusion coefficients.  This was confirmed by the heat-maps showing the 
localisation of nanoparticle movement, the values calculated for the average distance 
travelled by the nanoparticles, and also the size of the area they are moving in. 
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Chapter 4    
Temperature responsive silica 
nanoparticles – particle solvation and 
diffusion                                       
4.1 Introduction 
This chapter describes studies using two temperature responsive polymers (TRP’s), 
poly(N-isopropyl acrylamide) (PNIPAM) and its structural isomer poly(2-n-propyl-
oxazoline) (PNPOZ), assessing how their structures change with temperature and 
consequential effects on their diffusion coefficients in a series of organic solvents with 
different polarities. 
TRP’s exist in many forms, and can change properties depending on temperature.  There 
are many examples of TRP’s in the literature including poloxamers, poly(n-isopropyl 
acrylamide), and poly(2-oxazolines).  Indeed, most polymers will have either a lower 
critical solution temperature (LCST), or upper critical solution temperature (UCST), 
however these are often at either very high or very low temperatures, and so will not be 
relevant for most pharmaceutical applications.1 
When a polymer exhibits a response to a temperature its conformational and physical 
properties will change.  The LCST is the critical temperature above which a polymer 
becomes immiscible with a solvent (e.g. water).  At temperatures below the LCST, it is 
hydrophilic in nature and above the LCST it becomes hydrophobic.  Likewise, UCST is the 
critical temperature below which a polymer becomes immiscible with a solvent.  If the 
temperature of a system is below the LCST of a polymer, then the Gibbs free energy will 
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be negative, and the polymer will dissolve in solution.  However, if the temperature 
changes and increases to above the LCST, the Gibbs free energy will change from 
negative to positive, thus causing the polymer to become immiscible.2  Summarily, the 
Gibbs free energy goes from positive to negative as temperature rises for the UCST.    
By functionalising nanoparticle surfaces with TRP’s both the LCST and UCST of a 
polymer changes due to steric hindrance, caused by the dense packing on the surface.3  
This is an important factor to consider when combining TRP’s with nanoparticle 
formulations (especially for pharmaceutical applications), as the properties of the modified 
particle can be different than predicted compared to free polymer. 
PNIPAM is a widely studied temperature responsive polymer, with a reported LCST of    
32 oC.  There have been many reported applications for PNIPAM functionalised onto the 
surface of different nanoparticles, ranging from “smart-glass,”4 photo-thermal therapy,5,6 
remote-controlled triggered drug release,7 and bioimaging.8  By taking advantage of the 
LCST and combining with the unique properties of nanoparticles, it is possible to design 
highly versatile systems with very tuneable properties, ideal for the pharmaceutical 
industry.  PNPOZ on the other hand is not as extensively studied as PNIPAM, and very 
little experimental data exists looking at the size changes occurring around this polymer 
when grafted to nanoparticles.  With an LCST of 25 oC, and good biocompatibility, this 
polymer is growing in popularity for drug delivery systems. 
One of the most beneficial techniques to measure the change in structure of 
polymers/nanoparticle composites in response to an external stimulus is to use scattering 
techniques, such as Small Angle Neutron (SANS) or Small Angle X-ray Scattering 
(SAXS).  Both SANS and SAXS provide similar data, and are often used as 
complementary techniques.   
In a SANS experiment, a collimated neutron beam is fired through a sample, which then 
scatters off any molecules/particles in said sample, which can then be detected by a 3He 
detector.  As SANS employs elastic scattering, there is no measurement of energy 
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transfer between the incident neutron beam and the sample, as they will be the same 
(inelastic scattering causes a difference in energy transfer).  Only scattered neutrons are 
measured, and therefore a high flux is needed.  To perform a SANS experiment, samples 
need to be suspended in D2O, as deuterium provides greater contrast to neutrons 
compared to hydrogen and reduces the incoherent background from the solvent.  The 
data generated from a SANS experiment is expressed as value of Q, which is defined in 
Equation 4.1. 
𝑄 =
4𝜋 sin
𝜃
2
𝜆
     Equation 4.1 
Where θ is the incidence angle of the neutron beam, and λ is the wavelength.  Q 
represents the scattering in reciprocal space, and is the Fourier transformation of 
scattering in real, or D, space.  By plotting the intensity, the “I(Q)”, against Q, it is possible 
to establish structural features and size dimensions existing in the system, such as shape, 
Rg, protein structure, and general morphology.
9  From these data it is possible to assess 
any interactions the sample may be exhibiting.  Scattering at low Q values gives 
information on large structural features within the sample, and scattering at high Q values 
gives information on smaller structural features. 
One of the main advantages SANS has over similar techniques (such as SAXS), is the 
ability to perform contrast variation experiments.  This is carried out by placing a sample in 
different ratios of D2O and H2O, allowing the neutron beam to mask out specific areas of 
the sample (Fig 4.1).10   
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Fig 4.1 The principle of contrast matching.  By placing a sample in 100% D2O (top left), it is 
possible to analyse the whole particle such as the core (red) and shell (blue) structure.  By placing 
the sample in a matched solvent system (made-up of different D2O:H2O ratios), it is possible to 
mask out different parts of the system, allowing for direct measurement of either the core or shell. 
 
Using contrast variation, it is possible to assess any structural changes occurring in 
different locations on the particle, i.e. changes in the core, or shell of the particle. 
The aim of this study was to investigate temperature effects on the size and structure of 
TRP-functionalised nanoparticles using a variety of techniques including DLS, NTA and 
SANS, and critically assess how these properties affect nanoparticle diffusion through a 
variety of solvents varying in polarity.   
4.2 Materials and methods 
4.2.1 Materials 
The nanoparticles used in this study were the PNIPAM functionalised silica and the 
PNPOZ functionalised silica nanoparticles synthesised in Chapter 2.  In addition to the 
particles, D2O (VWR International, UK), DMSO (Fisher, UK), ethanol, and methanol 
(Sigma-Aldrich, UK) were used. 
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4.2.2 DLS 
In addition to the characterisation carried out on these particles in Chapter 2, further DLS 
experiments were performed to assess the particles temperature responsive nature.  
Samples were diluted 1:10 into either ultrapure water or methanol, placed in low volume 
cuvettes (Fisher, UK), and sealed with a stopper and parafilm to avoid solvent 
evaporation.  A temperature ramp- study was then carried out using the Zetasizer NanoZS 
(Malvern Instruments Ltd, UK) between 20 and 50 oC.  The SOP allowed 10 minutes 
equilibration before each measurement was carried out to ensure an even distribution of 
temperature. 
Each recording consisted of 12 runs of 10 seconds, which was repeated three times.  
Three independent recordings were made, and the data presented as mean ± standard 
deviation. 
In addition to particle size experiments, ξ-potential experiments were also performed in 
DTS-1070 folded capillary tubes (Malvern Instruments Ltd, UK).  Samples were again 
diluted by 1:10 into ultrapure water, placed into the cuvettes and sealed with PTFE 
stoppers and parafilm.  The samples were then measured using the same temperature 
ramp and equilibration time as described above.  A Smoluchowski model (Fκa = 1.50) was 
used in all cases and values were recorded over 20 runs, in triplicate. 
In all cases, data are presented as mean size (from 3 repeats) as a function of 
temperature. 
4.2.3 Small Angle Neutron Scattering 
4.2.3.1 Sample preparation 
Small angle neutron scattering (SANS) was used to measure the structure and 
interactions of the particles at different temperatures.  One day of beam-time was 
obtained on the D11 instrument at the Institut Laue-Langevin (ILL, proposal number 9-12-
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422) with the aim of using contrast matching to observe changes in the polymer corona 
independent of the core silica particle.   
Prior to the experiment, samples were dialysed into D2O using a 7 kDa molecular-
weight cut-off membrane (Medicell International, UK).  A 1 mL aqueous suspension 
of particles was placed into the membrane and sealed, before being placed into a 
vial containing ~30 mL D2O.  D2O was replaced every 6 hours for a total of 3 
changes.  Following dialysis, samples were stored in glass vials, sealed with 
parafilm at 4 oC. 
4.2.3.2 Contrast match experiments 
In order to obtain the contrast match point for the unfunctionalised thiolated silica 
nanoparticles, a stock solution of particles in 100% D2O (5.5 mg/mL) was diluted 1:10 into 
a series of different ratios of D2O:H2O.  The volumes chosen were 100% D2O, 75% D2O, 
50% D2O, 35% D2O, and 20% D2O.  The scattering profiles were obtained and normalised 
to the same I(Q) values (Fig 4.2) by subtracting the incoherent background.   
From this, a single value in Q was taken for each ratio, and the square root of the intensity 
at that point was plotted against the volume fraction of H2O (Fig 4.3).  The point at which 
this line crossed the x-axis was taken as the contrast match point.  In this experiment it 
was found to be 20%.  In all cases, the incoherent background was subtracted for 
D2O/H2O mixture scattering profile. 
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Fig 4.2 SANS profile for thiolated silica diluted in different volumes of D2O and H2O, 
normalised against the incoherent background. 
 
Fig 4.3 Contrast match point as determined by taking the square root for I(Q) values as a 
function of D2O concentration.  The circled area represents the contrast-match point  
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4.2.3.3 SANS experiments 
From the above, the PNIPAM functionalised silica nanoparticles and the PNPOZ 
functionalised silica nanoparticles (5.5 mg/mL) were diluted 1:10 into 20% D2O.  In 
addition, PNIPAM-silica, PNPOZ-silica and unfunctionalised silica nanoparticles in 100% 
D2O, again diluted by a factor of 1:10, were assessed.  Samples were placed in 700 µL 
Hellma cuvettes sealed with a PTFE stopper, and placed in the beam-line.  An 
incident wavelength of 8 Å at 3 detector distances of 1.2 m, 8 m and 28 m were used to 
cover a large Q-range from 2 x10-3 to 0.3 Å−1. All samples were measured at 25, 30, 34, 
and 40 ˚C, where the temperature was controlled by an external water circulation system.  
The data were then merged over all the detector distances, and the incoherent 
background subtracted. 
Data fitting used the SASview programme (http://www.sasview.org/), using DLS and TEM 
data to provide the parameters.  Various models were used depending on the sample and 
temperature and are discussed in further detail in section 4.3.4. 
4.2.4 Nanoparticle diffusion 
NTA was used to measure the diffusion coefficient for functionalised and unfunctionalised 
nanoparticles suspended in different solvents at different temperatures.  Solvents were 
chosen based on their polarity and compatibility with the system.  Based on these 
parameters, the solvents were water, ethanol and DMSO.  Preliminary experiments with 
chloroform found the solvent to be unsuitable with the system and causing expansion of 
the rubber O-ring, and the samples to leak. 
All measurements were performed using the NanoSight LM10 system, with LM14 metal 
top plate, green 532 nm laser, SCMOS camera, and syringe pump.  Before videos were 
recorded, the stock solution of nanoparticles was diluted down to a working concentration 
of 1:10,000 by serial dilutions into the appropriate solvent.  The final 1 mL suspension was 
then injected into the NanoSight system and the syringe placed in the syringe pump.  For 
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all experiments, the flow-rate was set at 30 AU.  6×60 second videos were recorded at 25, 
30, 35 and 40 ⁰C.  Each particle type was measured in triplicate.  For analyses, viscosity 
values (shown in Table 4.1, Fig 4.4) were taken from the literature.11–13 
Table 4.1 Reported viscosities of different solvents at 25, 30, 35, and 40 
o
C.
11–13
 
 
 
Fig 4.4 Viscosity of different solvents as a function of temperature. 
 
4.2.5 Statistics 
Data are presented as the means of 3 repeats ± standard deviation.  For comparison of 
diffusion coefficients, a 2-way ANOVA was carried out using a Bonferroni post-hoc test 
(p<0.05). 
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4.3 Results and discussion 
4.3.1 Nanoparticle characterisation 
The nanoparticles used in this study were the PNIPAM functionalised silica, and PNPOZ-
functionalised silica synthesised in Chapter 2.  These polymers are reported to have 
LCST’s of 32 and 25 oC, respectively.  A summary of the size data (from Chapter 2, 
section 2.3.2) can be in Table 4.2.   
Table 4.2 Size and PDI of functionalised and unfunctionalised silica, determined using DLS 
(a) and NTA (b)  
 
 
 
 
 
4.3.2 DLS 
In addition to using DLS to determine the initial particle size following functionalisation, a 
temperature ramp study was used to assess how the particle diameter, PDI and ζ-
potential changed with temperature.  The temperature range chosen (20-50 oC) provided 
information above and below the reported LCST of both polymers. The unfunctionalised 
thiolated silica particles were also subjected to the same temperature ramp studies to 
verify that the changes observed were due to the presence of the polymer and not a trait 
exhibited by the unfunctionalised particles.  Fig’s 4.5, 4.6, and 4.7 shows how the size, 
PDI, and ζ-potential values change as a function of temperature.   
 
 
Sample 
Z-average 
(nm)a 
PDI a 
Modal 
particle 
size (nm)b 
Thiolated silica 52±1 0.072±0.003 54±1 
PNIPAM-silica 70±1 0.111±0.004 63±3 
PNPOZ-silica 61±1 0.194±0.018 58±1 
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Fig 4.5 Size (A) and PDI (B) values for functionalised and unfunctionalised nanoparticles as 
a function of temperature.  Means ± standard deviation, n=3.  
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 Fig 4.6 Size and PDI of PNIPAM functionalised silica nanoparticles between 20 and 34 
o
C.  
Means ± standard deviation, n=3.  
 Fig 4.7 ζ-potential of functionalised and unfunctionalised nanoparticles as a function of 
temperature.  Means ± standard deviation, n=3.  
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From the size of the nanoparticles (Fig 4.5A), it is clear that as temperature increases the 
size of the functionalised nanoparticles also changes significantly.  The PNIPAM-silica 
nanoparticles show a steady decrease in size up to 34 oC, followed by an increase 
between 34 and 40 oC, before it plateaus.  The slow size decrease was found to be linear 
with an R2 of 0.98 (Fig 4.6).  A similar trend is shown with the PDI values (Fig 4.5B) 
suggesting that the particles are forming aggregates as the temperature increases above 
34 oC, although was not found to be linear.  Interestingly, the PDI values remains 
essentially constant between the 3 independent repeats, with very small error bars shown.   
From Fig 4.6, it is clear that the size decrease occurs independently of any change in PDI.  
This particle size decrease has been noted by other authors,14,15 although there is little 
explanation for this.  It is feasible that the polymer is undergoing phase-transition 
prematurely, however if this were the case, one would expect the PDI to change in a 
similar manner as the size.  In addition, the size changes would be sudden, occurring at a 
specific temperature rather than the subtle linear decrease as is shown here.  It is more 
likely that this change is due to changes occurring in the hydration shell around the 
particle, where interactions between water and the polymer are becoming weaker, thus 
forcing water into the surrounding media, leading to shrinkage of the hydration shell.  This 
size decrease would cause the PDI values to remain relatively constant, as is the case 
here.  If the polymer was undergoing premature LCST, it would be expected that the PDI 
values change accordingly. 
Following the decrease, a size increase can be noted at 34 oC.  Given that the LCST of 
free PNIPAM is 32 oC,16 this alteration is probably due to the brush conformation adopted 
by the polymer around the particle.  Due to the dense polymer packing, the LCST will shift 
to a higher temperature, due to steric hindrance around the particle, a change noted in the 
literature.3 As the temperature continues to ramp, the particle size eventually plateaus 
(>40 oC).  This trend is mimicked by the PDI values which also increase, followed by a 
plateau, confirming that the particles are aggregating.  It is interesting to note that the 
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error bars for the sizes and PDI’s are very small, which would not be expected if the 
particles were strongly aggregating with each other in a random manner.  This suggests 
that the particles are aggregating in a controlled fashion, which is unreported in the 
literature.  Due to the similarity between the PDI and size data, it is most likely that, as the 
particles are interacting with each other and approach equilibrium, clusters of several 
nanoparticles are formed.  With the steady increase in particle size (and PDI) between 34 
and 40 oC, it is likely that one particle is interacting with another particle, then as 
temperature ramps these small clusters are further interacting to form a small cluster of 
nanoparticles.  However, once equilibrium has reached these clusters cease to interact 
any further.  This is further described in the context of the SANS data in section 4.3.3.  
As with the PNIPAM-silica nanoparticles, the PNPOZ-silica nanoparticles also undergo a 
phase transition, which causes changes in particle size.  The reported LCST of PNPOZ is 
25 oC,17 which here shifts to ~28 oC due to steric hindrance around the particles.  
However, the particles do not show the size decrease shown by PNIPAM, and the size 
remains relatively stable up to 28 oC, when the size starts to increase and the particles 
aggregate.  Again, the particle size increases steadily, followed by a plateau which is 
reached at 37 oC.   Once the particle size has plateaued >37 oC, the error bars become 
very large, as would be expected for a truly aggregated system.  However, between 28 
and 37 oC, when the particle size is increasing exponentially, the error bars remain small, 
suggesting weak but uniform aggregates are forming.  These trends are also mimicked in 
the PDI values for the particles over the same temperature range, confirming this 
interpretation.  The unfunctionalised silica nanoparticles show no change in size or PDI 
across the temperature range studied, as would be expected. 
In addition to the size and PDI of the particles, their ζ-potential was also measured across 
the same temperature range (Fig 4.7).  From the data, it is clear that there are changes in 
ξ-potential as temperature increases across all samples.  For unfunctionalised silica (Fig 
4.7; green), there is a clear decrease in the negative ξ-potential as the temperature 
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increases and there is a significant difference between the ξ-potential at 20 oC (-54±1 mV) 
and that at 50 oC (-43±2 mV) (p>0.05, Student’s t-test).  Though only a few studies 
describe the effect of temperature on the ξ-potential of silica nanoparticles, this 
phenomenon has been noted by other authors and is a property of the silica nanoparticles 
itself.  Several papers report on a decreasing ξ-potential as the temperature increases,18–
20 thought to be due to the dissolution of surface sialic moieties as the temperature 
changes.21 
For the PNIPAM functionalised nanoparticles, although there is apparently a slight 
increase in ξ-potential across the temperature range, the change is not significant 
(p<0.05).  These data suggest that the particles remain stable in suspension, confirming 
the earlier findings from size and PDI data: the ξ-potentials remain low enough so there 
will be minimal interactions between the particles.  This effect on ξ-potential has been 
reported by other authors22 although again there is very little literature data on this. 
The changes in ξ-potential occurring for PNPOZ are the most interesting.  The ξ-potential 
remains relatively constant until 27 oC, when it changes significantly (p<0.05) and 
becomes more negative up to 31 oC (from -31 to -46 mV), followed by a steady decrease 
between 32 and 40 oC (from -46  to -34 mV) when it remains essentially constant up to 50 
oC.  Although no significant difference can be observed between the initial ξ-potential and 
the final ξ-potential (p<0.05), there is a significant difference when the ξ-potential drops to 
its lowest value; -46 mV (p<0.05).  Considering this inflection alongside the size and PDI 
data (Fig 4.5/4.6), this change occurs as the particles undergo the phase-transition i.e. on 
the slope as the particles are aggregating.  The point at which the ξ-potential starts to 
increase (27 oC) is the point at which the size and PDI also start to increase.  Likewise, 
once the ξ-potential has “recovered”, the particle size and PDI has plateaued.  Based on 
these observations, it is possible to conclude that as the particles are aggregating they are 
151 
 
becoming more stable; however this is only an intermediate step before the particles 
become fully aggregated, when the ξ-potential starts to decrease again. 
Considering all the DLS data, some very interesting phenomena are occurring.  The 
PNIPAM-silica nanoparticles show changes in hydration shell thickness below the LCST 
followed by an equilibrated aggregation, a trend not mimicked in PNPOZ-silica 
nanoparticles.  No changes occur in the unfunctionalised silica nanoparticles, confirming 
that the presence of the polymer is causing these thermal events.  To confirm these 
finding, SANS experiments were employed. 
4.3.3 Small Angle Neutron Scattering 
4.3.3.1 Silica-matched SANS 
The initial proposal to measure the structural changes observed by DLS was to use 
contrast variation to assess changes occurring in the shell around the silica nanoparticle 
at different temperatures.  Initially the silica was matched out by placing particles in a 
solvent mixture of 80% H2O and 20% D2O (as discussed in 4.2.4), and then placed in the 
beam-line at temperatures chosen based on the DLS data.  Following data collection 
however, no contrast was observed from polymer shell (Fig 4.8) and so unfortunately the 
data could not be used.   
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Fig 4.1 Contrast matched silica nanoparticles functionalised with PNPOZ (A) or PNIPAM (B).  
Data is the reduced scattering data for the shell only at different temperatures. 
 
From the data, it is clear that no structural features can be determined based on the 
scattering.  As the I(Q) is a flat line, it suggests no contrast meaning no structural 
information can be assessed.  The reason for this could be 2-fold; time, and match-point.  
The strongest limitation to the study was time, and the matched sample could not be 
detected above the background due to lack of time on the beam-line.  Given more time, it 
could be possible to draw-out some structural information by minimising the background 
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scattering and improving the statistics.  The other limitation is the match-point itself.  It is 
well known that D2O is much better at scattering neutrons than H2O, hence why it is used 
in scattering experiments.  As the sample is 80% H2O and only 20% D2O, it means there 
will be a very high background due to a large amount of incoherent scattering, and any 
information on the sample will be lost.   
Despite the disappointing lack of results, when placed in a non-matched system (i.e. in 
100% D2O) the spectra did show some structural features that were possible to analyse.   
4.3.3.2 Scattering in 100% D2O 
The reduced scattering data for PNIPAM and PNPOZ functionalised silica can be found in 
Fig 4.9, with the incoherent background subtracted. 
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Fig 4.2 Raw scattering data for PNIPAM-silica and PNPOZ-silica nanoparticles at 25, 30, 35, 
and 40 
o
C obtained on the D11 instrument at the ILL. 
 
Looking at these data, it is clear that the samples change upon heating.  PNPOZ has a 
lower LCST than PNIPAM, and this is reflected in the scattering data.  Nothing appears to 
be changing in the particles at high Q values (known as the Porod region), however at low 
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Q values (the Guinier region) the scattering patterns start to separate to higher I(Q) values 
as temperature increases, indicating the presence of a large structure.  A definition of 
these regions can be found in Fig 4.10. 
 
Fig 4.3 SANS scattering profile for PNIPAM functionalised silica nanoparticles at 40 
o
C, 
indicating particle-particle interactions (A), the Guinier region (B), the Porod region (C), the 
Debye region (D), and (E) incoherent background (subtracted from final results). 
 
Regions of low Q values (shown in Fig 4.10A) define the bulk-structure of the particles, 
and are used to assess particle-particle interactions.  By fitting this region to a specific 
model it is possible to generate information on particle aggregates, and interactions.  This 
region is of great interest in the determination of quaternary protein structure.23 The 
Guinier region (Fig 4.10B) defines the size of particles, which is dependent on intensity, 
I(Q).  In a monodisperse system, the Guinier region will be flat, indicating a purely 
monodisperse system of a given size.  Here, the Guinier region starts to level off, but the 
intensity increases again, indicating aggregation amongst the samples.  The Porod region 
(Fig 4.10C) defines the surface of the particle, and (in the case of functionalised 
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nanoparticles) will provide information on the shell-structure.  At larger Q values (>1), it is 
possible to determine the molecular structure of a crystalline material.  It is this region 
where Bragg peaks exist, and as such typically no Bragg peaks occur in a SANS 
experiment.  The Debye region (Fig 4.10D) defines the shape of a particle.  By fitting the 
spectra obtained from a neutron scattering experiment to a defined model, it is possible to 
provide information on the particle.  If this information is then applied to another model, it 
is possible to establish interactions between the particles, and how they are aggregating.  
Finally, Fig 4.10E shows the incoherent background, which was removed from the final 
data series. 
One of the key parameters needed in SANS fitting is the scattering length density (SLD) 
for the particles, polymer and background solvent.  This value is based on the sum of 
individual neutron scattering lengths for atoms making up the unit cell.  Each element, and 
isotope of said element, has a specific scattering length i.e. depending on the nuclear 
make-up of the element, spin properties and energy levels; neutrons will scatter at a 
specific wavelength.  The scattering length density, defined by Equation 4.2, represents 
the scattering power from a given system, or unit cell.   
𝑆𝐿𝐷 =
∑ 𝑏𝑖
𝑁
𝑖=1
𝑉𝑚
     Equation 4.2, 
where N is the number of atoms in a unit cell, bi is the scattering length contribution from 
each individual atom and Vm is the volume of the unit cell.   It is the SLD that makes it 
possible to carry out contrast-matching experiments.  Given the large differences in SLD 
between H2O (-5.61 x10
-7 1/Å2) and D2O (6.35 x10
-6 1/Å2), it is possible to mix the two 
solvents together in different ratios to match the SLD of a system.  For example, the SLD 
of SiO2 nanoparticles is 3.48 x10
-6,24 so with a mixture of 35% D2O and 65% H2O, it is 
possible to match-out the silica, essentially making it invisible to the neutrons.  However, 
in 100% D2O, as shown here, all the particles (core and shell) are visible to the neutron 
beam. 
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4.3.3.2.1 PNIPAM-silica 
For PNIPAM-silica nanoparticles, the fitting parameters were first established using the 
scattering profile for unfunctionalised silica alone fitted to a sphere model.  Data were 
fitted to pre-defined form factors built into the SASview software, which define the model 
being studied.  To fit the data accurately, several parameters need to be known, shown in 
Table 4.3. 
Table 4.3 List of parameters used to fit SANS data to a sphere model, and the definitions of 
each parameter.  Fitting is for thiolated silica nanoparticles.  
Parameter Value Definition 
Background 0.05 The baseline at high Q 
Scale factor 0.001 Volume fraction 
Radius 137.2 Å Particle radius 
SLD(solvent) 6.35 x10
-6 1/Å2 Scattering length density of D2O 
SLD(core) 3.2 x10
-6 1/Å2 Scattering length density of silica 
PDI 0.35 Polydispersity 
 
By placing constraints into the model using known experimental values (for example the 
volume fraction, size and PDI), it is possible to determine the shape and size of the 
particles.  Here, the Q range was shortened to between 0.007 and 0.1 Å-1, removing the 
large background from the sample, as no change in scattering occurred at values above 
0.1 Å-1, as well as the particle interactions shown at low Q, which will be separately 
studied.  The fitting profiles can be found in Fig 4.11. 
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Fig 4.4 Scattering profile and fit to a sphere molecule for thiolated silica. 
 
Due to the presence of large error bars at high Q values (~0.06 Å-1) it was not possible to 
gain a more accurate fit (Chi2 = 23).  Despite this, a diameter of 28 nm was obtained, 
which corroborated with the literature values using SANS on these 50 nm silica 
nanoparticles,25 and the TEM data (see Chapter 6 for details).  
The values obtained for unfunctionalised silica (namely core radius and PDI) were used 
as set parameters in further fitting experiments.  PNIPAM-silica and PNPOZ-silica spectra 
were also fitted to this model, and in all cases a diameter of 28 nm was obtained. 
Unfortunately, due to lack of contrast between the polymer and the D2O background it was 
not possible to obtain any information on the corona around the particle.  Therefore, the 
data was only fitted to a sphere model.  The scattering profile for PNIPAM-silica 
nanoparticles at different temperatures can be found in Fig 4.9. 
It is clear that at low Q values (due to the increase in intensity in the Guinier region) larger 
aggregates form even below the LCST.  This can be seen by an increase in intensity 
rather than a levelling off.  The reason for this could be two-fold; a high concentration of 
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particles, causing particles to interact more readily in a confined environment, or sample 
contamination.  General aggregation of the sample is unlikely as (based on the DLS data) 
the sizes at lower temperatures suggest no aggregation (due to low PDI and particle sizes 
similar to that of the unfunctionalised silica).  In addition, ξ-potential values are around -30 
mV, suggesting that very few particle interactions could occur.  However, it is possible that 
the dilutions used in DLS experiments may not be best suited for SANS experiments. 
From fitting the spectra to a sphere, the inter-particle interactions were determined.  For 
this, the particles were fitted to either a linear pearls model, or a fractal model depending 
on the temperature.  These fits can be found in Fig 4.12, and the findings summarised in 
Table 4.4. 
 
 
 
Fig 4.5 Fitting profile of PNIPAM-silica nanoparticles to a linear-pearls model (at 25, 30, and 
34 
o
C), or a fractal model (40 
o
C) 
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Table 4.4 Data obtained from the fits of PNIPAM-silica nanoparticles at different 
temperatures.  Samples at 25, 30, and 34 
o
C were fitted to a linear-pearls model, whereas 40 
o
C 
was fitted to a fractal model. 
Temperature 
(oC) 
Number of 
pearls 
Distance 
between 
pearls (nm) 
Fractal 
dimension 
Size of 
aggregate 
(nm) 
25 3 2.3 x10-8 - - 
30 3 2.0 x10-8 - - 
34 14 5.3 x10-7 - - 
40 - - 2.5 84 
 
From these data, it is possible to conclude that at lower temperatures (i.e. below 30 oC) 
the particles are loosely agglomerated (possibly due to a high concentration).  This is 
represented by a very close proximity of particles to each other.  It should be noted that in 
fitting, the value representing “number of pearls” did not affect the fit, and changing this 
number resulted in very minor changes to the Chi2 of the fit, further suggesting particle 
agglomeration.  However, at 34 oC, the point at which the particles undergo phase-
transition (shown by DLS), the particles become less tightly aggregated, but the number of 
particle interactions increases.  This time, changing the number of pearls does alter the fit, 
suggesting only a limited number of particles are interacting with each other, confirming 
the equilibrium hypothesis discussed earlier.  Finally, at 40 oC, the particles no longer 
fitted to a linear-pearl model, and instead were fitted to a fractal model.  Here, it is 
possible to conclude that the final agglomerates have a well-defined structure, with a 
fractal dimension of 2, with a definitive size, as predicted by DLS.  From this, a proposed 
model for the agglomerates can be deduced (Fig 4.13).   
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Fig 4.6 Proposed structure of PNIPAM-silica nanoparticles in an aggregated state at 40 
o
C. 
 
Given that the silica core has a radius of 14 nm (diameter 28 nm), and the overall size of 
the aggregate is 84 nm, 3 nanoparticles appear to interact to form this 3D structure.  
Depending on the spatial orientation of these particles, this data is corroborated by DLS 
(Chapter 2, and Table 4.2).  The 84 nm aggregate size predicted by SANS fits the DLS 
size of 106 nm at the same temperature (when one takes into consideration the addition 
of a hydration shell around the aggregate which is not detected by SANS). 
The SANS data is in good agreement with the DLS data (Chapter 2, and Table 4.2), and 
confirms the hypothesis that at higher temperatures (above 34 oC), the functionalised 
nanoparticles form small clusters with a very uniform overall size.  It is likely that the 
temperature will dictate how tight the interactions between the particles are given the 
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changes observed in DLS: higher temperatures cause tighter interactions.  From these 
data it is not possible to describe the interactions occurring in the particles between 34 
and 40 oC (shown in DLS) due to lack of SANS data. 
4.3.3.2.2 PNPOZ-silica 
In addition to PNIPAM-silica, PNPOZ-silica was also measured at the same temperatures.  
As with the PNIPAM-silica; the particles were first fitted to a sphere model, followed by the 
fractal model.  Due to the high levels of hydration exhibited by the PNPOZ 
macromolecules, it was not possible to differentiate between the core and the shell of the 
particle, given that the shell is masked by D2O surrounding the particle i.e. in the hydration 
shell.  Previous studies looking at POZ macromolecules have shown that they become 
highly hydrated, explaining the lack of contrast shown here.26,27  As such, the particles 
were fitted to a sphere model alone, resulting in a size of 28 nm.  Again, all fits were 
between 0.007 and 0.1 Å-1. 
From these fits, the particle interactions were again modelled to either a linear-pearls 
model or fractal model depending on the temperature.  These data can be found in Fig 
4.14, and summarised in Table 4.5. 
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Fig 4.7 PNPOZ-silica nanoparticles fit to a linear pearls model at 25 and 30 
o
C, and a fractal 
model at 34 and 40 
o
C 
 
Table 4.5 Summary of the data obtained from PNPOZ-silica fitting. 
Temperature 
(oC) 
Number of 
pearls 
Distance 
between 
pearls (nm) 
Fractal 
dimension 
Size of 
aggregate 
(nm) 
25 2 2.8 x10-8 - - 
30 3 2.8 x10-8 - - 
34 - - 2 7854 
40 - - 3 237 
 
From these data two conclusions can be made.  Firstly at 25 and 30 oC, there is some 
aggregation suggesting a high concentration of particles, as was seen with the PNIPAM-
silica particles.  At higher temperatures however, there appears to be bulk aggregation of 
the samples, as shown in the fractal model.  Unlike the PNIPAM-silica particles, the 
aggregate size here is very large, and varies markedly.  Indeed, an aggregate size of 7.8 
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µm (at 34 oC) shows that the particles are simply aggregating randomly together in 
suspension, unlike the PNIPAM-silica particles.  DLS data (Fig 4.5), showed large error 
bars at higher temperatures (i.e. above 34 oC), along with a large increase in PDI (up to a 
PDI of 1), confirming the formation of large aggregates.  Although both polymers are 
structural isomers (Fig 4.15), it is problematic to make a direct comparison, as PNIPAM 
contains an isopropyl group, whereas PNPOZ contains an n-propyl group.   
 
 
 
 
 
Fig 4.8 Molecular structure of PNIPAM (A) and PNPOZ (B). 
 
However, it could be that the position of the nitrogen atom plays a key role in how the 
particles are aggregating, whether uniformly or randomly.  Given that the nitrogen atom in 
a secondary amide is more accessible, it is able to form stronger hydrogen bonds with 
water molecules in the surrounding media.28  A tertiary amide however (as found in 
PNPOZ) will form fewer hydrogen bonds, thus binding more weakly to water molecules.  
Assuming this is the case and that PNPOZ is interacting more weakly with water, the 
hydration shell around the particles will be more unstable (both above and below the 
LCST), causing a weaker hydration shell.  To test this hypothesis, additional SANS and 
DLS data on poly(2-isopropyl-2-oxazoline) will be required. 
Considering the DLS data, as already discussed, it is clear that the hydration shell around 
PNIPAM plays a strong role in how it behaves at different temperatures (based on the 
initial size decrease, followed by aggregation).  Given that there is no size decrease in the 
PNPOZ-silica nanoparticles, it suggests that the hydration shell is weaker (as water is 
A) B) 
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more loosely bound and will not change at lower temperatures), which leads to more 
random aggregation.  This is confirmed using SANS analysis and the inter-particle 
interactions. 
4.3.4 Diffusion in organic solvents 
Given the structural changes shown by these particles at different temperatures, the 
diffusion coefficient variation in different solvents with different polarities was studied.  
Here, the diffusion of functionalised and unfunctionalised nanoparticles was measured in 
3 different solvents; water, ethanol and DMSO at different temperatures (Fig 4.16).  The 
temperatures were chosen based on the phase of the polymer-nanoparticle composite, 
shown by the DLS data (Fig 4.5), and reflect those used in SANS experiments.  
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Fig 4.16 Diffusion coefficients for functionalised and unfunctionalised silica nanoparticles in 
water, ethanol, and DMSO at different temperatures.  Means ± standard deviation, n=3, *P<0.05 
against unfunctionalised silica at the same temperature. 
The data show clear differences between the solvents.  As would be expected, the 
particles are most diffusive in water, followed by ethanol, and DMSO.  This is due to 
changes in viscosity between the solvents.  Water at 25 oC has a viscosity of 0.89 cP, 
whereas ethanol has a higher viscosity (1.04 cP) at the same temperature and DMSO 
higher still (1.99 cP), meaning the particles will diffuse slower.  
Similarly, as the temperature increases, the diffusion coefficient also increases.  Again, 
this is to be expected as (by increasing the temperature) the viscosity decreases due to a 
weakening of the intermolecular interactions between molecules, caused by an increased 
amount of energy in the system.  This causes the particles to diffuse faster because the 
viscosity is reduced. 
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Interestingly, it appears as though functionalising the nanoparticles causes them to diffuse 
significantly faster in ethanol (p<0.05 for both PNIPAM and PNPOZ, Student’s t-test), and 
water (p<0.05 for PNPOZ and PNIPAM at 40 oC, Student’s t-test).  This phenomenon has 
been noted before,25 and is likely due to the “hairy” nature of the particles disrupting the 
normal laminar flow of the particles, this providing them with extra mobility, causing them 
to propel through the media faster.  
Since both PNIPAM and PNPOZ undergo a coil to globule transition, causing the particles 
to become more hydrophobic in nature, it would be expected that placing the particles in a 
more polar environment would alter their diffusive properties.  This can be seen from the 
diffusion coefficient of the particles, compared to the unfunctionalised silica.  In DMSO, 
the least polar of the three solvents, the functionalised particles start to move more rapidly 
at the higher temperatures compared to the thiolated silica.  This difference was found to 
be significant (p>0.05) at 40 oC for PNPOZ-silica.  It should be noted that, as the particles 
are diluted from their stock-solution in water into the solvent, a co-solvency effect will exist 
between the water bound to the particles themselves and the solvent in the external 
environment.  This will cause the particles to behave differently depending on the 
temperature.  Indeed, PNIPAM-silica nanoparticles suspended in methanol measured 
using the same temperature ramp experiments show no phase transition, however they 
did exhibit the subtle decline in particle size (Fig 4.17). 
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Fig 4.17 Size of PNIPAM-silica nanoparticles suspended in water (blue) and methanol (red) 
recorded using DLS.  Means ± standard deviation, n=3 
 
As can be seen, a co-solvency effect between the particles in water and the particles in 
methanol exists which eliminates the phase-transition. This will affect their diffusion 
coefficient by minimising the changes caused by the LCST of the polymer, thus explaining 
the pattern in diffusion coefficients of particles in DMSO.  Previous research has 
suggested that the addition of methanol to PNIPAM-functionalised nanoparticles, leads to 
a decrease in LCST,29 which would explain why the size appears much larger than the 
unfunctionalised particles; they have already undergone phase transition and formed 
aggregates.   
Given that the LCST is dependent on several factors, concentration of solvent, size of 
PNIPAM chain, and grafting density,30 the co-solvency effect has a dramatic effect on 
apparent size and state of the particles (i.e. aggregated vs free) in solution, which would 
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further affect their diffusion coefficients.  This could explain the phenomenon here, and 
why the effects seen are not as marked as would be expected. 
Considering the diffusion coefficients for the more polar solvents (water and ethanol), 
there is an increase in diffusion coefficient both above and below the LCST for PNIPAM 
and PNPOZ-silica nanoparticles.  It would be expected that the diffusion coefficient would 
decrease in samples above the LCST, mainly due to the formation of aggregates and the 
more hydrophobic nature of the polymer shell.  However, this does not appear to be the 
case, and the phase of the shell around the particle does not affect the diffusion 
coefficient.  It is possible to rule out particle aggregation based on the fact that the 
concentration of particles (as determined by NTA) does not change between samples.  It 
has been suggested in the literature that PNIPAM is not fully hydrophobic both below and 
above the LCST,31 meaning that the hydrophobic nature of the shell will be significantly 
weakened.  By relating this to the diffusion coefficients, it means that the particles will not 
show decreased movement based on hydrophobic interactions.  Although there is no 
research relating the same principle to PNPOZ, given that PNIPAM and PNPOZ are 
structural isomers of each other (the only difference being the isopropyl group in PNIPAM, 
and the 10/20 structure of the amide), it is possible that a similar phenomenon is occurring 
and that PNPOZ is also not fully hydrophobic after the LCST.  To assess how the diffusion 
of particles varies at higher concentration in these solvents, additional experiments could 
be carried out, using DOSY. 
Given the LCST of PNIPAM and PNPOZ is 32 and 25 oC respectively, it is possible to 
conclude that the phase and size of the solvation shell around the particles does not affect 
the diffusion coefficient. For ethanol, this can be explained by the co-solvency effect 
described above, and in water systems this is due to the hydrophobic nature of the 
polymer.   
These findings show that the LCST of a polymer can be greatly affected by the 
physicochemical properties of the surrounding media.  This is important in many areas, 
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including drug delivery given the continuing interest in the development of “smart” 
nanoparticle systems which are responsive to temperature. 
4.4 Conclusions 
This study investigated the temperature responsive nature of two different polymers 
(PNIPAM and PNPOZ) grafted to silica cores and how the phase transition affects their 
diffusion in organic solvents with different polarities.  Using a combination of SANS and 
DLS, it is possible to conclude that the PNIPAM-silica nanoparticles undergo a phase-
transition at 34 oC, after which they form controlled aggregates of similar sizes based on 
an equilibrium.  This effect was not seen in the PNPOZ-silica nanoparticles which form 
random clusters in solution.   
Regarding their diffusion coefficients, it is clear that both the addition of a polymer shell 
around the particles and the polarity of the solvent play a key role in determining the 
particles diffusion coefficient.    In DMSO, the least polar of the solvents studied, the 
unfunctionalised particles diffuse at a similar rate regardless of temperature.  A similar 
observation was seen for the functionalised particles below the LCST of the polymer shell, 
whereas above the LCST the particles are much more diffusive.  This is to be expected as 
the particles are more hydrophobic in nature.  In addition, in more polar solvents (namely 
water and ethanol) the functionalised particles appear to diffuse faster after 
functionalisation.  This is likely due to the polymer shell interacting strongly with the 
surrounding media, causing the particles to move faster under Brownian motion, and 
indeed the diffusion coefficients of both types of functionalised particle (PNIPAM-silica and 
PNPOZ-silica) appear relatively similar.  The effect of phase transition shows a continuing 
increase in diffusion coefficient.  This is likely due to the hydrophobic nature of the 
particles repelling water, causing them to move faster, rather than aggregating and 
moving slower.   
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This study is the first to examine the molecular effects of temperature responsive 
nanoparticles in different polar environments, and shows that functionalised particles will 
diffuse more rapidly than unfunctionalised particles regardless of environment, and the 
transition of the polymer has no effect, except in more polar systems.  This study is useful 
for multiple industries, given the wide applications of TRP-functionalised nanomaterials 
appearing in the literature. 
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Chapter 5                           
Diffusion and penetration of 
PEGylated and POZylated 
nanoparticles through gastric mucus 
5.1 Introduction 
This chapter discusses the diffusive properties of PEGylated and POZylated nanoparticles 
through mucin dispersions, and assesses their ability to penetrate into gastric mucosa.  It 
has previously been shown that poly(ethylene glycol) (PEG) can enhance nanoparticle 
diffusion through a mucin network,1,2 however poly(2-oxazolines) (POZ) have not been 
studied for this phenomenon. 
PEG is an important pharmaceutical polymer, and is used in multiple dosage formulations 
and marketed drugs.  It is a biocompatible, non-toxic polymer which also exhibits “stealth” 
properties, making it undetectable by the immune system, hence its wide number of 
applications in the pharmaceutical industry.3  In addition, it has been shown that by 
functionalising nanoparticles with PEG it is possible to reduce the surface interactions 
between the core particles and the external environment, thus enhancing biocompatibility 
whilst maintaining the unique properties of a nanomaterial.4  This concept led investigators 
to study the effects of PEGylated polystyrene nanoparticles on diffusion though mucus 
barrier.5,6  It was found that upon functionalisation, the particles were significantly more 
diffusive through fresh mucosa than the unfunctionalised particles, which became trapped 
and did not diffuse at all.  This finding is of great interest, as it provides the potential for 
hydrophobic drugs (which would normally be trapped in mucus) to be delivered by less 
invasive routes, e.g. by the oral route or airways in the form of an aerosol. 
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POZ macromolecules show similar pharmaceutical properties as PEG in that they are 
non-toxic, biocompatible polymers which exhibit similar “stealth” properties.7  However, 
they carry some significant advantages over PEG which makes them an increasingly 
popular polymer in both academia and industry, and there are examples of POZ 
formulations currently undergoing clinical trials, highlighting their importance as the next-
generation PEG.8  Despite this, POZ is not currently FDA approved, although approval is 
expected within the next few years.9   
As already stated, POZ has some significant advantages over PEG.  Under some 
conditions, it has been shown that PEG can bioaccumulate and form vacuoles in certain 
organs.  POZ however does not show this effect and is more readily cleared from the 
body via renal clearance than PEG, with no reported bioaccumulation.10,11    However, the 
biggest advantage POZ has over PEG is a functionalisable alkyl side chain, allowing for 
easy modification such as the binding of a pro-drug,12,13 or a specific ligand allowing for 
targeted drug delivery.14 
POZ is synthesised using a cationic ring-opening polymerisation reaction of 2-
oxazolines.15  This method of synthesis allows highly controllable synthesis, resulting in 
POZ macromolecules of different molecular weights where the PDI can be kept low.  PEG 
is synthesised by the ring-opening of ethylene oxide, under anionic conditions.16  As 
ethylene oxide is more toxic compared to 2-oxazolines, there is reduced risk of adverse 
effects if the polymer contains any starting material, providing a further advantage of POZ 
over PEG.    
With the known mucus penetrating abilities of PEG, it is valuable to examine whether POZ 
has the same ability.  In this study, the mucus penetrating effects of POZ were assessed 
by grafting 5 kDa poly(2-ethyl-2-oxazoline) to 50 nm silica nanoparticles.  In addition, 5 
kDa PEGylated silica was used as a positive control, based on the fact that it has 
previously shown mucus penetrating abilities.1,2 
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Prior to synthesis and functionalisation (described in Chapter 2), the particles were 
fluorescently labelled with either BODIPY TMR C5 maleimide, or fluorescein-O-
methacrylate.  This allowed the particles to be visible over the mucin dispersion, making it 
possible to measure their diffusion coefficient in a dispersion using Nanoparticle Tracking 
Analysis (NTA).  In addition, a novel technique was developed in order to measure how 
far the particles could permeate through a fresh gastric mucosa. 
5.2 Materials and methods 
5.2.1 Materials 
Unfunctionalised thiolated silica, PEGylated silica and POZylated silica nanoparticles were 
used (see Chapter 2 for details).  Here, POZ was purchased from Sigma. 
Fluorescein-O-methacrylate, BODIPY TMR C5 maleimide and DMSO were purchased 
from Fisher (UK).  Porcine gastric mucin type II, triethylamine (TEA), and kaolinite were 
purchased from Sigma-Aldrich (UK).  All the water used was ultrapure and particle free 
(18 ΩM).  For the permeation study, a fresh porcine stomach was obtained from a local 
abattoir (P.C.Turner Abattoirs, Farnborough, UK).  
5.2.2 Synthesis of fluorescently labelled nanoparticles 
Two different fluorophores were used; BODIPY TMR C5 maleimide (excitation 544 nm, 
emission 570 nm), and fluorescein-O-methacrylate (excitation 490 nm, emission 520 nm).   
All particles were fluorescently labelled prior to polymer functionalisation.  Based on the 
results of the Ellman’s assay (Chapter 2, 2.3.1), nanoparticles were labelled with 
fluorophore so that only 5% of the free thiol groups were reacted, leaving 95% free for 
polymer functionalisation. This loading was selected from an optimisation study wherein a 
series of increasingly fluorescent nanoparticles were produced and their fluorescence 
spectra determined, compared to that of a 1% w/v mucus dispersion. Given that mucin 
has an intrinsic fluorescence, it is important to determine a quantity of fluorophore needed 
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to make the particles visible.  It was found that 5% labelling was sufficient to ensure that 
the particles were detectable above the background fluorescence.  
380 µL aqueous BODIPY (1.8 mM) was reacted with a 5 mL suspension of nanoparticles 
(19±3 mg/mL). The fluorophore and nanoparticles were reacted for 24 hours in the dark, 
and then purified by dialysis in 4 L deionised water (again in the dark), using a 12-14 kDa 
cut-off membrane.  The water was changed over a 48 hour period with a minimum of 8 
changes.   
For fluorescein labelling, fluorescein-O-methacrylate was initially dissolved, in a 50:50 % 
v/v ethanol - deionised water solution, to a final fluorescein concentration of 1.8 mM.  
Additionally, a 5 mL nanoparticle suspension (19±3 mg/mL) was diluted with 5 mL DMSO.  
Following this, 0.4 mL of ethanolic fluorescein-O-methacrylate solution was added (so the 
final concentration of fluorescein in the reaction mixture was 0.066 mM), along with 200 
µL TEA (0.033 mM final concentration). The reaction was left to stir in a flask for 24 hours 
in the dark.  Particles were purified by dialysis once the reaction was complete. 
5.2.3 Characterisation of mucin dispersion 
Prior to the diffusion studies, mucin dispersions were assessed for their rheological 
properties in order to identify the viscosity of the dispersion.  Three fresh solutions of 1, 2, 
and 3% w/v porcine gastric mucin type II were prepared in 50 mL miliQ water. 
Rheological analysis used an AR 2000ex rheometer (TA Instruments, UK) with a 40 mm 
parallel plate and solvent trap.  Initially, samples were measured to determine the linear 
viscoelastic region at 25 ⁰C.  Two experiments were performed; an amplitude sweep and 
a frequency sweep, using the 3% dispersion.  Initially, a frequency sweep was performed, 
scanning between 0.1 and 10 Hz, at set amplitudes of 1 %.  Following this, an amplitude 
sweep was performed, between 0.1 and 10%, at a fixed frequency of 3 Hz.  All 
experiments were performed at ambient temperature.  The final optimal parameters 
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employed were; amplitude 1 % and frequency 3 Hz.  These were applied for all remaining 
rheological experiments. 
After determination of the linear viscoelastic region, samples were subjected to a 
temperature ramp in order to measure the viscosity of the dispersions.  Here, the 
instrument was set to increase by 1 ⁰C/min, between 20 and 40 ⁰C.  Viscosity was then 
plotted as a function of time, and the line equation used to determine the viscosity the 
mucin dispersions at 25 and 37 ⁰C. Each solution was measured 3 times, for each 
parameter (amplitude, frequency, and temperature), resulting in a total of 9 readings for 
each concentration.  
5.2.4 Nanoparticle diffusion in a mucus dispersion 
NTA was used to measure the diffusion coefficients for BODIPY labelled nanoparticles. All 
measurements were performed using a NanoSight LM10 system, with LM14 laser module 
and metal top plate, SCOMS camera, green 532 nm (50 mW) laser, and syringe pump.  
Before any videos were recorded, the stock solution of nanoparticles was diluted down to 
a working concentration of 1:1,000 by serial dilutions into milliQ water.  10 µL of the final 
dilution was then added to 990 µL of 1% w/v gastric mucin dispersion, resulting in a final 
dilution of 1:10,000. 
The final 1 mL suspension was then injected into the NanoSight system and the syringe 
pump, using plastic 1 mL syringes, used to flow the sample.  For all experiments, the flow-
rate was set at 70 AU in order to minimise fluorescent bleaching of the nanoparticles 
during analysis.  All videos were recorded through a long pass filter with a wavelength cut-
on of 550 nm (Thorlabs, UK). 6×60 second videos were recorded at both 25 and 37 ⁰C.  
Each independent stock dispersion of mucin was measured three times for each 
nanoparticle type, resulting in a total of nine 6x60 second videos for each temperature, for 
each type of nanoparticle.  Following recording, the videos were analysed using NTA v2.3 
and the diffusion coefficient of the particles determined.  The viscosity determined from 
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rheological analyses (20 cP and 23 cP for 25 and 37 oC, respectively) was used during 
analysis. 
5.2.5 Nanoparticle penetration through a mucosal barrier 
The fresh porcine stomach was dissected to remove any connective tissue and muscle, 
leaving only the mucosa, submucosa, and stomach lining intact.  4×1 cm2 sections were 
cut and placed on a glass plate, with the mucosal layer facing upward.  200 µL of 
fluorescein labelled nanoparticles (5 mg/mL) were then pipetted onto the sections and left 
to incubate over 4 time periods; 0, 15, 30, and 45 minutes at room temperature.  
Deionised water was used as a blank control.  At the end of the incubation period, each 
section was placed mucus side up into a small (3.5×5.5 cm) weighing boat (Fisher 
Sceintific, UK), half filled with Optimum Cutting Temperature (OCT) media, a 
cryoprotective embedding medium, and placed on dry ice, before being completely 
embedded in OCT to preserve the particle-loaded mucus membrane.  Once all sections 
were embedded, samples were left on dry ice for 3-4 hours, before being transferred to a -
80 ⁰C freezer for 24 hours. 
Following the time-dependent penetration experiment, samples were sectioned for 
fluorescent microscopy analysis.  Here, samples were removed from the -80 ⁰C freezer 
and placed on dry ice before being mounted onto a standard solid object holder, 22 mm in 
diameter using OCT.  This was then left for at least 30 mins in dry ice to ensure the OCT 
had fully set.  30 µm sections were cut transversely using a standard 189 × 27 × 10 mm 
microtome blade at 22º, placed onto superfrost glass slides (VWR, UK) and left to air dry 
for 30 minutes before being stored in a slide box.  All sections were cut from interior to 
exterior (i.e. upwards through the mucosal layer) in order to avoid forced penetration of 
particles into the biological tissue during the cutting process. All sections were cut using a 
Bright 5040 cryostat in a Bright Model PTF freezing chamber at -20 ⁰C (Bright Instrument 
Co. Ltd, UK).  2 slides were prepared for each sample, each containing 5 tissue sections. 
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Once all the sections had been collected, the penetration of the nanoparticles could be 
assessed.  This was carried out by placing the slides under a Leica MZ10F 
stereomicroscope (Leica Microsystems, UK) and recording images through an ET-GFP 
filter.  Exposure times of 0.8 ms and a gamma setting of 1 were used for all experiments.  
Three images were taken for each section, for both slides. 
ImageJ software (National Institute of Health, USA, v1.43, http://imagej.nih.gov/ij/) was 
used to quantify the degree of penetration for each nanoparticle used in this study.  For 
each image (six for each particle type at each time point); a line was drawn across the 
mucus barrier, measuring 1.5 mm in length, and the “plot profile” measured.  This was 
repeated 5 times at random locations along the mucus barrier for each image, providing a 
total of 15 (3×5) profiles for each sample. Each individual profile was then assessed for 
the degree of penetration.  This was done by measuring the width of the predominant 
peak using Excel, 2010.  After each profile had been analysed, the mean distances were 
calculated.  The value obtained for the blank tissue (tissue with water containing no 
particles) at the appropriate time point was then subtracted from the other values at the 
same time point in order to determine penetration.  Fig 5.1 provides a step-by-step 
description of this process. 
For each image, the background was subtracted off, allowing any background 
fluorescence to be removed, resulting in measurements being made from the same pixel 
intensity.   
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Fig 5.1.  Step by step description (using screen shots) for the method used to measure 
nanoparticle penetration through a gastric mucosa (section 5.2.5). A) and B) show subtraction 
of the background (process>subtract background).  C) and D) show how the scale was set.  E), F), 
and G) show the analysis. The profile from g) was exported and plotted in Excel in order to 
measure the peak width.  
 
A) B) 
C) 
 
D) 
F) 
) 
 a) 
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5.2.6 Statistics  
Each experiment was repeated 3 times (unless otherwise stated), and the data presented 
as mean ± standard deviation. Two-way ANOVA statistical analyses were performed on 
GraphPad Prism v5.0 using Tukey’s post hoc test, where P>0.05 was considered to be 
statistically insignificant.  Tukey’s was used to compare the differences between the 
groups, allowing for the identification of significant differences between the functionalised 
and unfunctionalised particles at different temperatures/time points. 
5.3 Results and discussion 
5.3.1 Nanoparticle characterisation, and fluorescence 
The nanoparticles used in this study were previously characterised as described in 
Chapter 2.  Table 5.1 shows the DLS and NTA data for the specific particles used in this 
study. 
Table 5.1.  The size and of the functionalised and unfunctionalised nanoparticles as 
determined by DLS (a) and NTA (b) (see Chapter 2 for details).  All values show the mean ± 
standard deviation of three independent repeats 
 
 
 
 
 
 
 
 
Fluorescent labelling was carried out before functionalisation.  In order to determine the 
minimum level of fluorescence labelling required to allow the particles to be visible above 
the background fluorescence of the mucin, a pilot study was carried out whereby the 
fluorescence of 1% w/v gastric mucin dispersions were compared to particles labelled with 
an increased concentration of fluorophore (Fig 5.2) 
Sample 
Z-average 
(nm)a 
PDIa 
Modal 
particle 
size (nm)b 
Thiolated silica 48±1 0.137±0.050 47±3 
PEGylated silica 70±1 0.175±0.070 63±2 
POZylated silica 56±2 0.130±0.010 57±2 
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Fig 5.2.  Fluorescence spectrum for a 1% w/v gastric mucin dispersion, and thiolated silica 
nanoparticles labelled with different degrees of BODIPY TMR C5 maleimide. 
 
From this pilot study, 5% coverage of fluorophore was sufficient to make the particles 
visible above the background fluorescence of the mucin dispersion.  Therefore, 5% of the 
reactive thiol groups were covalently bound to fluorophore by calculating the molar 
equivalent of fluorophore needed to bind to 1.8 mM free thiol groups on the nanoparticle 
surface.  These particles were then used for polymer functionalisation. 
5.3.2 Characterisation of the mucin dispersion 
As shown by the Stokes-Einstein equation, viscosity is a key parameter when calculating 
the diffusion coefficient for nanoparticles in suspension.  Therefore prior to any diffusion 
experiments, the mucin dispersions needed to be fully characterised.  In this study, three 
mucin dispersions were made; 1%, 2%, and 3% w/v.  Physiological mucus contains 
between 2 and 5% w/v of mucins,17 depending on the disease state of the organism.  NTA 
has optimum working viscosities of 0 to 10 cP, therefore an optimum concentration needs 
to be determined that is both close to physiological relevance, and also fulfils the criteria 
allowing it to be used in NTA.  Although a small sheer will exist when the dispersion is 
passing through the syringe pump, this will only be small, and NTA effectively works as a 
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zero-sheer system.   It is important to note however, that given the flow set-up utilised in 
these experiments, there could be potential disruption of mucin fibres.  However, given 
that the dispersion is being uniformly moved through the system, it is unlikely this will alter 
the results to much.   
Rheology is the study of the flow conditions of a liquid system.  By applying a fixed force 
and amplitude, it is possible to determine the viscosity of a system based on the amount 
of friction exerted on the liquid.  Prior to measuring the viscosity, experiments need to be 
performed ensuring the mucin remains in the linear viscoelastic region.  These 
experiments were performed on the 3% w/v dispersion only, as the rheological properties 
of a high concentration polymer will be the same as a lower concentration of the same 
polymer (excluding the viscosity).18  Initially a frequency sweep experiment was performed 
to understand how the storage and loss moduli change as a function of oscillation 
frequency.  The data shows the angular frequency (rad/s), which was converted to 
frequency (Hz) using Equation 5.1, where ν is the frequency (Hz), and ω is the angular 
frequency (rad/s). 
𝜈 = 2𝜋 × 𝜔    Equation 5.1 
From this, the frequency distribution could be plotted (Fig 5.3). 
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Fig 5.3 Frequency sweep showing the storage and loss modulus of a 3% w/v mucin 
dispersion.  Values represent the means of 3 repeats. 
From Fig 5.3, it is clear that the storage modulus changes as a higher frequency is 
applied.  The frequency chosen for future experiments was 3 Hz, as both the storage and 
loss moduli are linear at this frequency.  Following the frequency sweep, a strain sweep 
experiment was performed where the frequency was set at 3 Hz, and the strain was 
measured between 0.5 and 10%.  These data can be found in Fig 5.4. 
 
Fig 5.4 Strain sweep showing the storage and loss modulus of a 3% w/v mucin dispersion.  
Values represent the means of 3 repeats. 
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As with the frequency sweep, a point needs to be selected where both the storage and 
loss moduli are linear.  Based on this, 1% amplitude was chosen to perform the 
temperature ramp study. It should be noted that the mucin dispersions presented here are 
not a gelled system, unlike physiological mucus, as the storage modulus is below the loss 
modulus.  Physiological mucus exists as a gel.  This is known for powdered mucin 
dispersions.19 
After determining the above parameters, the viscosity of the dispersions was measured as 
a function of temperature.  This was carried out on 1, 2, and 3 % w/v gastric mucin 
dispersions.  The results are in Fig 5.5. 
 
Fig 5.5 Viscosity of 1, 2, and 3% w/v gastric mucin dispersions as a function of temperature.  
Mean ± standard deviation, n=3. 
 
Using the equation for each line (shown in Fig 5.5), it is possible to calculate the viscosity 
of the dispersions at 25 and 37 oC, the temperatures at which the diffusion experiment will 
be performed (Table 5.2) 
 
y = 0.1947x + 15.483 
R² = 0.0723 
y = 0.3753x + 15.423 
R² = 0.3269 
y = 0.2775x + 22.392 
R² = 0.1905 
0
5
10
15
20
25
30
35
40
45
20 25 30 35 40
V
is
co
si
ty
 (
cP
) 
Temperature (oC) 
1% w/v 2% w/v 3% w/v
187 
 
Table 5.2 Viscosity of mucin dispersions at 25 and 37 
o
C as calculated from the rheology 
data. 
[Mucin dispersion] 
(w/v) 
Viscosity at 25 oC 
(cP) 
Viscosity at 37 oC 
(cP) 
1% 20.3 22.6 
2% 24.8 29.3 
3% 29.2 32.5 
 
Considering the data as a whole, 1% w/v mucin dispersions were chosen for diffusion 
experiments, as the particles are visible at this concentration and the mucin dispersion 
has the lowest viscosity for NTA analysis.  During preliminary experiments it was found 
that the particles were not visible in the 2 and 3% w/v dispersions, due to the consistency 
of the dispersion.  
5.3.3 Diffusion and penetration of nanoparticles through a gastric mucosa 
5.3.3.1 Nanoparticle diffusion in a gastric mucus dispersion 
NTA has previously been used to study the diffusion of nanoparticles through solutions of 
different polymers, namely poly(acrylic acid), poly(N-vinylpyrrolidone), poly(ethylene 
oxide), and hydroxyethylcellulose.4  This study was the first to use NTA to measure the 
diffusion of nanoparticles through a biological dispersion.20  Previous studies looking at 
the diffusion of nanoparticles through mucus dispersions and gels used a technique called 
multiple particle tracking (MPT).  Similar to NTA, this technique measures the movement 
of individual particles over a given period of time, and maps their trajectories.  Based on 
their movement over a given time-scale, it is possible to calculate the mean-squared 
displacement followed by a diffusion coefficient.21  This technique has been used to track 
the movement of nanoparticles,22 proteins,23 and vesicles24 inside living cells and other 
biological milieu, and allows the calculation of the micro-rheology of a given 
environment.22   
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Based on the results from rheology experiments, a 1% w/v solution was chosen to 
measure diffusion coefficients, due to the working viscosity limits of the system.  The 
mean diffusion coefficient were then calculated at two temperatures; 25 and 37 oC, room 
and physiological temperature.  The results are shown in Fig 5.6, and the distribution of 
diffusion coefficients can be found in Fig 5.7 for the functionalised and unfunctionalised 
nanoparticles in mucin dispersions. 
 
Fig 5.6 Diffusion coefficient for thiolated (blue), PEGylated (red), and POZylated (green) 
nanoparticles in a gastric mucin dispersion, measured using NTA.  Mean ± standard 
deviation, n=3. Values marked * show significant differences compared to thiolated silica 
nanoparticles (p<0.05).  No significant difference exists between the diffusion coefficients 
determined at 25 
o
C and those at 37 
o
C, or between PEG and POZ (p>0.05). 
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Fig 5.7 Distribution of diffusion coefficients for thiolated, PEGylated, and POZylated silica 
nanoparticles in 1% w/v gastric mucus at 25 
o
C (A) and 37 C (B).  Mean distributions, n=3. 
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From Fig 5.6 and 5.7, it is clear that upon functionalisation their diffusion coefficient is 
significantly higher.  Thiolated species are well known to be mucoadhesive,25–28 and so 
the particles used in this study will inevitably demonstrate the same mucoadhesive 
interactions.  Indeed, the thiolated silica used in this study has previously been studied for 
retention on bovine cornea29 and bladder mucosa,30 confirming this hypothesis. The 
particles have a very small diffusion coefficient, 46±12 x104 nm2/s (as seen in Fig 5.6) 
compared to the particles in water (788±20 x104 nm2/s).  It is likely that, due to their small 
size, they diffuse around the mucus network and so do not contact the protein, thus not 
adhering to them; the reported diameter for a mucus network is 200-300 nm.31  As the 
mucus dispersion used here was prepared from freeze-dried processed mucus and not 
fresh mucus, it is also likely that during the processing procedure many of the cysteine 
residues have been lost, thus allowing fewer mucoadhesive interactions. 
By functionalising nanoparticles (or even proteins) it is possible to reduce their surface 
interactions with the surrounding medium, thus minimising the mucoadhesive effects.  It 
has previously been reported by several authors that by functionalising polystyrene 
nanoparticles with PEG it is possible to enhance their diffusion through a mucosal 
barrier1,32.  The data presented in Fig 5.6 confirms this, as the PEGylated nanoparticles 
are significantly more diffusive than the unfunctionalised silica nanoparticles, where the 
diffusion coefficients were 127±34 x104 nm2/s for PEGylated silica, compared to 46±12 
x104 nm2/s for thiolated silica at 25 oC.  This is mimicked in the distribution for diffusion 
coefficients (Fig 5.7), where there is a clear shift to the right after functionalisation. 
In addition, this study also looked at the addition to POZ to a particle surface and whether 
this polymer-nanoparticle composite shows similar enhanced diffusion coefficients as 
exhibited by PEG.  As Fig 5.6 shows, there is a statistically significant increase in diffusion 
coefficient with POZylation, where the diffusion coefficient increases from 46±12 x104 
nm2/s (unfunctionalised silica) to 208 ±31 x104 nm2/s (POZylated silica).  Again, this is 
further illustrated by the distribution of diffusion coefficients (Fig 5.7), where there is a 
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clear shift to the right upon functionalisation.  No statistically significant difference was 
noted between PEG and POZ (p>0.05).  It should be noted that as the mucin dispersions 
are under flow, there could be a disruption of the fibrous network.   By forcing the 
dispersion through the syringe pump, a sheer will be placed on the mucin which will 
break-up the mesh-like structure the protein exhibits, reducing the diffusion coefficients 
determined less physiologically relevant. 
Based on these data, it is clear that the addition of either PEG or POZ to the surface of 
the nanoparticles significantly increased their diffusion coefficient through the mucin 
dispersion compared to the functionalised silica.  Limitations to the Stokes-Einstein 
equation were described in Chapter 1, section 1.2.4; here, diffusion coefficients for the 
functionalised and unfunctionalised nanoparticles in mucus were calculated using the 
equation (Fig 5.8). 
 
Fig 5.8 Calculated diffusion coefficients for functionalised and unfunctionalised silica 
nanoparticles in mucus at 25 and 37 
o
C.  Data are based on the nanoparticle size obtained by 
DLS ± SD. 
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As can be seen, based on the calculated diffusion coefficients it would be expected that 
the unfunctionalised silica nanoparticles diffuse the fastest, as they are the smallest in 
size, followed by POZylated nanoparticles and PEGylated nanoparticles respectively.  
However that is not the case.  When looking at the experimentally determined diffusion 
coefficients (Fig 5.6), there are clear discrepancies between the two data sets.  The 
calculated and experimentally determined diffusion coefficients for thiolated silica at 37 oC 
(blue), 34 ± 1 x104 nm2/s and 46 ± 12 x104 nm2/s respectively, are relatively similar, and 
within the standard deviation of each-other (i.e. not significant, P<0.05, Student’s t-test).  
However, the calculated diffusion coefficients for PEGylated silica (23 ± 3 x104 nm2/s) and 
POZylated silica (29 ± 1 x104 nm2/s), are clearly different from the experimentally 
determined diffusion coefficients (127 ± 36 x104 nm2/s and 208 ± 31 x104 nm2/s for PEG 
and POZylated silica respectively.   
As expected, the calculated diffusion coefficients for both PEGylated and POZylated 
nanoparticle is smaller than that of the thiolated silica, as the particle size is larger, and 
will therefore diffuse slower under Brownian motion.  However, when considering the 
experimentally determined diffusion coefficient for these particles, there is a clear 
difference to those calculated.  The reason for this could be two-fold; the functionalised 
surface of the particles is causing the particles to diffuse faster (a factor not considered in 
the Stokes-Einstein equation), and/or a deviation from the Stokes-Einstein equation due to 
the presence of non-spherical particles with a “hairy” surface, a widely studied limitation of 
this equation,33,34 as confirmed by TEM and TGA analysis (Chapter 2, Section 2.3.2). 
Despite differences between the two sets of data, it is clear that experimentally, 
functionalisation causes the nanoparticles to diffuse more rapidly through a mucus 
dispersion compared to unfunctionalised particles.  To corroborate these data, further 
experiments were carried out designed to investigate the penetration of a nanoparticle 
suspension though a fresh gastric mucosa. 
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5.3.3.2 Nanoparticle penetration through a gastric mucosa 
Although NTA has been shown to be a useful technique in the assessment of nanoparticle 
diffusion, it does not necessarily provide a real-life description of how the particles are 
behaving.  Therefore, a new technique was developed to measure nanoparticle 
penetration through a mucosal barrier using fluorescence microscopy. 
In this methodology, fluorescent particles were placed directly onto the surface of a 
mucosa and left to penetrate through the barrier.  By taking 30 µm sections of the tissue 
and assessing the band of fluorescence, it is possible to establish the degree of 
penetration, whilst keeping the mucus layer intact.  It would be expected that the thickness 
of this band increases depending on the functionality of the particle, and as time 
progresses. The images obtained can be found in Fig 5.9.    
Although they provide good qualitative data, the images themselves show no quantitative 
data.  Therefore ImageJ was used, a piece of software which is regularly used to obtain 
quantitative information from qualitative data such as images,35 to measure the thickness 
of the band and establish the degree of penetration (Fig 5.9).  
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Fig 5.9 Penetration of fluorescently labelled fluorescent nanoparticles through a porcine 
gastric mucosa.  Images shown are exemplar at magnification x4; scale bar = 1 mm.  The green 
line represents the surface of the mucosa.  Graph shows the distance of nanoparticle permeation 
as determined by ImageJ analysis on the images (means ± standard deviation, n=3).  All values 
were subtracted from values obtained for control sections with no particles. * represents significant 
differences (p<0.05) compared to thiolated silica at the same time point.   
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From simple observation of the images obtained, it is hard to quantify any information, and 
there is little clear difference between the particle types.  However following ImageJ 
analysis, it was possible to determine that the functionalised nanoparticles were more 
penetrative than the unfunctionalised nanoparticles, thus complementing the NTA data.   
The thiolated nanoparticles show very little penetration into the gastric mucosa, even 
following 45 minutes of treatment, whereas PEGylated and POZylated particles have 
greater penetration into the biological tissue.  Given the large error bars, it is likely that 
some degree of penetration of the thiolated material is occurring in the tissue, albeit very 
limited due to the mucoadhesive nature of the particles.  The enhanced penetration of 
PEG and POZylated nanoparticles into the gastric mucosa, compared to their thiolated 
counterpart, are in agreement with the data of their diffusivity in mucin dispersions, 
demonstrated using NTA.   
This finding is notable on two counts; 1) it confirms the reliability of NTA to measure 
nanoparticle diffusion through mucin dispersions, and 2) it confirms that POZylated 
nanoparticles enhance nanoparticle permeation and diffusion to a similar degree as 
PEGylated silica.  Due to the advantages that POZ has over PEG (Chapter 5, section 
5.1), this information provides impetus for the use of this polymer in the future design of 
orally administered nanoparticle formulations, once FDA approval is granted.   
Based on the data here, it is not possible to elucidate a mechanism for the enhanced 
penetration.  Despite this, it is possible to speculate that the enhanced penetration is due 
to two main factors.  Firstly, the presence of the polymer on the nanoparticle surface 
masks the strong negative charge of the particle, and also the free thiol groups.  Both of 
these factors encourage mucoadhesion by the formation of disulphide bonds with free 
cysteine residues, or by forming electrostatic interactions with the glycoprotein.  Secondly, 
the polymers (both hydrophilic in nature) provide a more hydrophilic environment around 
the particle (due to entrapment of water molecules), thus encouraging their diffusion 
through the mucus. 
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5.4 Conclusions 
The above data explored enhancement of thiolated silica nanoparticle diffusion through a 
mucosal barrier.  The nanoparticles were functionalised with either PEG or POZ, fully 
characterised, and their diffusion through mucin dispersion measured using NTA.  In 
addition, a novel method was developed to assess the penetration of nanoparticles 
through an ex vivo mucosa, attempting to mimic how the particles would behave in a 
biological setting.  It was found that, upon functionalisation, the nanoparticles were 
significantly more diffusive than the unfunctionalised nanoparticles, thus confirming their 
ability to rapidly penetrate though a mucosal barrier.  It has previously been shown that 
the addition of PEG to a particle surface encourages mucus penetration; however this is 
the first time POZ has been used in a similar application.  Given the advantages POZ has 
over PEG, this finding may allow the development of novel biologically compatible 
nanomedicines which can be delivered by the oral route.  
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Chapter 6                            
Effects of alkyl length on the 
penetration of poly(2-oxazoline) 
functionalised silica nanoparticles 
through mucus 
6.1 Introduction 
This chapter describes investigations of alkyl chain length effects on nanoparticle diffusion 
through a gastric mucosa.  As previously discussed, poly(2-oxazolines) (POZ) are 
synthesised by a living polymerisation cationic ring-opening reaction (CROP) (Fig 6.1).   
 
 
Poly(2-methyl-2-oxazoline  Poly(2-ethyl-2-oxazoline  Poly(2-methyl-2-oxazoline 
Fig 6.1 Reaction mechanism for the synthesis of poly(2-oxazolines) by a cationic ring-
opening polymerisation, and the chemical structure of the polymers used in this study.  The 
interchangeable R-group has been circled and highlighted. 
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CROP reactions proceed by forming a chain with a cationic centre, through which 
additional monomeric units can be added.1,2  The reaction proceeds through the SN1 route 
allowing  the synthesis of well-defined polymers.   
During the initiation step, the ring is activated by either a Brönsted acid, carbonium ion, 
onium ions, or a photo/covalent initiator.  This generates a cationic intermediate, centred 
on the nitrogen atom (Fig 6.1).  The reaction can then propagate by further addition of a 
monomer via the nitrogen atom which attacks the intermediate, causing the ring to open 
and the polymer to form.  This causes the new monomer to become charged, allowing the 
next monomer to react and add to the polymer chain.  The reaction is terminated by the 
addition of a nucleophile, which attacks the positive cationic intermediate, stabilising the 
complex and inhibiting the binding of any further monomers.  This causes the initiating 
molecule to reform and the reaction ceases. 
As shown in Fig 6.1, oxazolines contain an R group (circled) which allows further 
modifications to the monomer, coupling different moieties and so modifying the 
physicochemical properties of the polymer after synthesis.  There have been many types 
of POZ synthesised in the literature with functional side chains tailored to specific 
applications.  It is well known that by attaching an aliphatic chain onto this pendent group, 
it is possible to change the polymers response to external stimuli, such as temperature, by 
changing its lower critical solution temperature (LCST).3,4 However, there are examples of 
other chemistries in the literature, attaching more complex molecules onto the pendent 
group of the POZ molecule. 
Cesans et al. (2006)5 synthesised POZ macromolecules with functional amino side chains 
by attaching a Boc-protected amino group onto the oxazoline monomer.  This was then 
polymerised into the functional polymer using the CROP method described above.  This 
demonstrates that it is possible to attach biologically active molecules, such as proteins,  
receptor ligands,6 and siRNA.7  Given the good biocompatibility of POZ (discussed in 
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Chapter 5), this makes POZ attractive to the pharmaceutical industry especially in 
controlled and targeted drug delivery.  There are other examples in the literature of POZ 
molecules with a wide variety of pendent groups including thiols, carboxylic acids, 
alcohols, and maleimides.8  These provide more targets for the attachment of further 
functional molecules and more complex systems. 
This chapter focuses on poly(-2-methyl-2-oxazoline) (PMOZ), poly(2-ethyl-2-oxazoline) 
(PEOZ), and poly(2-n-propyl-2-oxazoline) (PNPOZ), the structures of which can be found 
in Fig 6.1.  Through this series, the role of different alkyl chain lengths in the polymer on 
diffusion was examined.  It is well known that by changing the side-group on a polymer it 
is possible to change and tailor its fundamental physicochemical properties.  Factors such 
as viscosity, degree of swelling, and response to certain stimuli (such as temperature) can 
be readily changed using this method.  A study by Farhangi et al. described the chain 
dynamics of poly(alkyl methacrylate) in solution.9  By binding fluorophores to poly(alkyl 
methacrylate) molecules with different chain lengths they were able to probe the polymer 
chain dynamics, and their ability to form excimers.  They found that excimer formation 
decreased with increasing alkyl chain lengths, and polymers that were more flexible 
(based on their TG values) further increased excimer formation.  By translating this into 
functionalised nanomaterials, these minor modifications may cause dramatic changes to a 
nanoparticle’s diffusive properties.   
Based on the proposed mechanisms of mucus penetration, the increased alkyl chain 
length should cause the particles to diffuse slower, due to the relative hydrophobicity and 
hydration of the molecule.  Considering mucus from a chemical stand-point, the primary 
mechanism by which it entraps foreign objects is via strong adhesive interactions such as 
hydrogen bonding and Van der Waals forces.10  By minimising the points of contact 
between a nanoparticle and the mucus fibres, by coating with a hydrophilic, inert polymer, 
it is possible to generate mucus penetrating nanoparticles.11  Based on the principle that a 
longer alkyl chain (composed of repeat methyl groups) is generally more hydrophobic than 
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a short chain polymer,12,13 the aim of this study was to determine the extent of which 
hydrophobicity/alkyl chain length has on the rate of a polymer/nanoparticle complex 
diffusion through gastric mucin.  This provided; 1) some insights into the mechanism by 
which mucus penetration occurs, and 2) a good benchmark in the future design of mucus-
penetrating nanomaterials. 
6.2 Materials and methods 
6.2.1 Materials 
The particles used were the amorphous silica nanoparticles functionalised with different 
variations of POZ, provided by Prof Richard Hoogenboom (see Chapter 2 for details).  In 
addition, fluorescein-o-methacrylate, Alexa 546 C5 maleimide, and DMSO were 
purchased from Fisher (UK), and porcine gastric mucin type II and TEA was purchased 
from Sigma-Aldrich (UK).  All the water used was ultrapure (18 MΩ).  Haematoxylin and 
eosin were purchased from Brunel Microscopes Ltd (UK).  All other chemicals were of 
analytical grade purchased from Sigma-Aldrich (UK) unless otherwise stated. 
6.2.2 Synthesis of fluorescently labelled nanoparticles 
Previous studies showed that 5% of the nanoparticles free thiol groups needed to be 
functionalised to allow them to be visible above the background fluorescence of mucin.  
Fluorescein-O-methacrylate nanoparticles were synthesised according to the protocol 
described in Chapter 5. 
For Alexa 546 labelled nanoparticles, 1 mg of dye was dissolved in 5 mL water.  From 
this, 200 µL of aqueous fluorophore was added to a 2 mL aqueous suspension of 
nanoparticles (5 mg/mL).   The suspension was left stirring overnight, and purified by 
dialysis, as described in Chapter 2. 
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6.2.3 TEM 
TEM images were recorded on a Phillips CM20 analytical TEM using a 4 megapixel AMT 
camera.  An accelerating voltage of 200 kV was used.  Samples were prepared by placing 
a drop of nanoparticle suspension in aqueous dispersion onto a section of parafilm.  A 
Holey Carbon film 300 mesh copper grid (HC300Cu, EMResolutions, UK) was then 
placed onto the drop and left for 1 minute.  The grid was left to air dry before being placed 
in the instrument. 
6.2.4 Small Angle Neutron Scattering 
Small angle neutron scattering (SANS) experiments were performed on the D11 
instrument at the Institute Laue-Langevin (Grenoble, France).  Experimental set-up 
utilised the same procedure as discussed in Chapter 3, at 25 oC only.  Fitting used the 
SASview programme, using DLS and TEM data to fir the spectra to a sphere and core-
shell model, using the same SLD parameters as discussed in Chapter 4. 
6.2.5 Nanoparticle diffusion 
Diffusion experiments were carried out using the NTA LM10 system with LM14 metal top-
plate, sCMOS camera, green 532 nm laser and syringe pump.  Prior to analysis, 3x25 mL 
gastric mucin type II dispersions (1% w/v) in ultrapure water were made, and left to stir 
overnight to ensure complete hydration.  Alexa 546 labelled nanoparticles were diluted by 
a factor of 1:100 in water to form a stock solution.  10 µL of these particles was then 
spiked into 1 mL mucin dispersions (1% w/v) for analysis, resulting in a total dilution of 
1:10,000. 
Samples were injected into the NanoSight system and the flow-rate set at 50 AU in order 
to minimise fluorescent bleaching of the nanoparticles during analysis.  All videos were 
recorded through a 565 nm cut-on filter.  6×60 second videos were recorded at 25 and 37 
⁰C.  Each independent dispersion of mucin was analysed three times with each 
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nanoparticle type, resulting in a total of 9×6, 60 second videos for each temperature.  
Analysis was carried out using NTA v3.1 software. 
6.2.6 Mucus penetration study 
The mucus penetration study was carried out according to the protocol used in Chapter 5, 
with minor modifications.   
A fresh porcine stomach was obtained from a local abattoir (P.C.Turner Abattoirs, 
Farnborough, UK), and dissected to remove any connective tissue and muscle, leaving 
only the mucosa, submucosa, and stomach lining intact.  4×1 cm2 sections were cut and 
placed on a glass plate, with the mucosal layer facing upward.  200 µL of fluorescein 
labelled nanoparticles were pipetted onto the sections. Deionised water was also 
administered as a blank control.  Samples were left to incubate for 0, 15, 30, 45, and 60 
minutes, in a temperature controlled environment, at 37 oC.  Following each time point, 
tissue sections were placed mucus side up into a small (3.5×5.5 cm) weighing boat 
(Fisher, UK), half filled with OCT.  They were then placed on dry ice, before being 
completely embedded in OCT to preserve the particle-loaded mucus membrane.  Once all 
sections were embedded, samples were left on dry ice for 3-4 hours, before being 
transferred to a -80 ⁰C freezer for 24 hours until processing. 
For sectioning, samples were removed from the -80 ⁰C freezer and placed on dry ice.  
Each sample was mounted onto a standard solid object holder, 22 mm in diameter using 
OCT, and placed on dry ice for 30 mins until completely frozen. 20 µm sections were 
cryosectioned transversely using a standard 189 × 27 × 10 mm blade at 22º, placed onto 
superfrost charged slides (Life Technologies, UK) and left to dry in air for 30 minutes 
before being stored in a slide box.  All sections were cut from interior to exterior (i.e. 
upwards through the mucosal layer) in order to avoid carriage of particles into the 
biological tissue during the cutting process. All sections were cut using a Bright 5040 
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cryostat in a Bright Model PTF freezing chamber at -20 ⁰C (Bright Instrument Co. Ltd, 
UK).   
Sections were placed under a Leica MZ10F stereomicroscope (Leica Microsystems, UK) 
and images taken using an exposure time of 0.8 ms.  All images were recorded through 
an ET-GFP filter (Leica Microsystems, UK), enabling the particles to be detectible on the 
tissue, due to their fluorescent labelling.  Three images were taken for each section. 
ImageJ software (National Institute of Health, USA, v1.43, https://imagej.nih.gov/ij/) was 
used to quantify penetration of the nanoparticles.  For each image (10 for each particle 
type at each time point, from a different tissue section), the background was subtracted, a 
line drawn across the mucus barrier, and the “plot profile” measured.  This was repeated 5 
times at random locations along the mucus barrier for each image, providing a total of 50 
(10×5) profiles for each sample. Each individual profile was then assessed for the degree 
of penetration.  This was done by measuring the width of the predominant peak using 
Microsoft Excel 2010.  After each profile had been analysed, the mean values were 
calculated.  The value obtained for the blank tissue at the appropriate time point was then 
subtracted from the other values at the same time point in order to determine penetration.   
6.2.7 Histological analysis 
In addition to fluorescent analysis, some sections were used for histological analyses.  For 
staining, sections were initially immersed in a 1% v/v haematoxylin solution, and left for 5 
minutes.  The samples were then washed using deionised water to remove any excess 
solution, followed by another wash with 0.1 M ethanolic HCl for 10 seconds and a final 
wash with deionised water.  The section was then counterstained with eosin for 2 minutes 
before a final washing step in deionised water. 
The sections were examined under a light microscope (Leica DM2500 M, Leica, UK), and 
images obtained using an Infinity 1-1C camera (Lumenera, UK). 
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6.2.8 Statistics 
Statistical analysis was carried out using GraphPad Prism, v5.0.  Means ± standard 
deviations were determined and assessed for significance using 2-way ANOVA with a 
Bonferoni post hoc test.  Values of p<0.05 were considered to be significant.  Bonferroni 
was used to compare the differences between the groups, allowing for the identification of 
significant differences between the functionalised and unfucntionalised particles at 
different temperatures/time points. 
6.3 Results and discussion 
3.1 Nanoparticle characterisation 
The nanoparticles used in this study were characterised previously (Chapter 2).  Table 6.1 
shows the size and PDI as determined by Nanoparticle Tracking Analysis (NTA) and 
Dynamic Light Scattering (DLS).  All POZ macromolecules used in this study were 
synthesised by Richard Hoogenboom.  It should be noted that during synthesis the PEOZ-
silica synthesised by Richard Hoogenboom was compared to the PEOZ-silica purchased 
from Sigma (Chapter 2).  No significant differences were found between the two so the 
later was not used in this study. 
Table 6.1 The size, and PDI of the functionalised and unfunctionalised nanoparticles used in 
this study, determined by DLS (a) and NTA (b) (see Chapter 2 for details).  Mean ± standard 
deviation, n=3 
 
 
 
 
 
 
Nanoparticle 
z-average 
(nm)a 
PDIa 
Mode diameter 
(nm)b 
Thiolated silica 52±1 0.072 54±1 
PMOZ-silica 61±4 0.188 61±4 
PEOZ-silica 59±1 0.106 59±1 
PNPOZ-silica 61±1 0.194 63±3 
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In addition to the characterisation carried out in Chapter 2, TEM images were also 
recorded for unfunctionalised silica.  No images were recorded for the functionalised 
silica, as it was not possible to identify the polymer corona around the particles (due to 
lack of contrast).  TEM images can be found in Fig 6.2. 
 
Fig 6.2 TEM images recorded for unfunctionalised silica nanoparticles.  The scale bar in A) 
and B) represents 100 nm, and the scale bar in C) represents 50 nm. 
 
From the TEM images, the particle size 28±2 nm (i.e. particles without the hydration shell) 
and they are approximately spherical.  
6.3.2 SANS 
SANS can probe both the external and internal structure of nanoparticles. Here, SANS 
was used to determine the structure of functionalised silica nanoparticles and to confirm 
that decorating the particle surface with POZ has no detrimental effects to the core 
particle itself. 
The scattering profiles for these particles are shown in Fig 6.3; fitting to a sphere model 
for each particle type is given in Fig 6.4. The scattering profile for thiolated silica was 
initially fitted to a spherical form factor, using DLS and TEM data as a guide. The particle 
was found to have a radius of 137 Å, resulting in a diameter of 28 nm, which is 
A) 
B) C) 
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significantly (P<0.05) smaller than the size determined by DLS (52 nm) but corroborates 
the size established by TEM.  
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Fig 6.4 Raw scattering data (blue) and fits (red) for functionalised  
and unfunctionalised silica nanoparticles.  A) Thiolated silica, B) PMOZ-silica,  
C) PEOZ-silica, and D) PNPOZ-silica 
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Fig 6.3 SANS profiles for thiolated silica (blue), pMOZ-silica (red), pEOZ-silica (green), and 
pNPOZ-silica (purple) nanoparticles.  Scattering profiles were recorded on D11 at 25 
o
C. 
 210 
 
Previous studies by Mun et al.14 (who studied the core-shell structure of PEGylated MPTS 
silica nanoparticles) showed sizes of 30 nm for these particles using SANS. The 
discrepancy between the sizes determined by SANS analysis with that from DLS is due to 
the presence of a solvation shell around the particle.  The solvation shell is detected by 
DLS (shown by the rh), however is not shown in SANS.  The large 20 nm hydration shell 
around the particle is due to a large abundance of surface -SH and -Si-O- groups, leading 
to strong interactions between water molecules and the nanoparticle surface. 
Upon functionalisation, only minor changes in the scattering pattern arise (at high Q 
values ~0.03 Å-1). A study of the swelling behaviour of PMOZ and PEOZ showed that 
POZ macromolecules are highly hydrated and bind tightly to water, and that PMOZ is 
significantly more hydrated than PEOZ.15 This phenomenon explains why the shell is 
barely visible using SANS; it is highly hydrated and offers no contrast to the D2O 
background, and so cannot be seen. It was found during curve fitting that changing the 
size of the shell (in a core-shell model) did not affect the curve. Based on this, the 
particles were fitted to a spherical form-factor only, and displayed a size of 28 nm for all 
particles. With no significant change in size or scattering observed, it can be concluded 
that the addition of the polymer shell does not change the nanoparticles core architecture 
during the functionalisation reaction. 
Although the SANS data could not be fitted to a core-shell model, the size of the hydrated 
polymer shell can be estimated. From the SANS/TEM data, the core diameter is 28 nm. 
Light scattering sizes include the hydration shell and provide a diameter of 52 nm for the 
thiolated particles; from this, a hydration layer of ~13 nm for the non-polymer coated 
particles can be postulated. The particle diameters from DLS data in Table 1 for the 
functionalised nanoparticles then indicate shell thicknesses of 4, 3, and 5 nm for PMOZ, 
PEOZ, and PNPOZ, respectively. Similar values have been reported in the literature for 
PMOZ functionalised silica.16 It should be noted that these sizes are estimates based on 
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the difference in hydration shell thickness. Clearly it is feasible that some polymer is 
present within the hydration shell, which would suggest a larger shell thickness.  
6.3.3 Diffusion through a mucus dispersion 
Fig 6.5 shows the mean diffusion coefficients of the thiolated and POZylated nanoparticles 
in a gastric mucin dispersion. 
 
Fig 6.5 Mean diffusion coefficients of thiolated and POZylated nanoparticles in gastric 
mucin dispersions.  Mean ± standard deviation, n=3. Columns noted with capital letters are 
significantly different from their lower case counterparts (P<0.05).  
 
Figure 6.5 clearly shows that the diffusion coefficient changes as the particle becomes 
functionalised.  Although the diffusion coefficient at 37 oC is greater than the diffusion 
coefficient at 25 oC, no significant difference was noted.  This is to be expected, as an 
increase in temperature causes a change in viscosity, and also an increase in energy in 
the system, thus allowing the particles to diffuse more rapidly, as predicted by the Stokes-
Einstein equation. 
As previously shown, the thiolated silica has a diffusion coefficient of ~60 x104 nm2∙s.  
Following POZylation, the diffusion coefficient drastically increases to ~200 x104 nm2∙s for 
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PMOZ, and ~130 x104 nm2∙s for PEOZ.  It was found that by varying the alkyl chain length 
on the functionalised POZ macromolecules drastic changes to the diffusion coefficient 
were found.  PMOZ was significantly more diffusive than PEOZ and PNPOZ; and PEOZ 
was significantly more diffusive than PNPOZ.   
PNPOZ-silica nanoparticles shows similar diffusion coefficients to the unfunctionalised 
silica, with no significant differences noted between the two.  This is likely due to the 
increasing hydrophobicity of the particles.  As the chain length increases, the 
hydrophobicity of the polymer chain also increases, thus causing the particles to become 
more immobile though mucus.  Although mucus is a complex mixture of proteins, 
carbohydrates and salts, the primary solvent is still water, so an increased hydrophobicity 
will cause more immobile particles. 
These results provide insights into factors that could govern mucus penetration.  
Previously it has been hypothesised that it was the masking of the surface properties of 
the core nanoparticle itself that caused the increased mucopenetration,11,17,18 however this 
study shows that the hydrophobicity/hydration of the shell also plays an important role.  
The masking of the surface properties on the particle (i.e. high surface charge and free 
thiol groups) is of fundamental importance when looking at a mucus penetrating system.  
However this study suggests that hydrophobicity and degree of polymer hydration can 
also play a key role in determine the rate of mucus penetration. 
To corroborate the diffusion data established by NTA and confirm the influence of 
hydrophobicity, nanoparticle penetration across a gastric mucosa was measured. 
6.3.4 Penetration through a gastric mucosa and histology 
In order to assess penetration of the functionalised nanoparticles into gastric mucosa, 
fluorescence microscopy was employed.  Fig 6.6 shows the penetration of nanoparticles 
into a gastric mucosa, as measured by fluorescence microscopy and ImageJ analysis, 
and provides exemplar microscopy images taken using the stereo microscope.   
 213 
 
 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
Thiolated silica PMOZ-silica PEOZ-silica PNPOZ-silica
P
en
et
ra
ti
o
n
 (
m
m
) 
0 mins
15 mins
30 mins
45 mins
60 mins
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
Fig 6.6 Penetration of thiolated and POZylated silica nanoparticles across a mucosa.   
Images are exemplar images, with at a magnification of x4.  The scale bar represents 1 
mm.  Chart shows permeation across 10 different sections, ± standard deviation.  
* significant differences (p>0.05) compared to thiolated silica at the same time point.  The 
green represents the surface of the mucosa, with the mucus layer above it. 
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From Fig 6.6, it is clear that PMOZ-silica nanoparticles are significantly more penetrating 
than both PEOZ, and PNPOZ (p>0.05), in accord with the diffusion coefficients for the 
particles in Fig 6.5.  Data on the penetrative abilities of nanoparticles is strongly 
corroborated by the diffusion coefficients measured by NTA i.e., that functionalisation 
increased penetration, and PMOZ appears more penetrating than PEOZ and PNPOZ.  
Considering the fluorescent images generated (Fig 6.6), a relatively thick green band can 
be seen for PMOZ and PEOZylated silica as time progresses compared to the 
unfunctionalised thiolated silica.   
For PNPOZ-silica nanoparticles, there is no significant increase in diffusion coefficient 
compared to the thiolated parent particles.  However there is a significant difference 
observed in their penetration into a mucosa at the longer time periods, also evident in the 
images.  This is due to the interactions between the mucus and the particles.  Although 
the diffusion coefficients of the nanoparticles are similar (77±6 or 51±8 x104 nm2∙s for 
silica and PNPOZ-silica, respectively), the thiolated silica is mucoadhesive in nature and 
will therefore stick to the surface of the mucosa and not penetrate through (Fig 6.6).  It is 
unlikely that PNPOZ is mucoadhesive, as the polymer remains water-soluble.  As such, 
the particles will permeate through the mucus, just at a reduced rate compared to the 
shorter aliphatic chained-polymers. 
Further, penetration of the particles was linear with time, with R2 values of 0.95, 0.98, and 
0.92 for PMOZ, PEOZ, and PNPOZ, respectively (Fig 6.7).   
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Based on the SANS data and previous reports, the difference in diffusion coefficient and 
permeation is likely due to the hydration of the polymer.  PMOZ is significantly more 
hydrated than PEOZ, which explains this trend and, although not reported elsewhere, it is 
logical to conclude that PNPOZ will be less hydrated than the other polymers.  This shows 
that the hydrophobicity of polymer grafted onto the surface of a nanoparticle plays a key 
role in the degree of penetration for nanoparticles through mucus barriers, and minor 
alterations can lead to large changes.  It is well known that hydrophobic molecules are 
poorly penetrating through mucus barriers,19 in agreement with these results, as 
methylated polymers are more hydrophilic than propylated polymers.  Based on the data 
presented here and the findings of the data presented in Chapter 5 and subsequent 
publication,20 it is possible to conclude that PMOZ may be better at enhancing diffusion 
compared to PEG and PEOZ.   
The variance in rates of penetration accords with the diffusion coefficients for the particles 
in the mucin dispersion (Fig 6.6).  As the alkyl chain length increases (from methyl to 
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Fig 6.7 The linear nature of nanoparticle penetration with time for thiolated, PMOZ, 
PEOZ, and PNPOZ-silica nanoparticles as a function of time.  Data represent the 
means of 3 repeats ± standard deviation 
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propyl) there is a significant (P<0.05) change in both penetration and diffusion coefficient 
for PMOZ and PEOZ-silica nanoparticles, again a trend which was found to be linear 
when plotted against number of methyl groups.   This was found for both the penetration 
and diffusion coefficients (Fig 6.8).   
 
 
Fig 6.8 The penetration at 60 mins (A) and diffusion coefficient (B) of nanoparticles 
functionalised with POZ as a function of alkyl chain length.  Values represent the mean of 3 
repeats ± standard deviation. 
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These results show that the length of the alkyl chain of a polymer grafted onto the surface 
of a nanoparticle can have a significant effect on their ability to diffuse through a gastric 
mucosa.  Using the equation generated by Fig 6.8A, it could be possible to design 
polymers with the specific intention of acting as enhancers of mucus penetration.  
However, it is clear that the linear relationships above may only apply to aliphatic pendent 
groups and further work would need to be carried out to determine if the same trend is 
true for aromatic pendent groups, and other more complex models (such as amino acids, 
sugar residues, or drugs). 
Previous mechanisms of how polymer-functionalised nanoparticles diffuse through a 
mucus barrier suggest that the main reason for the enhanced penetration is due to a 
masking of the nanoparticles surface properties.  However, the above results suggests 
that if a polymer is designed to be highly hydrophilic as well as containing these “stealth” 
properties, the diffusion of the particles will be significantly enhanced. The thiolated silica 
nanoparticles do not show any mucopenetrating abilities, and are well known to be 
mucoadhesive.21,22   
In addition to fluorescence microscopy, some sections (chosen at random) were used for 
histological analysis.  Fig 6.9 shows sections of a porcine stomach stained with 
hematoxylin and eosin. Hematoxylin and eosin are commonly used to assess the 
pathology of a section, to determine disease states and toxicity.  In this study, histology 
was used to assess the structure and integrity of the porcine stomach. 
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Fig 6.9, shows the histology of a porcine stomach lining, clearly showing the gastric pits 
and underlying muscle tissue. Comparing these sections to the fluorescent images in Fig 
6.6, it is possible to conclude that the PMOZ and PEOZ functionalised nanoparticles are 
beginning to diffuse into the gastric pits.  This shows they have successfully and rapidly 
crossed the mucosal barrier and have reached the underlying cells.  Based on this 
evidence, either PMOZ or PEOZ could be used in the development of a formulation which 
could enhance the delivery of a drug into the gastric pits, where it can then either enter 
into systemic circulation or have a local effect, for example against cancer. 
The evidence presented here clearly shows that the length of the alkyl chain has a 
significant effect on both the diffusion coefficient and degree of penetration of 
nanoparticles through a mucosal barrier.  Given this, it is also possible to conclude that 
the hydrophobicity/hydration of the nanoparticle surface plays an important role in this 
diffusion phenomenon.   
Fig 6.9 Histology sections of a porcine mucosa, 
stained with haematoxylin and eosin.  The section 
clearly shows the mucosa and gastric pits in the 
stomach. Also included is an image showing how par the 
particles are permeating into the tissue. 
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6.4 Conclusions 
The effects of the alkyl chain length of poly(2-oxazolines) on nanoparticle diffusion and 
permeation into a gastric mucosa were investigated.  Chapter 2 shows that by 
functionalising with PEOZ, there is a significant enhancement in nanoparticle diffusion 
coefficient, similar to that of PEG.  This study extends this work by showing that by 
decreasing the length of the alkyl pendant group on the poly(2-oxazoline) macromolecule 
the particles will diffuse significantly quicker through a mucus dispersion, and as a result 
penetrate further through a mucosal barrier.  This provides a basis for the design of 
potential mucus penetrating nanoparticles by showing that hydrophobicity plays a key role 
in determining the penetrative effects of a nanoparticle suspension. 
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Chapter 7                            
Concluding remarks and future work                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
7.1 Concluding remarks 
Given recent technological development and the increasing popularity of nanoparticles in 
multiple industries, the need to understand how these particles behave in solution on a 
molecular level is evident, and in particular their diffusive properties in different 
environments which is often overlooked.  Given the current trend in functionalised 
nanomaterials, especially as drug delivery systems, there is a growing need to learn more 
about how they are behaving in specific environments, how they diffuse differently 
depending on their surface chemistry, and how external factors (such as pH, temperature, 
or charge) can affect their diffusion.   
The aims of this thesis were to synthesise and characterise a series of functionalised 
nanomaterials, and assess how their diffusion can be manipulated in a variety of different 
media, primarily focused on the development of novel nanomaterials for enhanced 
transmucosal delivery by the oral route.  This was achieved by focusing on several key 
areas; how different sized nanoparticles diffuse through a complex viscous environment, 
mimicking that of a biological system, the effects of structure and aggregation state on 
diffusion at different temperatures and how this affects diffusion in polar environments, 
culminating in how the nanoparticles physicochemical properties of functionalised 
nanomaterials can affect diffusion and permeation through a gastric mucosa.   
As has been described throughout the course of this thesis, nanoparticles have been 
widely studied as drug delivery systems, and there is a large increase in popularity of 
developing so-called mucus penetrating systems.  Functionalising nanoparticles with PEG 
has been shown to decrease the surface interactions between the particle and the 
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surrounding mucus environment, thus causing them to diffuse more readily.1  However, 
since this initial discovery there have been very few fundamental studies investigating the 
physical and chemical forces governing mucus penetration.  One goal of this research 
was to understand the fundamental forces governing this process.   
The first portion of this study explored the diffusion of different sized gold nanoparticles in 
suspension with different concentration of Pluronic F-127, a temperature responsive block 
co-polymer which, depending on the concentration, forms micelles followed by gels upon 
heating.  Here, we wanted to assess how the changing nature of a complex polymer 
environment affected the diffusion of particles, based on the state of the system (i.e. free 
polymer to micelles, to gel).   The polymeric system chosen (Pluronic F-127) provided a 
well defined mimic for a complex biolgical medium such as mucus making it possible for 
the effect of size to be explored.  It was found that although the transition between free 
polymers to micelle to gel can constraint the system causing the particles to travel in a 
smaller area, however can lead to an increased diffusion coefficient due to changes in the 
local micro- (or nano-) environment.  This was confirmed using a bespoke script which 
plotted particle movement and calculated the average distance travelled by individual 
particles and also the total area they moved in. 
The next step looked at how a polymer corona around a particle affected diffusion; and 
whether the physicochemical properties of said shell changed the particles diffusion 
coefficient.  Poly(2-oxazolines) were chosen as model polymers in this regard for several 
reasons; good biocompatibility and similarity to PEG, ease in synthesis and 
functionalisation, and finally a functionalisable side chain, making it possible to tune the 
polymer to have different properties.  In addition, POZ macromolecules exhibit a 
temperature-responsive nature, which can be exploited for pharmaceutical applications. 
Continuing on from looking at how particle size affects diffusion, the next step was to 
assess how structural features of polymer functionalised nanoparticles and how minor 
changes to the molecular isomeric structure of the polymers can alter the aggregation 
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state of temperature responsive polymers.  By switching between a secondary or tertiary 
amine, drastic changes in the interactions and aggregation behaviour of PNIPAM-silica 
and PNPOZ-silica nanoparticles can be seen.  However, the influence of the amine has 
not been definitively proven since it is not only this amine that is changing in our system; 
PNIPAM has a secondary amine with an isopropyl side chain attached, whereas PNPOZ 
has a tertiary amine with a linear propyl chain attached.  It could be that changing 
between an isopropyl or n-propyl chain could also be causing this effect.  However, the 
temperature of the system can result in interesting diffusive properties of the particles in 
different polar environments, ascribed to a co-solvency effect between the hydration shell 
around the particles (consisting of water), and the solvent environment the particles are 
suspended in. 
Finally, POZ-functionalised nanoparticles were assessed for their ability to permeate 
through a mucosa.  The first study in this regard, directly compared the mucus penetrating 
abilities of PEG and POZ.  It was found that POZylation increased the diffusivity of the 
nanoparticles just as effectively as PEGylation did.  Given the advantages POZ has over 
PEG, this finding suggests potential future use of POZ in nanoscale drug delivery 
systems.2  Subsequently, the role of side-chain dynamics of the polymer shell on 
nanoparticle mucus permeation was explored.  POZ derivatives with 3 different moieties 
(methyl, ethyl and propyl) were used in this study.  In addition to confirming the results of 
the previous study (that PEOZ-silica allows nanoparticles to diffuse more readily), it was 
found that the hydration/hydrophilicity of the polymer plays a key role in mucus 
permeation.  PMOZ-nanoparticles were significantly more diffusive than PEOZ and 
PNPOZ functionalised silica, a trend that was found to be linear.  This adds further data 
on the previous report and looks at the fundamental forces governing mucus penetration, 
a factor not previously studied. 
To draw the research together, this thesis has provided fundamental studies into how 
nanoparticle diffusion can be manipulated by changing subtle natures of a system, be it a 
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polymer corona around the particle, or the environment it is moving in.  With the surge in 
popularity of functionalised nanomaterials reaching consumer products, it is clear that 
much is still unknown about how these particles actually behave in different systems, and 
how their diffusion can vary with marginal changes to said system.  The main findings of 
this thesis summarise some of these changes and highlight how little is actually known 
about the nature of nanoparticle diffusion, and how these properties cannot necessarily be 
easily predicted based on their chemical and physical properties.  Despite this, the field of 
nanoparticle diffusion is expanding rapidly, yet much more work is needed to detail the 
fundamental science underlying this process, before the development of novel particles 
with manipulated diffusion coefficients can be designed. 
7.2 Future work 
Given the multidisciplinary nature of this thesis, proposed future works are split into three 
different areas; mucus-penetration, stimuli-responsive nanomaterials, and physical effects 
on diffusion. 
7.2.1 Mucus penetration 
The work in this thesis further adds to current scientific understanding of mucus 
penetrating nanoparticles, by describing how POZ can enhance permeation into a mucosa 
in addition to PEG.  In addition, the work on the effects of alkyl chain-length has further 
advanced this understanding and provided information on a potential mechanism of action 
for mucus penetrating nanoparticles.  Despite this, there are still several effects to study in 
this regard; molecular weight of the polymer itself and also size and composition of core 
particle. 
Research into the diffusion of polymer molecular weight (in this case PEG) on modified 
silica nanoparticles has been carried out by Mun et al,3 in different polymer solutions. 
However, no work currently exists exploring the effect of polymer molecular weight on 
nanoparticle diffusion and permeation into a gastric mucosa.  By taking the findings of 
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Mun et al, it would be expected that smaller molecular weight polymers would diffuse 
faster, due to resulting smaller particles.  However, this area would need further study to 
confirm this hypothesis.  In addition, by changing the core-silica size one would expect the 
diffusion coefficient to vary accordingly; larger particles diffusing more slowly.   
Given the wide range in nanoparticle size and functionality studied in the literature, 
drawing on these different parameters, including the findings here where the 
hydrophobicity of a polymer was found to play an important role on mucus penetration, it 
could be possible to create a model/computer simulation of how particles could diffuse 
through a mucosa, and perhaps allow rational design of coatings to enhance diffusion. 
7.2.2 Diffusion of temperature responsive particles 
Continuing the work examining temperature responsive polymers grafted to nanoparticles, 
and how their aggregation state influences their diffusion has potential.   
To corroborate and expand on the diffusion studies carried out using NTA, DOSY would 
provide information on how the bulk of the particles were behaving in solution, providing 
further insight into how the particles were behaving in different states in different polar 
environments.  This will provide more insight into the processes discussed, and determine 
any other effects seen in the diffusion regarding the bulk aggregates. 
As discussed in the thesis, one limitation to this study was the use of PNPOZ over poly(2-
isopropyl-2-oxazoline) (PIPOZ).  Given this, the same series of experiments should 
investigate the temperature responsive nature of PIPOZ-silica nanoparticles and whether 
they conform to the same trend as seen in PNIPAM-silica nanoparticles.  This will provide 
a more comprehensive understanding of how the structure of the polymer (i.e. primary, 
secondary or tertiary amide) can affect both the structure, interactions and diffusive 
properties of the nanoparticles. 
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7.2.3 Diffusion of nanoparticles in a complex micellar suspension/gel 
Given the bespoke application of a novel script designed to capture the distance travelled 
by nanoparticles and the area they move in, there are numerous possibilities to explore.  
These include applying this code to the mucus penetrating particle above, to assess how 
not only diffusion coefficient is affected but also net movement.  The limitation is, however, 
that for the code to be applied, NTA needs to work in static mode.  Given that the 
nanoparticles are prone to fluorescent bleaching this may not be possible; however by 
recording short videos (<10 sec), it may be possible to generate some data though pilot 
work will need to be carried out to confirm this.   
In addition, if a highly porous gel is injected into the NTA system, which contains particles, 
more detailed information regarding their interactions and net movement could be 
determined through application of this code, potentially making it very useful in the 
polymer physics field. 
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